Back grey_arrow_rt.gif
 
Recent articles on HIV. Check out articles on HIV related Bone Issues and HIV and Aging.
 
null.gif
 
 
  1. IAC: Vienna Intl AIDS Conference Thoughts from Jules Levin, NATAP - (07/23/10)
     
  2. Vitamin D and UVB Radiation: How Much Is Necessary? "Exposure to a UVB dose of 1 SED every second week to ~88% body area is sufficient for maintaining summer 25(OH)D levels during the winter." - pdf attached - (02/03/12)
     
  3. Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke D.A.D - (01/24/12)
     
  4. Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection - (01/23/12)
     
  5. Vitamin D Supplementation, HIV, HAART, Bone Health, Fractures - (01/23/12)
     
  6. Vitamin D Improves Bone Health/Reduces Fracture Risk-Bone Loss: IOM, Endocrine Society - How Much Vit D Supp?/Calcium - (01/23/12)
     
  7. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection - (01/19/12)
     
  8. Coping with HIV/Aging: managing health & psychological factors & HCV - (01/15/12)
     
  9. 2nd Intrntnl Wrkshp HIV & Women: Sexual Abuse as Child Raises Heart Disease Risk in HIV-Positive Women - (01/14/12)
     
  10. Viral Load Key to HIV Transmission - (01/13/12)
     
  11. Probability of Heterosexual HIV-1 Transmission per Coital Act in Sub-Saharan Africa - Editorial - (01/13/12)
     
  12. Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1-Serodiscordant Couples - (01/13/12)
     
  13. 2nd Intrntnl Wrkshp HIV & Women: Gardasil Study - Most Young HIV-Positive Women Still Negative for Key HPV Genotypes (01/11/12)
     
  14. 2nd Intrntnl Wrkshp HIV & Women: Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Naïve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials (01/11/12)
     
  15. Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough? - Editorial - - (01/10/12)
     
  16. Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy - (01/10/12)
     
  17. 2nd Intrntnl Wrkshp HIV & Women: Lopinavir Side Effects Differ by Weight in Women, But RNA Response Does Not (01/11/12)
     
  18. 2nd Intrntnl Wrkshp HIV & Women: Differences Between Women and Men on Rilpivirine vs Efavirenz for 96 Weeks (01/11/12)
     
  19. 2nd Intrntnl Wrkshp HIV & Women: Hormonal Contraceptives Tied to Non-AIDS Disease or Death in HIV+ US Women: 'doubles Non-AIDS Risks' (01/11/12)
     
  20. 2nd Intrntnl Wrkshp HIV & Women: Treatment Access Biggest Trial Plus in Survey of Women/Minority GRACE Study (01/11/12)
     
  21. 2nd Intrntnl Wrkshp HIV & Women: One Third of HIV+ South Carolina Women Not Getting Regular Pap Test (01/10/12)
     
  22. 2nd Intrntnl Wrkshp HIV & Women: US Girls With HIV Have Doubled Rate of Anal HPV and Related Conditions (01/10/12)
     
  23. 2nd Intrntnl Wrkshp HIV & Women: More Depression in HIV+ Women Than Men, Regardless of ART, in 15-Country Study (01/10/12)
     
  24. 2nd Intrntnl Wrkshp HIV & Women: Cervical Lesion Excision Does Not Boost Genital HIV Shedding in Small Cohort (01/10/12)
     
  25. (Issentress) Raltegravir for Pediatrics: Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (CT) Formulation in Children 2-5 Years - CROI 2011 Presentation & attached FDA Label containing pediatric safety, PK, dosing, efficacy - (01/09/12)
     
  26. Herpes simplex virus: a new era? commentary - shedding persisted in study despite acyclovir, valaciclovir therapy - (01/09/12)
     
  27. Efficacy Results of a Trial of a Herpes Simplex Vaccine - HSV2 Efficacy Not Observed - (01/09/12)
     
  28. Hi Fat Diet Injures Brain in mice - Obesity is associated with hypothalamic injury in rodents and humans - (01/09/12)
     
  29. Hi Fat Diet May Injure Brain - Alteration of hypothalamic cellular dynamics in obesity - Commentary - (01/09/12)
     
  30. Remodeling of the arcuate nucleus energy-balance circuit is inhibited in obese mice - (01/09/12)
     
  31. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - (01/07/12)
     
  32. Electrocautery Ablation of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Negative and HIV-Positive Men who have sex with Men - (01/07/12)
     
  33. A Comparison of 3 Regimens to Prevent Nevirapine Resistance Mutations in HIV-Infected Pregnant Women Receiving a Single Intrapartum Dose of Nevirapine - (01/05/12)
     
  34. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons - (01/04/12)
     
  35. Preventing Deaths in Persons With HIV/Hepatitis B Virus Coinfection: A Call to Accelerate Prevention and Treatment Efforts - EDITORIAL - (01/02/12)
     
  36. Hepatitis B Virus Coinfection Negatively Impacts HIV Outcomes in HIV Seroconverters - (01/02/12)
     
  37. The Economic Cost of Advanced Liver Disease - (01/02/12)
     
  38. Breakthrough of the Year, 2011 Science 23 December 2011: "in May of this year, the 052 clinical trial conducted by the HIV Prevention Trials Network reported that ARVs reduced the risk of heterosexual transmission by 96% - (01/02/12)
     
  39. A New Link Between Aging Cells and Aging People - (01/02/12)
     
  40. Vitamin D, Calcium Intakes Guidelines - 3 Reports - (01/02/12)
     
  41. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force - (01/02/12)
     
  42. AntiAging Cancer Drug - Ageing: A midlife longevity drug? - (01/02/12)
     
  43. Blocking Vif, HIV protein, Can Block HIV Replication - (01/02/12)
     
  44. Global landscape of HIV-human protein complexes: "We aimed to identify host proteins associated with HIV-1 proteins" - (01/02/12)
     
  45. Viramune HIV Infant Prophylaxis Safe: "Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial" - (01/02/12)
     
  46. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial - (01/02/12)
     
  47. Testosterone replacement therapy and polycythemia in HIV-infected patients - (01/02/12)
     
  48. Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use: 'comorbidities cause work cessation' - (01/02/12)
     
  49. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging - (01/02/12)
     
  50. HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer - (12/22/11)
     
  51. First data to show antihypertensive therapy prolongs life - (12/21/11)
     
  52. Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival - (12/21/11)
     
  53. HIV Persistence during Therapy 5th International Workshop (Dec 6-9 2011 St Martin, West Indies) - Written by David Margolis MD, University of North Carolina at Chapel Hill (12/21/11)
     
  54. How might HPV testing be integrated into cervical screening? - (12/17/11)
     
  55. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial - (12/17/11)
     
  56. HPV Screen Detects Lesions Earlier than Pap Test - (12/17/11)
     
  57. 3 Integrase Inhibitors..... - (12/17/11)
     
  58. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells - (12/17/11)
     
  59. Treating HIV Early After Infection - new study - (12/16/11)
     
  60. Neither Branded Nor Generic Lopinavir/Ritonavir Produces Adequate Lopinavir Concentrations at a Reduced Dose of 200/50 mg Twice Daily - (12/15/11)
     
  61. A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz - (12/15/11)
     
  62. Emotional Impact of Premature Aging Symptoms in Long-Term Treated HIV-Infected Subjects - (12/15/11)
     
  63. Men Who Have Sex With Men Have a 140-Fold Higher Risk for Newly Diagnosed HIV and Syphilis Compared With Heterosexual Men in New York City - (11/30/11)
     
  64. HIV+ & HIV/HCV(tripled) Have Higher Fracture Rates Compared to General Population in Denmark - (11/28/11)
     
  65. Association of Low Level Viremia with Inflammation and Mortality in HIV-Infected Adults: "We conclude that there is little association of low level viremia with levels of CRP, fibrinogen, and IL-6" - (11/28/11)
     
  66. Projected life expectancy of people with HIV according to timing of diagnosis - (11/28/11)
     
  67. HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer: 'cd4 & viral load implicated as risk factors' - (11/28/11)
     
  68. HIV Infection, Immune Suppression, and Uncontrolled Viremia Are Associated With Increased Multimorbidity Among Aging Injection Drug Users (ALIVE Study): unrecognized high rates of of multucomordibities - (11/28/11)
     
  69. Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors? - (11/21/11)
     
  70. NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN) - (11/21/11)
     
  71. A Randomized, Controlled, Open-Label Study of the Long-Term Effects of NGX-4010, a High-Concentration Capsaicin Patch, on Epidermal Nerve Fiber Density and Sensory Function in Healthy Volunteers - (11/21/11)
     
  72. A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-associated Distal Sensory Polyneuropathy - (11/21/11)
     
  73. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy: "results suggest that NGX-4010 could provide a promising new treatment for painful HIV neuropathy" - (11/21/11)
     
  74. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders - (11/04/11)
     
  75. Aging/Wk: Statin Blocks PIs' Negative Impact on Bone Formation in Cell Studies - Written by Mark Mascolini - (11/03/11)
     
  76. EACS: Pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy (11/02/11)
     
  77. IDSA: Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Subjects: 96-Week Efficacy and Safety Results of the PROGRESS Study - (11/02/11)
     
  78. IDSA: A Seven-Year Review of AIDS and Non-AIDS related Malignancies in a Large HIV/AIDS Center in New York - (11/02/11)
     
  79. IDSA: Treatment of high grade anal lesions in high risk patients: outcome at an urban community health center - (11/02/11)
     
  80. Aging/Wk: Antiretroviral Levels With Two Common Regimens in Nonfrail Older Patients - see slides below report - Written by Mark Mascolini - (11/01/11)
     
  81. Aging/Wk: Cognitive Therapy Gives Boost to 50-Year-Olds With Long-Term HIV - Written by Mark Mascolini - (11/01/11)
     
  82. IDSA: Risk of Muscle Breakdown in HIV - see slides below article - (11/01/11)
     
  83. IDSA: Prevalence and Patterns of Echocardiographic Abnormalities in HIV-Infected, Black Individuals in an Inner City Teaching Hospital in Washington DC - (11/01/11)
     
  84. Early HIV Therapy in Patients With TB Saves Lives - (11/01/11)
     
  85. Integration of Antiretroviral Therapy with Tuberculosis Treatment - (11/01/11)
     
  86. Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis - (10/28/11)
     
  87. Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis - (10/31/11)
     
  88. IDSA: Peripheral mechanisms of CD4 T cell regeneration in HIV-1 elite controllers: naïve CD4s are severely depleted in elite controllers - (10/31/11)
     
  89. Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias: "Patients with AD were around half as likely to be prescribed ARBs" - (10/31/11)
     
  90. Aging/Wk: Half of HIV+ Middle-Aged Meet Social Security Disability Threshold in Walk Test - Written by Mark Mascolini - (10/31/11)
     
  91. Aging/Wk: CD4 Changes on Effective ART Similar in People Under and Over 50 Years Old - Written by Mark Mascolini - (10/31/11)
     
  92. Aging/Wk: CMV Antibody Levels Linked to Heart Disease Markers in Women On and Off ART - Written by Mark Mascolini - (10/31/11)
     
  93. Aging/Wk: HIV Linked to Frailty in Middle-Aged IDUs, Especially With Poor HIV Control - Written by Mark Mascolini - (10/31/11)
     
  94. Aging/Wk: Renal Function Drops With Age--and More With PIs--in London HIV Clinic - Written by Mark Mascolini - (10/31/11)
     
  95. Testosterone replacement therapy and polycythemia in HIV-infected patients - - (10/28/11)
     
  96. Risk of Cataract Surgery in HIV-Infected Individuals: A Danish Nationwide Population-Based Cohort Study - (10/28/11)
     
  97. Aging/Wk: Duration of ART and Specific Antiretrovirals Tied to Hypophosphatemia and Albuminuria - Written by Mark Mascolini - (10/28/11)
     
  98. Aging/Wk: Drug Interaction Rate No Higher With HIV Than Without in French Group Over 60 - Written by Mark Mascolini - (10/28/11)
     
  99. Aging/Wk: Falling Rate Similar in 45-to-65-Year-Olds With HIV and HIV-Negatives Over 65 - Written by Mark Mascolini - (10/28/11)
     
  100. 4 Aging Published Reports This Week: - (10/27/11)
     
  101. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia - (10/27/11)
     
  102. IDSA: Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network - (10/25/11)
     
  103. IDSA: Efficacy and hepatic safety of rilpivirine (RPV, TMC278) in treatment-naïve, HIV-1-infected patients co-infected with hepatitis B and/or C: pooled 96-week analysis of the Phase III ECHO and THRIVE trials - (10/25/11)
     
  104. IDSA: Analysis of lipid levels and neuropsychiatric events in treatment-naïve HIV-1-infected adults treated with rilpivirine or efavirenz over 96 weeks in ECHO and THRIVE - (10/25/11)
     
  105. IDSA: Rilpivirine Week 96 safety and efficacy by gender and race subgroups in treatment-naïve HIV-1-infected patients in the Phase III ECHO and THRIVE trials - (10/24/11)
     
  106. Updated NYS Syphillis in HIV+ Guidelines - (10/24/11)
     
  107. Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients - (10/24/11)
     
  108. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study - published The Lancet - (10/24/11)
     
  109. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial - (10/24/11)
     
  110. Assessment of population-level effect of Avahan, an HIV-prevention initiative in India - (10/24/11)
     
  111. EACS: High non-AIDS-related mortality among a cohort of HIV-positive men who have sex with men (MSM) in Stockholm Insulin resistance is a strong predictor of mortality- a 12 year follow (10/24/11)
     
  112. IDSA: Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (10/23/11)
     
  113. IDSA: Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naïve Patients: 192 Week Results from STARTMRK - (10/23/11)
     
  114. EACS: Predictors of Hepatitis C RNA Levels in HIV Co-infected Individuals in a Prospective Cohort Study (10/23/11)
     
  115. EACS: Factors influencing neurocognitive function in a large cohort of HIV infected patients on effective antiretroviral therapy (10/20/11)
     
  116. Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses - (10/21/11)
     
  117. Increased Coronary Artery Calcium Score and Noncalcified Plaque Among HIV-Infected Men: Relationship to Metabolic Syndrome and Cardiac Risk Parameters - (10/21/11)
     
  118. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study - (10/21/11)
     
  119. Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population - (10/21/11)
     
  120. Screening for Cognitive Impairment in Human Immunodeficiency Virus - (10/20/11)
     
  121. Viremia Copy-Years (Cumulative Viral Load Exposure) Predicts Mortality Among Treatment-Naive HIV-Infected Patients Initiating Antiretroviral Therapy - (10/20/11)
     
  122. EACS: Rilpivirine vs Efavirenz for 96 Weeks: Baseline Viral Load and Side Effect Details - Written by Mark Mascolini (10/19/11)
     
  123. EACS: IL28B gene polymorphisms and all-cause mortality in HIV infected patients (10/19/11)
     
  124. EACS: IL28B Genotype Linked to All-Cause Mortality in HIV+ People on cART - written by Mark Mascolini - (10/18/11)
     
  125. EACS: Half With Undetectable Plasma Load Have Neurocognitive Impairment in UK Group - written by Mark Mascolini - (10/18/11)
     
  126. EACS: Dolutegravir (GSK/ViiV Integrase) Treatment (with 50mg Once & Twice Daily) of HIV Subjects with Raltegravir Resistance & 3-Class ART Resistance: viral suppression at Week 24 in the VIKING Study (10/17/11)
     
  127. Gut Bacteria Influence Statin Treatment Response - (10/17/11)
     
  128. (Gut Bacteria) Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment - (10/17/11)
     
  129. EACS: Switching from Efavirenz/Emtricitabine/Tenofovir DisoproxilFumarate(EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir DisoproxilFumarate(FTC/RPV/TDF) STR in VirologicallySuppressed, HIV-1 Infected Subjects (10/17/11)
     
  130. EACS: Sustained Efficacy with Low and Similar Rates of Virologic Failures in Second Year Observed with Rilpivirine (RPV) versus Efavirenz (EFV) plus Emtricitabine/Tenofovir DF (FTC/TDF) in Treatment-Naïve, HIV-1 Infected Adults - Pooled 96-Week ECHO and THRIVE Analysis (10/17/11)
     
  131. EACS: Non-AIDS Cancer Incidence Remains the Same Over 2004-2010 in D:A:D Study Group - written by Mark Mascolini - (10/17/11)
     
  132. EACS: Half of HIV+ in France Still Coming to Care Late--With High Death Risk written by Mark Mascolini (10/17/11)
     
  133. EACS: Body Fat Distribution Changes After 96 Weeks of Therapy with Lopinavir/ritonavir (LPV/r) Plus Raltegravir (RAL) Compared with LPV/r Plus Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral (ARV)-Naïve, HIV-1-Infected Subjects from the PROGRESS Study (10/17/11)
     
  134. EACS: Efficacy and viral resistance are comparable when maraviroc is administered once daily or twice daily with boosted protease inhibitors in treatment-experienced patients (10/17/11)
     
  135. EACS: Pilot study evaluating an intensification of antiretroviral therapy with maraviroc in HIV-1-infected patients with controlled viral load exhibiting insufficient immune restoration (10/17/11)
     
  136. EACS: The incidence of serious non-AIDS bacterial infections in the EuroSIDA cohort (10/17/11)
     
  137. EACS: Interleukin-6 and C-reactive Protein Levels after 144 Weeks of Efficacy of Darunavir /Ritonavir Monotherapy versus DRV/r + 2NRTIs in the MONET Trial for Patients with HIV RNA < 50 Copies/mL at Baseline: COINFECTED PATIENTS HAD HIGHER IL-6, INFLAMMATION LEVELS (In SMART >3 mg/L was associated with progression), YOU CAN SEE 15% to 19% of PATIENTS HAD VERY HIGH hs-CRP (inflammation) (>3 mg/L), INFLAMMATION WAS MORE LIKELY TO BE HIGHER IF VIRAL LOAD WAS DETECTABLE (10/17/11)
     
  138. EACS: Long-term Efficacy of Raltegravir or Efavirenz Combined with TDF/FTC in Treatment-naïve HIV-1-infected Patients: Week-192 Subgroup Analyses from STARTMRK (10/14/11)
     
  139. Life expectancy in HIV - EDITORIAL, Better, but not good enough - (10/13/11)
     
  140. HIV Life Expectancy Increases In UK - 'life expectancy still 15 years lower with HIV compared to general population....starting HAART earlier matters' - (10/13/11)
     
  141. Initial Viral Decay (predicts viral suppression) to Assess the Relative Antiretroviral Potency of PI-, NNRTI- and NRTI-Sparing Regimens for First Line Therapy of HIV Infection - (10/12/11)
     
  142. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study - (10/11/11)
     
  143. Vitamin and Mineral Supplement Use in Relation to All-Cause Mortality in the Iowa Women's Health Study - Comment on "Dietary Supplements and Mortality Rate in Older Women" - (10/11/11)
     
  144. ICAAC: Pre-Therapy Detection of Transmitted Low-abundance HIV-1 Resistance Mutation-containing Variants in Antiviral-naïve Subjects and Implications for Subsequent Clinical Therapy Response - (10/10/11)
     
  145. ICAAC: Comparison of Population Genotype and Ultradeep Sequencing Results from Subjects with Virologic Failure in ARIES: Impact of Low-abundance HIV Variants on Outcome - (10/10/11)
     
  146. HIV Found in New Brain Cells, Should HAART Start Earlier To Prevent Brain Damage - (10/09/11)
     
  147. Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters - (10/09/11)
     
  148. ICAAC: Pre-Therapy Detection of Transmitted Low-abundance HIV-1 Resistance Mutation-containing Variants in Antiviral-naïve Subjects and Implications for Subsequent Clinical Therapy Response - (10/10/11)
     
  149. Changes in brain function in early HIV infection: A reliable indicator of disease prognosis? - (10/07/11)
     
  150. HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types - May Explain Persistent HIV Brain Damage - (10/07/11)
     
  151. ICAAC: Significant Reductions in the Prevalence of Protease Inhibitor and 3-Class Resistance: Recent Trends in a Large HIV-1 Protease/Reverse Transcriptase Database - (10/08/11)
     
  152. ICAAC: Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients - (10/08/11)
     
  153. Vitamin D, cardiovascular disease and mortality - (10/06/11)
     
  154. Vitamin B12, cognition, and brain MRI measures - - (10/05/11)
     
  155. Vitamins B12, B6, and folic acid Supplementationfor cognition in older men - (10/05/11)
     
  156. Hormonal contraception and HIV: an unanswered question EDITORIAL - (10/05/11)
     
  157. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study - (10/05/11)
     
  158. Oral Contraceptive Increases HIV Risk (for both men & women) - (10/05/11)
     
  159. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy - (10/05/11)
     
  160. ICAAC: Kidney Function Change With Cobicistat Calculated in HIV-Negative Volunteers - Written by Mark Mascolini - (09/30/11)
     
  161. ICAAC: Intracellular Raltegravir Concentrations Better With Twice-Daily Than Once-Daily Dosing - Written by Mark Mascolini - (09/30/11)
     
  162. ICAAC: TMC435 in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection: Week 24 interim analyses of Phase IIB PILLAR and ASPIRE trials - (09/30/11)
     
  163. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients - (09/29/11)
     
  164. ICAAC: HAART Treatment Interruption Following Adoptive Transfer of Zinc Finger Nuclease (ZFN) CCR5 Modified AutologousCD4 T-cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load - (09/29/11)
     
  165. ICAAC: ICAAC 2011: Medically Important Highlights - David H Shepp, MD, Hofstra NSLIJ Medical School Division of Infectious Diseases North Shore University Hospital - Manhasset- (09/29/11)
     
  166. ICAAC: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17-20, 2011 Chicago, IL - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (09/29/11)
     
  167. ICAAC: Responder-relapser (RR) patients might obtain benefit in liver fibrosis, after anti-HCV chemotherapy, in comparison to non-responders (NR) or non-treated (control) HIV- HCV coinfected patients - (09/27/11)
     
  168. ICAAC: Longitudinal assessment of liver fibrosis (LF) by non-invasive methods in HIV- HCV coinfected patients, after HCV chemotherapy - (09/27/11)
     
  169. ICAAC: Dolutegravir vs Resistant Mutants: Selective Advantage Profiles of HIV-1 Integrase Mutants in the Presence of Dolutegravir - (09/26/11)
     
  170. ICAAC: Liver Stiffness (LS) change in HIV/Hepatitis C (HCV) co-infected patients treated with CCR5 inhibitor based antiretroviral Therapy - (09/26/11)
     
  171. ICAAC: Under 10% in Large Canadian Cohort Reach Normal CD4/CD8 Ratio - (09/26/11)
     
  172. ICAAC: An Open-Label, Placebo-controlled Study to Evaluate the Effect of Dolutegravir (DTG, S/GSK1349572) on Iohexol and Para-aminohippurate Clearance in Healthy Subjects - Written by Mark Mascolini - (09/26/11)
     
  173. ICAAC: Dolutegravir & Creatinine Clearance - Written by Mark Mascolini - (09/26/11)
     
  174. ICAAC: Pharmacokinetic analysis of nevirapine extended release 400 mg QD vs immediate release 200 mg BID in patients with HIV-1 infection - (09/24/11)
     
  175. ICAAC: Nevirapine Concentrations With Once- Versus Twice-Daily Dosing - Written by Mark Mascolini - (09/24/11)
     
  176. ICAAC: Fosamprenavir/RTV Cuts Dolutegravir Levels: No Dose Change Needed for Naive - Written by Mark Mascolini - (09/24/11)
     
  177. ICAAC: HCV and Homocysteine Boost Risk of Covert Atherosclerosis in Spanish HIV Group - Written by Mark Mascolini - (09/24/11)
     
  178. ICAAC: Novel Boehringer-Ingelheim Integrase Inhibitor Retains Full Activity Against Raltegravir-Resistant Virus - Written by Mark Mascolini - (09/24/11)
     
  179. ICAAC: Effect of Fosamprenavir/Ritonavir on the Pharmacokinetics of the Integrase Inhibitor, Dolutegravir, in Healthy Subjects - (09/24/11)
     
  180. ICAAC: Safety, Tolerability, and Efficacy of Raltegravir (RAL) in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study - (09/22/11)
     
  181. ICAAC: Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race - (09/21/11)
     
  182. ICAAC: Durable and Consistent Efficacy of Raltegravir (RAL) With Tenofovir (TDF) and Emtricitabine (FTC) Across Demographic and Baseline Prognostic Factors In Treatment-naïve Patients (pts) From STARTMRK at Wk 156 - (09/22/11)
     
  183. ICAAC: Rilpivirine (TMC278) tolerability over the first 12 weeks of treatmentin the Phase III ECHO and THRIVE studies - (09/22/11)
     
  184. ICAAC: Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified Autologous CD4 T-cells (SB-728-T) to Aviremic HIV-infected Subjects with Suboptimal CD4 Counts (200-500 cells/mm3) - (09/22/11)
     
  185. ICAAC: Safety, Efficacy, and Pharmacokinetics of Ibalizumab in Treatment-Experienced HIV-1 Infected Patients: a Phase 2b Study - (09/22/11)
     
  186. ICAAC: The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers - (09/21/11)
     
  187. ICAAC: Recruiting Young LA Gays for HIV Survey by Social-Networking App - Written by Mark Mascolini (09/21/11)
     
  188. ICAAC: ART-HCV Protease Inhibitor BI-201335 Interactions - (09/21/11)
     
  189. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women - (09/21/11)
     
  190. ICAAC: Sangamo HIV Gene Therapy Data Reported at ICAAC Sept 19 2011 - (09/21/11)
     
  191. ICAAC: The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers - (09/21/11)
     
  192. ICAAC: (New BI Integrase Inhibitor) Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers - (09/21/11)
     
  193. ICAAC: BI 224436, a Non-Catalytic Site Integrase Inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1 - (09/21/11)
     
  194. ICAAC: Pharmacodynamics of BI 224436 for HIV-1 in an in vitro hollow fiber infection model system - (09/21/11)
     
  195. ICAAC: Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic Site Integrase Inhibitor - (09/21/11)
     
  196. ICAAC: Effect of Cobicistat on Glomerular Filtration Rate in Subjects with Normal and Impaired Renal Function - (09/21/11)
     
  197. ICAAC: HIV Risk Perception Does Not Match PrEP Interest in US Heterosexual Group - (09/21/11)
     
  198. ICAAC: Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort - Written by Mark Mascolini - (09/21/11)
     
  199. ICAAC: Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort - Written by Mark Mascolini - (09/20/11)
     
  200. ICAAC: Randomized Switch From Suppressive PI to Etravirine Safe and Effective - Written by Mark Mascolini - (09/20/11)
     
  201. ICAAC: Insulin Resistance Quadruples Liver Cancer Risk in People With HIV/HCV - Written by Mark Mascolini - (09/20/11)
     
  202. ICAAC: Switching From TDF/FTC to Raltegravir Improves Kidney Markers - Written by Mark Mascolini - (09/20/11)
     
  203. ICAAC: Higher Osteoprotegerin Linked to Lower Atherosclerosis Risk in Men With HIV - Written by Mark Mascolini - (09/20/11)
     
  204. ICAAC: Switching From Atripla to Complera Safe and Effective in 12-Week Study - Written by Mark Mascolini - (09/20/11)
     
  205. ICAAC: Risk of Neurosyphilis With Early Syphilis in German Group With HIV - Written by Mark Mascolini - (09/20/11)
     
  206. ICAAC: PHA Better Than PLA for HIV Facial Atrophy at 96 Weeks, But More Painful - Written by Mark Mascolini - (09/20/11)
     
  207. ICAAC: High Rates of SVR24 for BMS-790052, an NS5A Replication Complex Inhibitor, in Combination With PegIFN-alfa-2a and Ribavirin: Phase 2a Trial in Treatment-Naive HCV Genotype 1 Subjects - (09/19/11)
     
  208. ICAAC: BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients - (09/19/11)
     
  209. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women - (09/19/11)
     
  210. ICAAC: Better 1-Month Safety With Rilpivirine Than Efavirenz in Treatment-Naive - (09/19/11)
     
  211. ICAAC: Switching from Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV-1 Infected Subjects - (09/19/11)
     
  212. ICAAC: Detection of Baseline Resistance and HIV RNA Suppression to Week 48 in the SENSE Trial: Etravirine versus Efavirenz in Treatment Naïve Participants - (09/19/11)
     
  213. ICAAC: PI and 3-Class Resistance Drop Sharply in Monogram Database: 2003-2010 - Written by Mark Mascolini - (09/19/11)
     
  214. ICAAC: "Ultradeep" Detection of Pretreatment Mutations Has Little Impact on Long-Term PI (Reyataz/r) Response - Written by Mark Mascolini - (09/19/11)
     
  215. ICAAC: One Penicillin Dose as Good as Three for Early Syphilis in Men With HIV - Written by Mark Mascolini - (09/19/11)
     
  216. ICAAC: Adding Maraviroc May Reduce Liver Stiffness in People With HCV and HIV - Written by Mark Mascolini - (09/19/11)
     
  217. ICAAC: Some Lipids Improve With Switch From ABC/3TC to TDF/FTC, HIV Control Rates Similar - Written by Mark Mascolini - (09/19/11)
     
  218. ICAAC: Resistance Rates and Patterns Similar With Extended- and Immediate-Release Nevirapine - Written by Mark Mascolini - (09/19/11)
     
  219. ICAAC: Hospital Rate Lower With Atripla Than Other Combos in Medicaid Patients - Written by Mark Mascolini - (09/19/11)
     
  220. ICAAC: Delayed HIV Care Persists in Chicago Minorities Years After CDC Screening Advice - Written by Mark Mascolini - (09/19/11)
     
  221. ICAAC: Chicago Hospital Study Finds 11+ HIV Prescribing Errors Per 100 Patient-Days - Written by Mark Mascolini - (09/19/11)
     
  222. ICAAC: Gender or Race Does Not Affect Raltegravir Response in Diverse Group - Written by Mark Mascolini - (09/19/11)
     
  223. ICAAC: Dropping Inactive NRTI Does Not Compromise 4- or 5-Drug Salvage Combos - Written by Mark Mascolini - (09/19/11)
     
  224. ICAAC: "Selective Advantage" Analysis Sees Low Risk of Cross-Resistance With Dolutegravir - Written by Mark Mascolini - (09/19/11)
     
  225. ICAAC: Zinc Finger-Modified CD4-Cell Booster Transplant Working in Pilot Trial - Written by Mark Mascolini - (09/19/11)
     
  226. ICAAC: Pretreatment Mutations Do Not Affect Etravirine or Efavirenz Response in SENSE - Written by Mark Mascolini - (09/19/11)
     
  227. ICAAC: Large Sample Analysis Confirms Impact of Known Rilpivirine Mutations - Written by Mark Mascolini - (09/19/11)
     
  228. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons - (09/09/11)
     
  229. Hepatitis delta in HIV-infected individuals in Europe - (09/07/11)
     
  230. The Brittleness of Aging Bones - more than a Loss of Bone mass - (09/07/11)
     
  231. First study to quantify benefits of exercise on CHD risk Dose Response Between Physical Activity (15/day, 150, 300, 750-week minutes) and Risk of Coronary Heart Disease [reduced 14-25%] - (09/07/11)
     
  232. Menopause Role in Heart Risk Disputed (see editorial, full text below) - (09/07/11)
     
  233. HIV-Infection of Human Astrocytes Disrupts Blood-Brain Barrier Integrity by a Gap Junction-Dependent Mechanism - (09/07/11)
     
  234. Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of "Heart Positive," a Randomized, Controlled Trial - (09/07/11)
     
  235. Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus Raltegravir in Treatment-Naive HIV-1-infected Patients (ACTG A5262) - (09/07/11)
     
  236. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults - (09/06/11)
     
  237. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy: "initiation of CART as early as possible might reduce the risk of developing HAND, the most common source of NPI among HIV-infected individuals" - (09/06/11)
     
  238. Phase 2 double-blind, randomised trial of etravirine versus efavirenz in treatment-naive patients: 48 week results - (09/06/11)
     
  239. Cholesterol Lowering Diet Foods Reduce LDL-Cholesterol by 14% - (08/24/11)
     
  240. Coronary Calcium Better than CRP to Stratify Risk - (08/20/11)
     
  241. Even Short Workout (15 minutes) Could Extend Life Expectancy - (08/19/11)
     
  242. Minimum amount (15 minutes) of physical activity for reduced mortality and extended life expectancy: a prospective cohort study - (08/19/11)
     
  243. Editorial - Survival benefit associated with low-level physical activity: "the direct health benefits of exercise are irrefutable. Exercise can reduce cardiovascular mortality and, in particular, coronary mortality by many mechanisms, including improvements in endothelial function, autonomic tone, inflammation, and risk-factor control" - (08/19/11)
     
  244.  Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy - (08/19/11)
     
  245. Cardiovascular Disease Risk in Pediatric HIV: The Need for Population-Specific Guidelines/for HIV-infected children - (08/18/11)
     
  246. Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy - (08/17/11)
     
  247. Depression Increases Stroke Risk in Older Women - (08/15/11)
     
  248. HIV Cure Discovery: Functional HIV Cure in Rhesus Macaque Monkey Can Be Model for Humans - (08/15/11)
     
  249. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease - (08/15/11)
     
  250. Phase 2 Study of Cobicistat versus Ritonavir each with Atazanavir plus Fixed-Dose Emtricitabine/Tenofovir DF in the Initial Treatment of HIV Infection - (08/06/11)
     
  251. Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients: statins improve mortality - (08/04/11)
     
  252. IAS: Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents (6 to <18 years): Week 24 primary analysis of the Phase II PIANO study - (08/04/11)
     
  253. IAS: The MONET trial: Week 144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA <50 copies/mL at baseline - (08/04/11)
     
  254. IAS: The SENSE trial: Final 48-week analysis of etravirine (ETR) versus efavirenz (EFV) in treatment-naïve patients - (08/04/11)
     
  255. IAS: Long-term safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in ARTEMIS - (08/04/11)
     
  256. IAS: STEAL Study 2 Yrs Followup: Tenofovir Speeds BMD Loss vs Abacavir, But Does Not Raise Fracture Risk Over 2 Years Followup; Lower Fat Mass Also Predicts Bone Loss - written by Mark Mascolini - (08/01/11)
     
  257. IAS: HIV Complications & It's Treatment, Opportunistic Infections, New ART Drugs, Preventing HIV Transmission: IAS. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome 17-20 July, 2011 Written by Pablo Tebas, MD University of Pennsylvania. - (08/01/11)
     
  258. Relative Muscle Mass Is Inversely Associated with Insulin Resistance and Prediabetes. Findings from The Third National Health and Nutrition Examination Survey - (08/01/11)
     
  259. IAS: Women With HIV Have Lower Mortality Than Men in Europe, But Not in North America - written by Mark Mascolini - (08/01/11)
     
  260. IAS: Bone Loss Boosts Cardiovascular Risk 77% in French Aquitaine Cohort - written by Mark Mascolini - (08/01/11)
     
  261. IAS: Kidney Risk & ARTs in Aquitaine Cohort - written by Mark Mascolini - (08/01/11)
     
  262. IAS: HIV Prevention Report at IAS 2011 by Jared Baeten, MD & Connie Cellum, MD - (08/01/11)
     
  263. IAS: High Rates of Airflow Obstruction, Emphysema in Heavy-Smoking Spanish Group: average age 45...37% emphysema...marijuana doubled risk - (07/29/11)
     
  264. The Effect of Vitamin D on Falls: A Systematic Review and Meta-Analysis - (07/28/11)
     
  265. IAS: Microbial Translocation and Hepatitis C Disease Progression among HIV-infected Women - (07/27/11)
     
  266. IAS: Efficacy of maraviroc administered once-daily or twice-daily with boosted protease inhibitors to treatment-experienced patients - (07/27/11)
     
  267. IAS: 48 Week Results of Once-Daily Maraviroc (MVC) 150 mg in Combination with Ritonavir-Boosted Atazanavir (ATV/r) Compared to Emtricitabine/Tenofovir (FTC/TDF) + ATV/r in Treatment-Naïve Patients Infected with R5 HIV-1 (Study A4001078) - (07/27/11)
     
  268. IAS: Biomarkers Predict Hepatic Flares and Death in Hepatitis-Coinfected People Starting ART - written by Mark Mascolini - (07/26/11)
     
  269. IAS: Age, Race, Gender--But Not HIV--Tied to Hearing Loss in HIV+ People - written by Mark Mascolini - (07/26/11)
     
  270. IAS: Short-Term ART After Early Infection Does Not Delay AIDS or Death - written by Mark Mascolini - (07/26/11)
     
  271. IAS: Virologic Failure Rate Plummets From 31% to 5% in France From 1997 Through 2009 - written by Mark Mascolini - (07/26/11)
     
  272. IAS: Progressive Histological Liver Improvement After SVR in HCV/HIV Coinfected Patients Using Transient Elastography (Fibroscan) - (07/25/11)
     
  273. IAS: Temporal Trends in Liver-Related Mortality in a Prospective Cohort of HIV-Infected Patients in Spain 1997-2008: HCV/HIV Coinfected Death Rates Increase While Rates Decline Among HCV-/HIV+ - (07/25/11)
     
  274. IAS: Sustained Efficacy and Tolerability of Raltegravir after 240 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients: Final Analysis of Protocol 004 - (07/25/11)
     
  275. IAS: DIONE - 24 week efficacy, safety, tolerability and pharmacokinetics of DRV/r QD in treatment-na·ve adolescents, 12 to <18 years - (07/25/11)
     
  276. IAS: Cognitive Impairment Persists: Prevalence and risk factors for HIV associated neurococognitive disorders (HAND), 1996 to 2010: results from an observational cohort - (07/25/11)
     
  277. IAS: Prevalence and risk factors for HIV associated neurococognitive disorders (HAND), 1996 to 2010: results from an observational cohort - (07/25/11)
     
  278. IAS: Doubled Rate of Nonmelanoma Skin Cancer With HIV in California Comparison - written by Mark Mascolini - (07/24/11)
     
  279. IAS: Minority species resistance (Ultra-Deep Sequencing) present at screening does not affect outcomes at Week 48 in lersivirine (UK-453,061) Phase 2b study A5271015 in treatment-naïve patients - (07/24/11)
     
  280. IAS: Efficacy and safety of lersivirine vs efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: Week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase 2b trial (Study A5271015) - (07/23/11)
     
  281. IAS: More Than 25% in HIV-Positive SUN Study Cohort Have Insulin Resistance - written by Mark Mascolini - (07/22/11)
     
  282. IAS: CD4 Gains on cART Lower AIDS/Death Risk Even With High Starting CD4 Count - written by Mark Mascolini - (07/22/11)
     
  283. IAS: TDF/FTC PrEP Durable in MSM, But MSM and Transgender Responses Differ - written by Mark Mascolini - (07/22/11)
     
  284. IAS: Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004-2008 - (07/23/11)
     
  285. IAS: Safety Profile of Dolutegravir (DTG, S/GSK1349572), a Next Generation Integrase Inhibitor (INI) in Combination Therapy in Antiretroviral (ART)-naïve and ART-experienced Adults from Phase 2b Studies - (07/23/11)
     
  286. IAS: Switching from ABC/3TC to TDF/FTC Trims Risk of Virologic Failure - written by Mark Mascolini - (07/22/11)
     
  287. IAS: SWIFT Study: Switching From Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF) - (07/22/11)
     
  288. Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men --- New York City, 2005--2010 - (07/22/11)
     
  289. IAS: ViiV 'Next Generation' Integrase Dolutegravir, 48 Weeks SPRING-1 Study Naives - (07/21/11)
     
  290. IAS: First-Line Once-Daily Maraviroc Plus ATV/r Versus Triple Therapy - written by Mark Mascolini - (07/20/11)
     
  291. IAS: A Look Back at Once-Daily 150-mg Maraviroc for Experienced in MOTIVATE Trials - written by Mark Mascolini - (07/20/11)
     
  292. IAS: Frailty Rate in HIV+ mid-50 Women Matches Rate in 70-Year-Olds Without HIV - written by Mark Mascolini - (07/20/11)
     
  293. IAS: Heart Disease Signal and Low Femoral Density Linked in People With HIV - written by Mark Mascolini - (07/20/11)
     
  294. IAS: Elvitegravir Not Inferior to Raltegravir in Treatment-Experienced: Phase 3 - written by Mark Mascolini - (07/20/11)
     
  295. IAS: Tobira Therapeutics Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults - (07/20/11)
     
  296. IAS: IAS: PrEP Results Surprised Researchers - (07/20/11)
     
  297. IAS: Elvitegravir Once Daily is Non-Inferior to Raltegravir Twice Daily in Treatment-Experienced Patients: 48 Week Results From a Phase 3 Multicenter, Randomized Double-Blind Study - (07/20/11)
     
  298. IAS: Natural controllers of HIV infection are susceptible to immune perturbations similar to those associated with normal aging - implications for women aging with HIV infection - (07/20/11)
     
  299. IAS: Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults - (07/20/11)
     
  300. IAS: Interaction of Vascular and Bone Disease in HIV Infected Patients: Coronary Artery Calcification is associated with femoral but not lumbar spine mineral density - (07/19/11)
     
  301. IAS: Atazanavir Without Ritonavir as Simpler Maintenance: 144-Week ARIES Results - written by Mark Mascolini - (07/19/11)
     
  302. IAS: Late HIV Diagnosis Raises ICU Admission Rate 5 Times in London Group - written by Mark Mascolini - (07/19/11)
     
  303. IAS: Two More Randomized Trials Show that Daily TDF/FTC Protects From HIV - written by Mark Mascolini - (07/19/11)
     
  304. IAS: Good Kidney and Liver Transplant Results in Large Study of People With HIV - written by Mark Mascolini - (07/19/11)
     
  305. IAS: Slow Drop in HIV Neurocognitive Disorder in Italian HIV Cohort: 'cognitive impairment persists in HIV-positive people.....' - written by Mark Mascolini - (07/19/11)
     
  306. IAS: Rilpivirine (TMC278) vs Efavirenz at 96 Weeks in Antiretroviral Naive - written by Mark Mascolini - (07/19/11)
     
  307. IAS: Lersivirine, a New NNRTI, Versus Efavirenz as First-Line Therapy: 48 Weeks - written by Mark Mascolini - (07/19/11)
     
  308. IAS: Similar 48-Week Response Rates With New Integrase Inhibitor and Efavirenz in Naives - written by Mark Mascolini - (07/19/11)
     
  309. IAS: Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents - written by Mark Mascolini - (07/18/11)
     
  310. IAS: Brain-Breaching Antiretroviral Score Not Tied to Neuropsych Function in Canada - written by Mark Mascolini - (07/18/11)
     
  311. IAS: Antiretroviral Therapy Lowers HIV Transmission Risk in HIV+/HIV- Couples: "96% reduction in HIV transmission risk to an HIV-negative partner..... definitive proof of the concept that antiretroviral therapy lowers the risk HIV transmission" - written by Mark Mascolini - (07/18/11)
     
  312. IAS: Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents - (07/18/11)
     
  313. Immediate ART No Better Than Deferred in Asian Kids With Moderate CD4 Loss ! - Written by Mark Mascolini - (07/17/11)
     
  314. TMC278, Rilpivirine: 2 Phase 3 Studies ECHO/THRIVE Published & Commentary pdfs attached - (07/17/11)
     
  315. Intl Wrkshp Advrse Reactions & Comorbids HIV: Metabolic Risk Factors in Responders to Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, in HIV-Infected Patients with Excess Abdominal Fat - (07/17/11)
     
  316. Intl Wrkshp Advrse Reactions & Comorbids HIV: Bone Mineral Density (BMD) Analysis in Antiretroviral (ART)-Naïve Subjects Taking Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS Study - (07/17/11)
     
  317. Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary Cells - pdf attached - (07/13/11)
     
  318. Neurocognitive Impact of Substance Use in HIV Infection - (07/13/11)
     
  319. New MRI Protocol Refines CAD Risk Assessment - full text pdf publication attached - (07/13/11)
     
  320. CT Scan Detects Silent CV Risk (coronary calcium buildup) - (07/12/11)
     
  321. A Frailty-Related Phenotype Before HAART Initiation as an Independent Risk Factor for AIDS or Death After HAART Among HIV-Infected Men - pdf attached - (07/05/11)
     
  322. Human Immunodeficiency Virus Infection of Human Astrocytes Disrupts Blood-Brain Barrier Integrity by a Gap Junction-Dependent Mechanism - (07/05/11)
     
  323. Senescent phenotypes and telomere lengths of peripheral blood T-cells mobilized by acute exercise in humans - (07/05/11)
     
  324. Aging, Persistent Viral Infections, and Immunosenescence: Can Exercise ''Make Space''? - (07/05/11)
     
  325. Int'l Wrkshp HIV & HCV Resist & Curative Strategies: Report on the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies - June 7- 11, Cabo, Mexico - (06/30/11)
     
  326. Int'l Wrkshp HIV & HCV Resist & Curative Strategies: International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies - June 7- 11, Cabo, Mexico - (06/30/11)
     
  327. Mitochondria are sensors for HIV drugs - (06/28/11)
     
  328. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway - (06/28/11)
     
  329. HIV Itself Causes Mitochondrial Damage - (06/28/11)
     
  330. Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors - (06/28/11)
     
  331. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations - (06/27/11)
     
  332. (AZT Shortens Telomerase)Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines - (06/27/11)
     
  333. (AZT Shortens Telomerase) The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena - (06/27/11)
     
  334. Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study - (06/27/11)
     
  335. Increases in T Cell Telomere Length in HIV Infection after Antiretroviral Combination Therapy for HIV-1 Infection Implicate Distinct Population Dynamics in CD4+ and CD8+ T Cells - (06/27/11)
     
  336. T cell activation predicts carotid artery stiffness among HIV-infected women - (06/27/11)
     
  337. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis - (06/21/11)
     
  338. Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected Patients - (06/20/11)
     
  339. Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Women in the United States - (06/20/11)
     
  340. Elevated triglycerides and risk of MI in HIV-positive persons, the D:A:D study - (06/20/11)
     
  341. IL-32 and HIV Persistence - (06/20/11)
     
  342. HIV Reservoir Size - (06/20/11)
     
  343. Risk of cerebrovascular events in persons with and without HIV: A Danish nationwide population-based cohort study - (06/17/11)
     
  344. Vitamin D and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis - (06/17/11)
     
  345. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study: Vit D levels associated with HIV progression & mortality - (06/13/11)
     
  346. Premature aging seen as issue for AIDS survivors - (06/13/11)
     
  347. Increased Metabolic Rate May Lead to Accelerated Aging - (06/10/11)
     
  348. Sirtuins, Aging, and Medicine - (06/10/11)
     
  349. (Vitamin D Guidelines) Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline - (06/09/11)
     
  350. 'Exercise Cuts Stroke Risk in Elderly' - (06/09/11)
     
  351. Non-AIDS-Defining Malignancies in HIV-1-Infected Patients Receiving Combination Antiretroviral Therapy (ATHENA Cohort): "Cumulative exposure to CD4+ cell counts <200 cells/mm3 during cART was associated with an increased risk of infection-related non-AIDS-defining malignancies." - (06/01/11)
     
  352. High Calcium Intake No Better for Bone Health - full text pdf below - (05/25/11)
     
  353. Men Who Have Sex With Men, Risk Behavior, and HIV Infection: Integrative Analysis of Clinical, Epidemiological, and Laboratory Databases - (05/25/11)
     
  354. Past as Prologue: The Refractory and Evolving HIV Epidemic Among Men Who Have Sex With Men editorial - (05/25/11)
     
  355. Increasing Clarity on Bone Loss Associated With Antiretroviral Initiation - editorial - (05/24/11)
     
  356. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women - (05/24/11)
     
  357. Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 - pdf attached - (05/24/11)
     
  358. Researchers Develop Molecular (gene therapy) Microbicide Protection Against HIV Infection: put gene therapy into CD4s in mice & this prevented HIV transmission - (05/23/11)
     
  359. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up - pdf attached Original Article - (05/21/11)
     
  360. Calcium supplements and cardiovascular risk - 2 Letters To Editor (response below) - (05/21/11)
     
  361. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals: 'and to CD4 change after starting ART' - pdf attached - (05/19/11)
     
  362. Low Vitamin D Levels Seen in Parkinson's Patients - full text of study below - - (05/19/11)
     
  363. Vitamin D Status of HIV-Infected Women and Its Association with HIV Disease Progression, Anemia, and Mortality: "Women in the highest vitamin D quintile had a 42% lower risk of all-cause mortality, compared to the lowest quintile. Vitamin D status had a protective association with HIV disease progression, all-cause mortality" - (05/19/11)
     
  364. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons - (05/18/11)
     
  365. Cancer survivorship and sexual orientation - pdf attached - (05/11/11)
     
  366. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors - pdf attached - (05/10/11)
     
  367. Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy - pdf attached - (05/10/11)
     
  368. Could we - should we - calculate a risk exposure score for an HIV-negative individual in a serodiscordant couple? Editorial Comment - (05/09/11)
     
  369. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients - (05/09/11)
     
  370. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007 - (05/09/11)
     
  371. Prostate cancer risk (and Metabolics) in the Swedish AMORIS study - pdf attached - (05/09/11)
     
  372. Metabolic risk factors in prostate cancer - Editorial - (05/09/11)
     
  373. Vaginal Microbicide Gel New NNRTI for Delivery of IQP-0528, a Pyrimidinedione Analog with a Dual Mechanism of Action against HIV-1 - pdf attached - (05/09/11)
     
  374. Bisphosphonate Use and Atypical Fractures of the Femoral Shaft - (05/07/11)
     
  375. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure - (05/04/11)
     
  376. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? - (05/02/11)
     
  377. HIV Infection Ups Heart Failure Risk: "rate of incident heart failure was 7.12 per 1,000 person-years among those with HIV and 4.82 per 1,000 person-years in the rest of the cohort.....But the risk was not seen if baseline and recent HIV levels were less than 500 copies/mL" - (04/26/11)
     
  378. Wrkshp Clin Pharm HIV: 12th International Workshop on Clinical Pharmacology of HIV Therapy Report by Courtney Fletcher, PharmD - Courtney V. Fletcher, Pharm.D. - (04/26/11)
     
  379. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment - - (04/23/11)
     
  380. Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality - 'more profound inflammatory state in those HIV-HCV patients with decompensated cirrhosis....inflammation predicts mortality in these patients' - (04/23/11)
     
  381. Raltegravir in Salvage: Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors - (04/23/11)
     
  382. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection - (04/23/11)
     
  383. Peripheral neuropathy (persists) in HIV: prevalence and risk factors - (04/23/11)
     
  384. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment - - (04/23/11)
     
  385. Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality - 'more profound inflammatory state in those HIV-HCV patients with decompensated cirrhosis....inflammation predicts mortality in these patients' - (04/23/11)
     
  386. Raltegravir in Salvage: Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors - (04/23/11)
     
  387. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection - (04/23/11)
     
  388. Peripheral neuropathy (persists) in HIV: prevalence and risk factors - (04/23/11)
     
  389. How TRIM5 fights HIV - pdf attached - (04/20/11)
     
  390. Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice: HIV invades CNS within 1-2 weeks after infection, progressive viral infection correlated with loss of neuronal integrity. - pdf attached - (04/20/11)
     
  391. Wrkshp Clin Pharm HIV: Food and Fat Have Little Impact on Dolutegravir, a New Integrase Inhibitor - written by Mark Mascolini - (04/18/11)
     
  392. Wrkshp Clin Pharm HIV: Once-Daily 150-mg Maraviroc Explored in People Taking Atazanavir/Ritonavir - written by Mark Mascolini - (04/18/11)
     
  393. Wrkshp Clin Pharm HIV: Lopinavir Troughs Lower in Children on Once-Daily Dose Plus Efavirenz - written by Mark Mascolini - (04/18/11)
     
  394. Wrkshp Clin Pharm HIV: Atazanavir Levels Indicate Need for Higher Dose During Pregnancy - written by Mark Mascolini - (04/18/11)
     
  395. Wrkshp Clin Pharm HIV: Four-in-One Drug Affects Levels of Oral Contraceptives Components - written by Mark Mascolini - (04/18/11)
     
  396. Wrkshp Clin Pharm HIV: Older Age May Slow Clearance of Once-Daily Darunavir, Which Penetrates Cells Well - written by Mark Mascolini - (04/18/11)
     
  397. Wrkshp Clin Pharm HIV: Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily - written by Mark Mascolini - (04/18/11)
     
  398. Wrkshp Clin Pharm HIV: Impact of Stomach Acid Reducers on Cobicistat and Elvitegravir - written by Mark Mascolini - (04/18/11)
     
  399. Wrkshp Clin Pharm HIV: Levels of Novel HIV Attachment Inhibitor With or Without Ritonavir - (04/15/11)
     
  400. Wrkshp Clin Pharm HIV: Half-Dose Lamivudine Not Equivalent to Full Dose in Plasma or Cells - (04/15/11)
     
  401. Wrkshp Clin Pharm HIV: HIV Infection Affects Cellular Pharmacology of Zidovudine and Lamivudine: 3TC for prevention - (04/15/11)
     
  402. Wrkshp Clin Pharm HIV: Cobicistat Has Little Impact on Key Drug-Metabolizing Enzymes - (04/14/11)
     
  403. Wrkshp Clin Pharm HIV: No Dolutegravir (GSK572, integrase) Dose Adjustment Needed With Efavirenz or Tipranavir/Ritonavir - (04/14/11)
     
  404. Distribution of cancers in the HIV/AIDS population is shifting; New study finds a decrease in AIDS-defining cancers, offset by an increase in other cancers - pdf attached - (04/13/11)
     
  405. Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission - pdf attached - (04/13/11)
     
  406. Distribution of cancers in the HIV/AIDS population is shifting; New study finds a decrease in AIDS-defining cancers, offset by an increase in other cancers - pdf attached - (04/12/11)
     
  407. CROI: Inflammation and Intervention: how does HIV cause AIDS and how does it cause disease despite ART - David Margolis, MD University of North Carolina - (04/11/11)
     
  408. CROI: Vitamin D3 Supplementation Decreases Parathyroid Hormone (PTH) in HIV-Infected Youth Being Treated with Tenofovir-Containing Combination Antiretroviral Therapy: Randomized, Double-blind, Placebo-controlled Multicenter Trial Adolescent Trials Network (ATN) study 063 - (03/29/11)
     
  409. CROI: No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis - (03/29/11)
     
  410. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues - (03/29/11)
     
  411. "Test and Treat": Is It Enough? - (03/28/11)
     
  412. The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection - (03/28/11)
     
  413. No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT - (03/28/11)
     
  414. CROI: Risk of Fractures Associated with HIV/Hepatitis C Coinfection - (03/28/11)
     
  415. CROI: Bone and Vitamin D at CROI 2011 - By Todd T. Brown, MD, PhD - (03/26/11)
     
  416. CROI: Changes in Body Composition after Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir in Virologically Suppressed HIV-1-Infected Patients (SPIRAL-LIP substudy) - (03/26/11)
     
  417. CROI: Bone & HIV CROI 2011 - (03/26/11)
     
  418. CROI: COMPREHENSIVE LIPID EVALUATION IN PATIENTS SWITCHING FROM RITONAVIR BOOSTED PROTEASE INHIBITOR (PI/r)-BASED TO RALTEGRAVIR-BASED ANTIRETROVIRAL THERAPY: THE SPIRAL-met SUBSTUDY - (03/26/11)
     
  419. CROI: Antiretroviral CNS Penetration-Effectiveness (CPE) 2010 ranking predicts CSF viral suppression only in patients with undetectable HIV-1 RNA in plasma - (03/24/11)
     
  420. CROI: Early HAART in TB-Treated Patients Recommended in 2 Studies at CROI for Patients with <50 CD4s - (03/24/11)
     
  421. CROI: Turnover Following Viral Control Correlates with Markers of Microbial Translocation in Treatment-Naïve Patients Receiving Raltegravir (RAL)- based Antiretroviral Therapy (ART): Preliminary Results from ACTG A5248 - (03/24/11)
     
  422. CROI: CD4 Nadir Drives Persistence of Monocytes and T Lymphocytes Activation in Virologically Suppressed HIV-infected Patients - (03/24/11)
     
  423. CROI: Biomarkers of Inflammation, Coagulation and Monocyte Activation Are Strongly Associated with the VACS Index among Veterans on cART - (03/24/11)
     
  424. Quantification of Coronary Atherosclerosis and Inflammation to Predict Coronary Events and All-Cause Mortality J Am Coll Cardiol, March 29 2011 - (03/23/11)
     
  425. Calcium and C-Reactive Protein Hot Enough to Predict the Future? - (03/23/11)
     
  426. CROI: Bone Loss in HIV-Negatives in PrEP Study: 'a surprising percent of HIV-neg MSM had low bone mineral density before starting TDF, drug use associated with bone mineral density loss - vitamin D/calcium supplementation was protective'; in some HIV+ persons low BMD likely predated HIV-infection....in summary Kathy Mulligan said "it is not known whether there will be any long-term clinically important effects of PrEP with TDF/3TC (Truvada) on bone health" - (03/23/11)
     
  427. CROI: CROI 2011 Immunology Report - written by David Margolis, MD, University of North Carolina (03/22/11)
     
  428. CROI: BMD Loss in HIV TDF PrEP - 2 studies - (03/22/11)
     
  429. CROI: Advances in PrEP - (03/22/11)
     
  430. CROI: Adding Maraviroc Does Not Boost CD4s or Quiet T-Cell Activation - written by Mark Mascolini - (03/22/11)
     
  431. CROI: Risk of Stage 1 AIDS Dementia 12% Over 2 Years in Asymptomatic People - written by Mark Mascolini - (03/22/11)
     
  432. CROI: Sustained Response to Anti-HCV Therapy Higher During Acute Infection in HIV Positives - written by Mark Mascolini - (03/22/11)
     
  433. CROI: Boceprevir Boosts Sustained Virologic Response Rate With HCV Genotype 1 - written by Mark Mascolini - (03/22/11)
     
  434. CROI: Boceprevir Improves SVR With PegIFN/RBV After Failure or Relapse With HCV-1 - written by Mark Mascolini - (03/22/11)
     
  435. Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients: "MVC achieves concentrations within the EC90 range in CSF. All patients with undetectable plasma viral load although receiving nucleoside-sparing regimens including new drugs showed viral suppression in CSF." - (03/21/11)
     
  436. CROI: US Youngsters Start Antiretrovirals Late and Stop Early in HIV Research Network - written by Mark Mascolini - (03/21/11)
     
  437. CROI: HIV Affects Brain Immediately After Infection with HIV RNA in the CSF & Inflammation & Brain Injury Continues Unfolding During Chronic Infection & There is a Need for Routine Monitoring - (03/21/11)
     
  438. CROI: Lowest CD4 Count Below 200, by Itself, Raises Heart Disease Risk With HIV: HIV Is a Risk Factor for Heart Disease - (03/21/11)
     
  439. CROI: HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors - (03/21/11)
     
  440. CROI: High incidence rate of HCV reinfection after treatment of acute HCV infection in HIV-infected MSM in Amsterdam - (03/21/11)
     
  441. CROI: Therapeutic Darunavir and Etravirine Concentrations in Cerebrospinal Fluid - (03/21/11)
     
  442. CROI: Early Clearance of HCV RNA in HCV Genotype 1 Treatment-naïve Patients Treated with Telaprevir, Peginterferon and Ribavirin: Pooled Analysis of the Phase 3 Trials ADVANCE and ILLUMINATE - (03/21/11)
     
  443. CROI: Trunk and Visceral Fat Gains With Atazanavir & Efavirenz in ACTG A5224s - written by Mark Mascolini - (03/20/11)
     
  444. CROI: Vitamin D Supplements May Limit Tenofovir Bone Toxicity - written by Mark Mascolini - (03/20/11)
     
  445. CROI: Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members - (03/19/11)
     
  446. CROI: Comprehensive Lipid Evaluation in Patients Switching from PI/r-based cART to a RAL-based cART: The SPIRAL Substudy - (03/19/11)
     
  447. CROI: US Youngsters Start Antiretrovirals Late and Stop Early in HIV Research Network - written by Mark Mascolini - (03/19/11)
     
  448. CROI: On-Treatment Viral Loads Fell Steadily Since 1997 in Large US-Canadian Analysis: diaparities for Blacks & IDUs - written by Mark Mascolini - (03/19/11)
     
  449. CROI: Minocycline Does Not Improve HIV-Associated Neurocognitive Disorder - written by Mark Mascolini - (03/19/11)
     
  450. CROI: Early Brain Injury Visualized in People With Recent HIV Infection - written by Mark Mascolini - (03/19/11)
     
  451. CROI: Carotid Atherosclerosis Is Related to HIV Duration and Anti-inflammatory Profile and Not to ARV Exposure: The CHIC Controlled Study - (03/17/11)
     
  452. CROI: D-dimer Levels Correlate with Inflammatory and Endothelial Activation Markers in HIV-infected Adults - (03/17/11)
     
  453. CROI: (NIH Study) Circulating Markers of Endothelial Dysfunction, Coagulation and Tissue Fibrosis Prior to Incident Venous Thromboembolism in Patients with HIV Infection - (03/17/11)
     
  454. CROI: Kinetics of Platelet Counts following Interruption of ART: Results from the SMART Study (coagulation pathways, HIV replication itself or inflammation) - (03/17/11)
     
  455. CROI: Switch and Stop Rates 25% and 12% in First ART Year in 18-Cohort Study - written by Mark Mascolini - (03/17/11)
     
  456. CROI: ATN 083: Longitudinal Changes in Cardiovascular Risk Markers among HIV Infected and at Risk Adolescents: "Endothelial dysfunction as measured by sVCAM-1 is higher in HIV+ adolescents than HIV- individuals" - (03/16/11)
     
  457. CROI: Endothelial Dysfunction More Common in HIV-Positive Than Negative Adolescents - written by Mark Mascolini - (03/16/11)
     
  458. CROI: Mortality With Acute Coronary Syndrome Higher in People With HIV - written by Mark Mascolini - (03/15/11)
     
  459. CROI: Coronary Artery Plaque Linked to Low Fat in MACS Men With HIV - written by Mark Mascolini - (03/15/11)
     
  460. CROI: Integrating Integrase Inhibitors and other antiretroviral stories - Joe Eron MD Professor of Medicine; UNC Chapel Hill - (03/15/11)
     
  461. CROI: The Effect of Low-dose Ritonavir on the Pharmacokinetics of the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/15/11)
     
  462. CROI: Low CD4 Count on Effective HAART is Associated With Immunologic and Vascular Dysfunction - (03/15/11)
     
  463. CROI: Clinical Pharmacology at CROI 2011 (HIV & HCV) - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center (03/14/11)
     
  464. CROI: Viral Load (But Not Antiretrovirals) and HCV Tied to 10-Year Fracture Risk: fracture risk higher in HIV+ vs HIV-neg - written by Mark Mascolini - (03/14/11)
     
  465. CROI: Survival After Cancer Diagnosis Improves in US HIV Cohort: 'Incidence (new diagnoses) of AIDS cancers dropped, as did incidence of non-AIDS infection-related cancers. But incidence of non-AIDS cancers not related to infection rose since the arrival of triple antiretroviral therapy' - written by Mark Mascolini - (03/14/11)
     
  466. CROI: Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/r) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/r) help explain limited loss of bone mineral density over first 12 months after antiretroviral therapy (ART) initiation (03/14/11)
     
  467. CROI: Firstline HAART Causes Bone Loss (03/14/11)
     
  468. CROI: Glycated Hemoglobin A1C as Screening for Diabetes Mellitus in HIV Infected Individuals (03/13/11)
     
  469. CROI: Update on the "cure" and metabolic complications - written by Pablo Tebas MD University of Pennsylvania (03/13/11)
     
  470. CROI: LOW BONE MASS IN BEHAVIORALLY HIV-INFECTED YOUNG MEN ON ANTIRETROVIRAL THERAPY: Adolescent Trials Network (ATN) Protocol 021B (03/13/11)
     
  471. CROI: HAART-induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS (03/13/11)
     
  472. CROI: Changes in Bone Biomarkers in ARV-naïve HIV+ Men Randomized to NVP/LPV/r or AZT/3TC/LPV/r Help Explain Limited Loss of Bone Mineral Density over the First 12 Months after ART Initiation (03/13/11)
     
  473. CROI: Recombinant Interleukin-7 (CYT107) Expands CD4 T Cells in Peripheral Blood and Gut Mucosa of Chronically HIV-Infected Immunological Non-Responder Patients (03/13/11)
     
  474. Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000-2006 - pdf attached - (03/12/11)
     
  475. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection (SMART Study): - pdf attached - (03/12/11)
     
  476. CROI: Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks (03/12/11)
     
  477. CROI: Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 datafrom the randomized, double-blind, Phase III ECHO and THRIVE trials (03/12/11)
     
  478. Mediterranean [and exercise] Diet Helps Prevent Metabolic Syndrome, Abdominal Obesity, Elevated Lipids, Hypertension - pdf attached - (03/11/11)
     
  479. CROI: Bone Effects of Rosiglitazone in HIV-Infected Patients with Lipoatrophy (03/11/11)
     
  480. CROI: Recombinant IL-7 Expands CD4 T Cells in Peripheral Blood and Gut Mucosa of Chronically HIV-infected Immunological Non-responder Patients (03/11/11)
     
  481. CROI: Chronic Inflammation and HIV: CROI 2011 - David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine (03/10/11)
     
  482. HIV and Cancer in Germany - pdf attached - (03/10/11)
     
  483. CROI: Nutritional Intervention with NR100157 Restores Gut Microbiota in HIV-1-infected Adults Not on HAART and Reduces Systemic Immune Activation (03/10/11)
     
  484. CROI: Prompt, Significant Reduction of Activation and Proliferation Markers in CD4+ and CD8+ T Cell Subsets despite Incomplete Viral Suppression: Proof-of-Concept for AV-HALT-A New Class of Anti-HIV Therapeutics Inhibiting Both HIV Replication and Immune Activation (03/10/11)
     
  485. CROI: Immunomodulatory Effects of Hydroxychloroquine in HIV-Infected ART-Treated Immunological Non Responders: 'reduces inflammation & activation' (03/10/11)
     
  486. CROI: HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors (03/10/11)
     
  487. CROI: Diabetes Mellitus in Treated HIV-Infected Patients: Incidence over Ten Years in 1,046 patients from the ANRS CO8 APROCO-COPILOTE Cohort (03/10/11)
     
  488. CROI: Invasive Anal Cancer Seen With Relatively High CD4s and Low HIV Loads - written by Mark Mascolini - (03/9/11)
     
  489. CROI: Statins May Lower Risk of non-Hodgkin Lymphoma in People With HIV - written by Mark Mascolini - (03/9/11)
     
  490. CROI: Earlier Occurrence of the Frailty Phenotype in HIV-1-infected Men than in HIV-uninfected Men in the Multicenter AIDS Cohort Study (MACS) - (03/9/11)
     
  491. CROI: Prevalence and Prognostic Factors of Chronic Kidney Disease in HIV-infected Patients, HIV-NAT 006 Cohort, Thailand: "high prevalence of advanced chronic kidney disease...more diabetes/hypertension" - pdf attached - (03/9/11)
     
  492. CROI: Aging and Non-HIV-associated Co-morbidity in HIV+ Persons: The SHCS - pdf attached - (03/9/11)
     
  493. CROI: Microbial Translocation (MT)-induced Immune Activation Associates to Atherosclerosis in cART treated HIV pos Patients - (03/9/11)
     
  494. CROI: Immunologic Failure Despite Suppressive ART Is Related to Increased Inflammation and Evidence of Microbial Translocation and Inflammation & Activation Persist Even Despite Immune Success - (03/9/11)
     
  495. CROI: Renal Insufficiency among HIV-infected, ART-naïve Individuals in Lilongwe, Malawi: Implications for Tenofovir use in antiretroviral treatment and prevention of mother to child transmission programs. - (03/9/11)
     
  496. CROI: Earlier Occurrence of the Frailty Phenotype in HIV+ Men than in HIV- Men: The MACS - (03/9/11)
     
  497. CROI: Renal Insufficiency, Nephrotoxicity, and Mortality among HIV-infected Adults on TDF in a South African Cohort: A Marginal Structural Models Analysis - pdf attached - (03/9/11)
     
  498. CROI: Cystain C - 'Lipid Particle Concentrations and Markers of Renal Disease: SMART' - Unfavorable lipoprotein levels were associated with elevated cystatin C levels, but not with impaired eGFR. Cystatin C may better detect earlier reductions in kidney function - (03/9/11)
     
  499. CROI: Changing Patterns of Causes of Death in the Swiss HIV Cohort Study (SHCS) 2005-2009 - (03/9/11)
     
  500. CROI: QDMRK, A Phase III Study of the Safety & Efficacy of Once Daily (QD) Versus Twice Daily (BID) Raltegravir (RAL) in Combination Therapy for Treatment-Naïve HIV-Infected Patients (Pts) - (03/9/11)
     
  501. CROI: CROI 2011 Report Selected Topics - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine - (03/8/11)
     
  502. CROI: Telapravir Promotes Early Clearance of HCV RNA With PEG-IFN/RBV, Early Response Predicts Outcome (weeks 1,2,4) - written by Mark Mascolini - (03/8/11)
     
  503. CROI: Fibrosis Predicts Renal Trouble With Tenofovir in HIV/HBV-Coinfected - written by Mark Mascolini - (03/8/11)
     
  504. CROI: Liver Death Rate Twice Higher With HBV Than HCV in Gay HIV+ Men of MACS - written by Mark Mascolini - (03/8/11)
     
  505. CROI: HIV, Black Race, and Multiple Partners Raise Risk of Repeat Syphilis in California Gays - written by Mark Mascolini - (03/8/11)
     
  506. CROI: CD4 Decline Before ART Faster in More Recent Years in ATHENA Cohort: "may have implications for planning on when to start cART." - written by Mark Mascolini - (03/8/11)
     
  507. CROI: The Kidney at CROI - Christina M. Wyatt, MD Assistant Professor, Medicine Nephrology Mount Sinai School of Medicine New York, NY - (03/8/11)
     
  508. CROI: HIV Prevention at CROI 2011 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/8/11)
     
  509. CROI: Steady-state pharmacokinetic parameters of nevirapine extended release formulation tablets in children with HIV-1 infection: an open-label, multiple-dose, cross-over study - (03/7/11)
     
  510. CROI: Raltegravir (RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile Through 3 Years of Treatment (Tx): 156 Week (Wk) Results from STARTMRK - (03/7/11)
     
  511. CROI: Change in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults Receiving TMC278 Compared with Efavirenz: 48-week Results from the Phase III ECHO Trial - (03/7/11)
     
  512. CROI: The Effect of Bimonthly Supplementation with Oral Cholecalciferol and Calcium on 2 Year Bone Mass Accrual in HIV-infected Children and Adolescents - (03/7/11)
     
  513. CROI: Renal Impairment in Patients Receiving a TDF-based cART Regimen: Impact of TDF Concentration? - (03/7/11)
     
  514. CROI: Central Fat Accumulation in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a Substudy of ACTG A5202 - (03/7/11)
     
  515. CROI: Decreased Limb Muscle and Increased Central Adiposity Are Associated with 5-Year All-cause Mortality in HIV Infection - (03/7/11)
     
  516. CROI: Predictors of Chronic Kidney Disease in the SMART trial - (03/7/11)
     
  517. Safety Review update of Abacavir: no statistically significant association seen between myocardial infarction and ABC - (03/05/11)
     
  518. CROI: Maraviroc 300mg Once Daily + Darunavir/Ritonavir 800/100mg Once Daily Provides Maraviroc Trough Concentrations Comparable to Trough Concentrations in HIV-1 Patients Taking Maraviroc 300mg Twice Daily + Truvada: Implications for Phase 3 Studies - (03/5/11)
     
  519. Once Daily Administration of Maraviroc Submitted to EMA & FDA - (03/05/11)
     
  520. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy - pdf attached - (03/05/11)
     
  521. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient: 2nd case report - pdf attached - (03/05/11)
     
  522. Commentary Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule - pdf attached - (03/05/11)
     
  523. CROI: Genotypic Analysis of Cellular HIV V3 DNA to Predict Virologic Response to Maraviroc: Performance of Population-based and 454 Deep V3 Sequencing - (03/5/11)
     
  524. CROI: Gut-associated Lymphoid Tissue Fibrosis Is Associated with CD4+ T Cell Activation and Poor HIV-specific CD8+ T cell Responses During Suppressive Antiretroviral Therapy - (03/5/11)
     
  525. CROI: Impaired Endothelial Function Is Associated with Increased Frequencies of CCR5+ and HIV-specific T cells During Treated HIV Infection - (03/5/11)
     
  526. CROI: The Immunomodulatory Effects of Maraviroc Intensification among ART-suppressed Patients with Incomplete CD4 Recovery - (03/5/11)
     
  527. CROI: Antiretroviral Therapy Initiation during Acute/Early HIV Infection vs. Later ART Initiation is Associated with Improved Immunologic and Virologic Parameters during Suppressive ART - (03/5/11)
     
  528. CROI: Predicting maraviroc responses according to number or percentage of X4-using virus among treatment-experienced patients - (03/4/11)
     
  529. CROI: Neuroprotective MVC Monotherapy in SIV-infected Macaques - (03/4/11)
     
  530. CROI: Relative performance of ESTA, Trofile, 454 deep sequencing and "reflex" testing for HIV tropism in the MOTIVATE screening population of therapy experienced patients - (03/4/11)
     
  531. CROI: Interrupted Antiretrovirals Raise Chronic Kidney Disease Risk 50% in SMART - written by Mark Mascolini - (03/4/11)
     
  532. CROI: New Integrase Inhibitor Controls Toughest Raltegravir-Resistant Virus - written by Mark Mascolini - (03/4/11)
     
  533. CROI: Diabetes Incidence in People With HIV Falling Since 1999-2000 in France - written by Mark Mascolini - (03/4/11)
     
  534. CROI: Male-Female and White-Black ART Disparities Persist in US - written by Mark Mascolini - (03/4/11)
     
  535. CROI: Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks - written by Mark Mascolini - (03/4/11)
     
  536. CROI: Post-Menopausal Women Have increased HIV transmission risk and Higher TDF Blood Levels - (03/3/11)
     
  537. CROI: Creating an HIV-resistant Immune System: Using CXCR4 ZFN to Edit the Human Genome - (03/3/11)
     
  538. CROI: Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference - (03/2/11)
     
  539. CROI: Telaprevir + Peginterferon and Ribavirin: phase 2a study in coinfected patients on HAART Reported at CROI March 2 2011 - (03/2/11)
     
  540. CROI: Interim Analysis of Phase 2a Study of Telaprevir + Peginterferon/Ribavirin in HCV/HIV Coinfected Patients - (03/2/11)
     
  541. CROI: GSK1349572 Integrase in Raltegravir Resistant Patients - (03/2/11)
     
  542. CROI: GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir Disoproxil Fumarate During 14 Days of Monotherapy in HIV-1 Infected Subjects - (03/2/11)
     
  543. CROI: Diabetes and cIMT Linked to Worse Neurocognitive Performance With HIV written by Mark Mascolini - (03/2/11)
     
  544. CROI: Poor CD4 Response Despite Undetectable Load Marked by Vascular and T-Cell Dysfunction written by Mark Mascolini - (03/2/11)
     
  545. CROI: Vitamin D3 Supplements May Thwart Diabetes Emergence in People With HIV written by Mark Mascolini - (03/2/11)
     
  546. CROI: Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks written by Mark Mascolini - (03/2/11)
     
  547. CROI: Duration of PIs or NNRTIs Has No Consistent Impact on Non-AIDS Cancer Rates written by Mark Mascolini - (03/2/11)
     
  548. CROI: Low Limb Muscle, High Visceral Fat Double 5-Year Risk of Death in US Cohort written by Mark Mascolini - (03/2/11)
     
  549. CROI: Vitamin D Boost Does Not Improve Endothelial Function With HIV written by Mark Mascolini - (03/2/11)
     
  550. CROI: FDA Trial Meta-Analysis Does Not See Higher MI Risk With Abacavir written by Mark Mascolini - (03/2/11)
     
  551. CROI: Cancer Risk Remains High for People Who Had AIDS as a Child written by Mark Mascolini - (03/2/11)
     
  552. CROI: Sangamo's Gene Therapy for HIV is Safe, Helps Immune Cells in Early Trial - (03/2/11)
     
  553. CROI: Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions - (03/2/11)
     
  554. CROI: Pharmacokinetic Interactions Between Antiretroviral Agents and the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/2/11)
     
  555. CROI: Lower "Community Viral Load" in SF Linked to Fewer New HIV Cases written by Mark Mascolini - (03/1/11)
     
  556. CROI: Higher Fracture Rate With HIV + HCV Than With Either Virus Alone written by Mark Mascolini - (03/1/11)
     
  557. CROI: Intensification With Raltegravir Has No Impact on Reservoir of Replicating Virus written by Mark Mascolini - (03/1/11)
     
  558. CROI: Viral Load and CD4 Changes With Ritonavir-Boosted and Unboosted Attachment Inhibitor written by Mark Mascolini - (03/1/11)
     
  559. CROI: HIV Duration, Not ART, Tied to Atherosclerosis Marker in Large Case-Control Study written by Mark Mascolini - (03/1/11)
     
  560. CROI: Black Race Tied to Virologic Failure in ACTG Trials--But Blacks Gained More CD4s written by Mark Mascolini - (03/1/11)
     
  561. CROI: Lower CD4 Count Before ART Tied to Higher Risk of Three Non-AIDS Diseases written by Mark Mascolini - (03/1/11)
     
  562. CROI: In Gay Men Over 50, Frailty More Common With HIV Than Without (MACS) written by Mark Mascolini - (03/1/11)
     
  563. CROI: Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, a Potentially First-in-Class Oral HIV Attachment Inhibitor - (03/1/11)
     
  564. High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial - pdf attached - (02/26/11)
     
  565. Statins as Anti-inflammatory Therapy in HIV Disease? Editorial - pdf attached - (02/26/11)
     
  566. The Dual Impact of HIV-1 Infection and Aging on Naïve CD4+ T-Cells: Additive and Distinct Patterns of Impairment - From the Multicenter AIDS Cohort - (02/26/11)
     
  567. Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial - pdf attached - (02/18/11)
     
  568. Testosterone Treatment of Older Men-Why Are Controversies Created? Editorial - (02/18/11)
     
  569. Do the Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, And Quality of Life Persist Six Months after Treatment in Intermediate-Frail and Frail Elderly Men? - pdf attached - (02/18/11)
     
  570. Why Is Androgen Replacement in Males Controversial? - CLINICAL REVIEW- pdf attached - (02/18/11)
     
  571. HIV Regimens Similar but Not Equivalent - ACTG5202 efavirenz vs Reyataz/r + TDF/FTC or abacavir/3TC - (02/17/11)
     
  572. Weighing the Benefits and Costs of HPV Vaccination of Young Men Perspective - (02/14/11)
     
  573. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males - pdf attached - (02/14/11)
     
  574. Gardasil in Older Women Aged 24-45 yrs old - (02/14/11)
     
  575. HAART Reduces HPV - (02/14/11)
     
  576. HIV CareLink newsletter for HIV/AIDS Primary Care Providers (Florida/Caribbean AIDS Education and Training Center - (02/14/11)
     
  577. Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection - pdf attached - (02/14/11)
     
  578. 'HIV Exposure Harms Infant Immunity' Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants - pdf attached - (02/14/11)
     
  579. Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis - pdf attached - (02/14/11)
     
  580. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression - pdf attached - (02/14/11)
     
  581. FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women - (02/12/11)
     
  582. Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period - (02/12/11)
     
  583. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry - pdf attached - (02/12/11)
     
  584. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death - pdf attached - (02/12/11)
     
  585. Associations between microalbuminuria and animal foods, plant foods, and dietary patterns in the Multiethnic Study of Atherosclerosis - pdf attached - (02/06/11)
     
  586. Association of Dietary Patterns With Albuminuria and Kidney Function Decline in Older White Women: A Subgroup Analysis From the Nurses' Health Study - pdf attached - (01/26/11)
     
  587. HIV Infection, Inflammation, Immunosenescence, and Aging - pdf attached - (02/06/11)
     
  588. 1st Int. Workshop on HIV & Aging Published REPORT pdf attached. 4 -5 October 2010, Baltimore, USA - (01/27/11)
     
  589. Bone Mineral Density and Testicular Failure: Evidence for a Role of Vitamin D 25-Hydroxylase in Human Testis - pdf attached - (01/27/11)
     
  590. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - pdf attached - (01/27/11)
     
  591. What Do We Tell Our Patients about Calcium and Vitamin D Supplementation? EDITORIAL pdf attached - (01/27/11)
     
  592. New Research Finds HIV causes rapid aging in key infection-fighting cells: "Successful ART treatment does not fully reconstitute the CD31-CD4+ naive T-cell subset"- pdf attached - (01/27/11)
     
  593. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients - pdf attached - (01/24/11)
     
  594. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy - pdf attached - (01/24/11)
     
  595. Increasing incidence of ischemic stroke in patients with HIV infection: HIV, HAART, metabolics, median age 50, absolute numbers small - pdf attached - (01/20/11)
     
  596. Gender, South, Race Affect Health Outcomes in HIV: - (01/19/11)
     
  597. 1st Intrnl Wrkshp HIV & Women: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/ritonavir (ATV/r) Once Daily Given in Combination With Twice Daily AZT/3TC During Pregnancy: Results of Study AI424182 - (01/19/11)
     
  598. 1st Intrnl Wrkshp HIV & Women: Reyataz During Pregnancy - written by Mark Mascolini - (01/16/11)
     
  599. Triple antiretroviral prophylaxis during pregnancy and breastfeeding is safe and reduces the risk of HIV transmission to infants. pdf attached - (01/16/11)
     
  600. 1st Intrnl Wrkshp HIV & Women: Efficacy, Safety and Tolerability of Lopinavir/ritonavir (LPV/r) in HIV-Infected Women: Results of a Meta-Analysis of 7 Prospective, Randomized Clinical Trials (RCTs) Through 48 Weeks - (01/15/11)
     
  601. 1st Intrnl Wrkshp HIV & Women: RNA and CD4 Response to Lopinavir Similar in Women and Men in 7-Trial Analysis - written by Mark Mascolini - (01/14/11)
     
  602. 1st Intrnl Wrkshp HIV & Women: Sex Transmission: Defining Mucosal Immune Factors That Stymie HIV Remains Tough Job - written by Mark Mascolini - (01/14/11)
     
  603. 1st Intrnl Wrkshp HIV & Women: Registry Sees No Increased Overall Birth Defect Risk With First-Trimester Antiretrovirals - written by Mark Mascolini - (01/11/11)
     
  604. 1st Intrnl Wrkshp HIV & Women: Low Bone Density Not Linked to Lipodystrophy in Small Group of Canadian Women (see report from Workshop below) - written by Mark Mascolini - (01/11/11)
     
  605. Low Vitamin D among HIV-Infected Adults: Prevalence of and Risk Factors for Low Vitamin D Levels in a Cohort of HIV-Infected Adults and Comparison to Prevalence among Adults in the US General Population - pdf attached (this was presented in poster at CROI) - (01/14/11)
     
  606. The Effect of Antiretrovirals on Vitamin D - pdf attached - (01/14/11)
     
  607. HIV & Aging Slide Talk CME - (01/12/11)
     
  608. Immune Activation & HCV-Infection: Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection - pdf attached - (01/12/11)
     
  609. Fractures In Aging >50 Yrs Old: associated with antiepileptic drugs, comorbidities, hypertension osteoprotective - pdf attached - (01/12/11)
     
  610. 1st Intrnl Wrkshp HIV & Women: Trough Levels of Four Key Antiretroviral Higher in Women Than General Population - written by Mark Mascolini - (01/11/11)
     
  611. 1st Intrnl Wrkshp HIV & Women: Women Report Better Quality-of-Life Gains Than Men in GRACE Trial of Darunavir - written by Mark Mascolini - (01/11/11)
     
  612. 1st Intrnl Wrkshp HIV & Women: Gender Not Linked to Liver Disease Progression in HIV/HCV+ Canadians - written by Mark Mascolini - (01/11/11)
     
  613. 1st Intrnl Wrkshp HIV & Women: Association of Sex and Race with Health-related Quality of Life in Patients Treated with Darunavir/ritonavir-based Therapy in the GRACE (Gender, Race And Clinical Experience) Trial - (01/12/11)
     
  614. 1st Intrnl Wrkshp HIV & Women: Switch to Opt-Out HIV Screening Promotes Testing in Women of Washington, DC - (01/11/11)
     
  615. 1st Intrnl Wrkshp HIV & Women: Half of HIV-Positive Women in Ontario Survey Have Unintended Pregnancies - (01/11/11)
     
  616. 1st Intrnl Wrkshp HIV & Women: ART Response and Rebound Worse in Female IDUs Than Male IDUs - (01/11/11)
     
  617. Liver Disease (ALTs/Fatty Liver) a Possible Predictor of Stroke - (01/11/11)
     
  618. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort - pdf attached - (01/11/11)
     
  619. Eradication/CNS Penetration: 'Eradication of HIV from the brain: reasons for pause' - pdf attached - (01/11/11)
     
  620. Immune Senescence & Activation Associated with Heart Disease in HIV+ editorial - (01/11/11)
     
  621. T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women - pdf attached - (01/11/11)
     
  622. Aging with HIV: As HIV population grows older, diseases of aging are a new dilemma New Aging Study/Clinic at SFGH - (01/08/11)
     
  623. Male circumcision and HPV transmission to female partners - Editorial - (01/08/11)
     
  624. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda - pdf attached - (01/08/11)
     
  625. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml - published pdf attached - (01/08/11)
     
  626. Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study - pdf attached - (01/07/11)
     
  627. Inflammation (lipodystrophy) Associated with Physical Performance Decline - (01/05/11)
     
  628. Gait speed was associated with survival in older adults - (01/05/11)
     
  629. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease - published pdf attached - (01/03/11)
     
  630. Inflammation & Kidney Disease - (01/03/11)
     
  631. Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl: kidney anti-inflammation drug - (01/03/11)
     
  632. Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease - press release - (01/03/11)
     
  633. 'Urinary Protein & Albumin Both Predict Mortality & Renal Outcomes' - Comparison of Urinary Albumin and Urinary Total Protein as Predictors of Patient Outcomes in CKD - (01/03/11)
     
  634. Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates - published pdf attached - (12/30/10)
     
  635. Preventing Cancer in HIV+: keep CD4 >700 & viral load undetectable, start HAART Early, control inflammation - (12/30/10)
     
  636. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  637. The Steady State Pharmacokinetics (PK) of Atazanavir/Ritonavir (ATV/RTV) During Pregnancy in HIV+ Women - (12/22/10)
     
  638. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
     
  639. Patterns of neonatal bilirubin following atazanavir/ritonavir (ATV/r) treatment of mothers during pregnancy: clinical and pharmacogenetic factors identified in study AI424182 - (12/19/10)
     
  640. Editorial NeuroAIDS review - pdf attached - (12/22/10)
     
  641. Brain Research Urged in Paper in AIDS: "HIV-1 infection and cognitive impairment in the cART-era: a review" - "studies....report abnormal scores on neuropsychological assessments in 15 - 50% of patients.....clinical course should be followed closely in large cohorts of patients.....promising therapies should be studied" - published pdf attached - (12/22/10)
     
  642. Association of Higher Levels of High-Density Lipoprotein Cholesterol in Elderly Individuals and Lower Risk of Late-Onset Alzheimer Disease - pdf attached - (12/22/10)
     
  643. Relationship between Vitamin D, Parathyroid Hormone, and Bone Health (vit D insufficiently defined)- publication pdf attached - (12/22/10)
     
  644. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
     
  645. Alternate Marker (Cystatin C) Picks Out High-Risk CKD Patients - published text below, pdf attached - (12/19/10)
     
  646. Lipoatrophy/Metabolics & Genetics: European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142 - pdf attached - (12/19/10)
     
  647. Mitochondrial damage in adipose tissue of untreated HIV-infected patients - publication pdf attached - (12/19/10)
     
  648. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations - publication pdf attached - (12/19/10)
     
  649. Update on U.S. Prescribing Information for ZERIT (stavudine) - (12/19/10)
     
  650. Capsid: New Class of HIV Drugs - (12/14/10)
     
  651. Testosterone Deficiency and Replacement in Older Men - Editorial - (12/09/10)
     
  652. Adverse Events Associated with Testosterone Administration - publication pdf attached - (12/09/10)
     
  653. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study: 40-83% Neuro Impaired/33% asymptomatic/low nadir cd4 predicts/comorbidities contribute - published pdf attached - (12/08/10)
     
  654. The persistence of HIV-associated neurocognitive dysfunction and the effects of comorbidities - Editorial - (12/08/10)
     
  655. Insulin metabolism and the risk of Alzheimer disease - full txt from Neurology below pdf attached - (12/05/10)
     
  656. 10th Congress Drug Therapy HIV: Nevirapine Versus Ritonavir-Boosted Atazanavir CombinedWith Tenofovir/ Emtricitabine in First-LineTherapy: NEWART 48-Week Data - (12/05/10)
     
  657. Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System - published pdf attached - (12/02/10)
     
  658. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - publication pdf attached - (12/02/10)
     
  659. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study - pdf attached - (12/01/10)
     
  660. mtDNA Damage & Heart Disease/End Organ Disease: Role of Pyrimidine Depletion in the Mitochondrial Cardiotoxicity of Nucleoside Analogue Reverse Transcriptase Inhibitors - pdf attached - (12/01/10)
     
  661. A randomized crossover study to compare efavirenz and etravirine treatment - pdf attached - (12/01/10)
     
  662. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine - published pdf attached - (12/01/10)
     
  663. Surgical correction of HIV-associated facial lipoatrophy - publication pdf attached - (12/01/10)
     
  664. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort - pdf attached - (12/01/10)
     
  665. Merck Reports Initial Results of Phase III Study of ISENTRESS® (raltegravir) Investigational Once-Daily Dosing in Treatment-Naïve Adult Patients Infected with HIV-1 - (11/30/10)
     
  666. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men - publication pdf attached - (11/29/10)
     
  667. Oral Preexposure Prophylaxis for HIV - Another Arrow in the Quiver? Editorial - (11/29/10)
     
  668. Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection - published pdf attached - (11/29/10)
     
  669. The Lesser-Known Complications (Bone) of HIV/AIDS (aging, complications) - (11/29/10)
     
  670. Telomerase reverses ageing process (full text; published pdf attached) - (11/29/10)
     
  671. 10th Congress Drug Therapy HIV: Analysis of BENCHMRK-1&2 Using PhenoSense Assay for Darunavir (DRV/r) Resistance and Exploration of Functional Monotherapy with RAL vs DRV - (11/29/10)
     
  672. 10th Congress Drug Therapy HIV: 48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) (2) - (11/22/10)
     
  673. Race/ethnic differences in bone mineral densities in older men - pdf attached - (11/21/10)
     
  674. Kidney Transplants in HIV+ Study published in NEJM: Tackling the Unknowns in HIV-Related Kidney Diseases/Editorial - full published study follows editorial below - pdf attached - (11/21/10)
     
  675. 10th Congress Drug Therapy HIV: 48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) - (11/18/10)
     
  676. 10th Congress Drug Therapy HIV: Population and Ultra-Deep Sequencing for Tropism Determination Are Correlated With Trofile-ES. Genotypic Re-Analysis of the A4001078 Maraviroc Study - (11/18/10)
     
  677. 10th Congress Drug Therapy HIV: No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects - (11/18/10)
     
  678. 10th Congress Drug Therapy HIV: The 10-Year Safety and Efficacy of Tenofovir DF (TDF)-Containing HAART in Antiretroviral Naïve Patients - (11/18/10)
     
  679. 10th Congress Drug Therapy HIV: Adherence to Antiretroviral Treatment Regimens and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States - (11/18/10)
     
  680. 10th Congress Drug Therapy HIV: The 5 Year Safety and Efficacy of the Once-Daily Antiretroviral-Naïve Patient Regimen of Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) - (11/18/10)
     
  681. 10th Congress Drug Therapy HIV: Adherence to Antiretroviral Treatment Regimens and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States - (11/18/10)
     
  682. 10th Congress Drug Therapy HIV: Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) Plus EFV Leads to Improved Perceptions of Treatment: Results from the ROCKET 1 Study - (11/18/10)
     
  683. 10th Congress Drug Therapy HIV: New Nonnucleoside Retains Activity Against Some Virus Resistant to Etravirine - (11/18/10)
     
  684. 10th Congress Drug Therapy HIV: Activity of Integrase Inhibitor, S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Week 24 Results of VIKING Study (ING112961) - (11/17/10)
     
  685. 10th Congress Drug Therapy HIV: PK/PD Modeling Supports Dose Escalation Decision in VIKING (50 mg twice-daily for highly raltegravir resistant patients) - (11/17/10)
     
  686. 10th Congress Drug Therapy HIV: Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile (activity vs etravirine resistance) - (11/17/10)
     
  687. 10th Congress Drug Therapy HIV: Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc, Zidovudine and Lamivudine (CBV) in Treatment-Naive Patients - (11/17/10)
     
  688. 10th Congress Drug Therapy HIV: Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc in Treatment-Naive Patients - (11/17/10)
     
  689. 10th Congress Drug Therapy HIV: Once-Daily S/GSK1349572 Combination Therapy in Antiretroviral-Naïve Adults: Rapod and Potent 24-Week Antiviral Responses on SPRING-1 Antiviral Responses - (11/17/10)
     
  690. 10th Congress Drug Therapy HIV: The SENSE trial: Etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients - (11/16/10)
     
  691. 10th Congress Drug Therapy HIV: Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE - (11/16/10)
     
  692. 10th Congress Drug Therapy HIV: Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the Phase III ECHO and THRIVE trials - (11/16/10)
     
  693. 10th Congress Drug Therapy HIV: Neuropscyh Side Effect Rate Lower With Etravirine Than Efavirenz at 12 Weeks - Written by Mark Mascolini - (11/15/10)
     
  694. 12th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Comparison of Bone and Renal Toxicities in the ASSERT Study: Final 96-Week Results From a Prospective Randomised Safety Trial - (11/15/10)
     
  695. 10th Congress Drug Therapy HIV: METABOLIK: Week 48 Comparison of Metabolic Parameters and Biomarkers in Subjects Receiving Darunavir/ritonavir or Atazanavir/ritonavir - (11/15/10)
     
  696. 10th Congress Drug Therapy HIV: Switching from Kivexa (KVX) + Efavirenz (EFV) to Atripla (ATR) Reduces Total Cholesterol in Hypercholesterolemic Subjects: Final Results of a 24-week, Randomised Study - (11/15/10)
     
  697. 10th Congress Drug Therapy HIV: Pooled Week 48 safety and efficacy results from the ECHO and THRIVE Phase III trials comparing TMC278 vs efavirenz in treatment-naïve HIV-1-infected patients - (11/15/10)
     
  698. 10th Congress Drug Therapy HIV: European Panel Recommends Either Geno (g2p) or Pheno (ESTA) for Tropism Testing - Written by Mark Mascolini - (11/12/10)
     
  699. 10th Congress Drug Therapy HIV: New S/GSK Integrase Inhibitor Looks Good at 24 Weeks in Phase 2 Trial - Written by Mark Mascolini - (11/12/10)
     
  700. 10th Congress Drug Therapy HIV: Higher AIDS and non-AIDS Rates With Uncontrolled HIV Despite CD4s Over 350 - Written by Mark Mascolini - (11/12/10)
     
  701. 10th Congress Drug Therapy HIV: Major and Minor PI Mutations in MONET Darunavir Monotherapy Trial - Written by Mark Mascolini - (11/12/10)
     
  702. 10th Congress Drug Therapy HIV: Vitamin D Deficiency in EuroSIDA Linked to All-Cause Mortality and AIDS - Written by Mark Mascolini - (11/12/10)
     
  703. 10th Congress Drug Therapy HIV: Long-Term T-cell Changes With Maraviroc in Four Randomized Trials - Written by Mark Mascolini - (11/12/10)
     
  704. 10th Congress Drug Therapy HIV: Adding Maraviroc Does Not Boost CD4s in Randomized Trial - Written by Mark Mascolini - (11/12/10)
     
  705. 10th Congress Drug Therapy HIV: Pretreatment Coreceptor Preference Affects Virologic Response in Naive - Written by Mark Mascolini - (11/12/10)
     
  706. 10th Congress Drug Therapy HIV: Atazanavir/RTV Stopped Less Than Other Key First-Line Drug in Large French Analysis - Written by Mark Mascolini - (11/12/10)
     
  707. 10th Congress Drug Therapy HIV: Muscle Weakness or Pain Analyzed as Possible Raltegravir Side Effect - Written by Mark Mascolini - (11/12/10)
     
  708. 10th Congress Drug Therapy HIV: Switch to Twice-Daily Unboosted Atazanavir Outdoes Switch to Once-Daily Dose - Written by Mark Mascolini - (11/12/10)
     
  709. 10th Congress Drug Therapy HIV: Switching From ABC/3TC to TDF/FTC Cuts Lipids in Randomized Trial - Written by Mark Mascolini - (11/12/10)
     
  710. 10th Congress Drug Therapy HIV: Dual Combo of Darunavir/Ritonavir and Etravirine Assessed in London Clinic - Written by Mark Mascolini - (11/10/10)
     
  711. 10th Congress Drug Therapy HIV: NRTI Exposure Tied to Age-Linked Mitochondrial DNA Deletions - Written by Mark Mascolini - (11/10/10)
     
  712. 10th Congress Drug Therapy HIV: Anemia in SMART Study Tied to Risk of non-AIDS Disease and Death - Written by Mark Mascolini - (11/10/10)
     
  713. 10th Congress Drug Therapy HIV: Vitamin D Deficiency in HCV/HIV-Coinfected People in the UK - Written by Mark Mascolini - (11/10/10)
     
  714. 10th Congress Drug Therapy HIV: Differing HCV Response Rates Depending on HIV in Prospective German Cohort - Written by Mark Mascolini - (11/10/10)
     
  715. 10th Congress Drug Therapy HIV:Extensive Three-Class Resistance May No Longer Predict Progression or Death - Written by Mark Mascolini - (11/09/10)
     
  716. 10th Congress Drug Therapy HIV:Darunavir Mutation Rate Dropping in Large Clinical Sample Survey - Written by Mark Mascolini - (11/09/10)
     
  717. 10th Congress Drug Therapy HIV:More Drugs in Regimen--Not Just More Pills--Hurt Adherence - Written by Mark Mascolini - (11/09/10)
     
  718. 10th Congress Drug Therapy HIV:PI MONOTHERAPY - Darunavir Monotherapy Equivalent to Triple Therapy in Meta-Analysis - Written by Mark Mascolini - (11/09/10)
     
  719. 10th Congress Drug Therapy HIV:Switch From Suppressive PI to Abacavir Combo Not Effective in French Cohort Study - Written by Mark Mascolini - (11/09/10)
     
  720. 10th Congress Drug Therapy HIV:Small But Significant CD4 Gains When Switching Antiretrovirals With Sub-50 Load - Written by Mark Mascolini - (11/09/10)
     
  721. 10th Congress Drug Therapy HIV:One Third in Large UK HIV Survey Have Fractures, 14% of Them Osteoporotic - Written by Mark Mascolini - (11/09/10)
     
  722. 10th Congress Drug Therapy HIV: Lifetime Spine Fracture Risk Greater With Than Without HIV in UK Comparison - Written by Mark Mascolini - (11/08/10)
     
  723. 10th Congress Drug Therapy HIV: Long-Term Resistance Rate Low When Starting ART Within Year of HIV Diagnosis - Written by Mark Mascolini - (11/08/10)
     
  724. 10th Congress Drug Therapy HIV: Good Adherence Lowers Hospital Risk 40% in Insured US Patients With HIV - Written by Mark Mascolini - (11/08/10)
     
  725. FDA and CONRAD Chart U.S. Regulatory Path for 1% Tenofovir Gel for HIV Prevention: FDA has granted Fast Track approval designation for 1% tenofovir gel - (11/01/10)
     
  726. Aspirin to prevent colorectal cancer: time to act? Editorial - (10/28/10)
     
  727. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials - pdf attached - (10/28/10)
     
  728. Calcium & Heart Disease - (10/28/10)
     
  729. Cancer and viral infections in immunocompromised individuals - pdf attached - (10/26/10)
     
  730. Cancer incidence and risk factors after solid organ transplantation - pdf attached - (10/26/10)
     
  731. Excess Mortality for Non-AIDS-Defining Cancers among People with AIDS - (10/22/10)
     
  732. Novel Bone Drug (odanacatib, cathepsin K inhibitor) Found Safe After Four Years - (10/22/10)
     
  733. Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study - pdf attached - (10/22/10)
     
  734. Low Bone Mineral Density with Tenofovir: Does Statistically Significant Mean Clinically Significant? - EDITORIAL COMMENTARY - (10/22/10)
     
  735. Immunosenescence & Aging in HIV - (10/22/10)
     
  736. Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens - pdf attached - (10/22/10)
     
  737. Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV - pdf attached - (10/22/10)
     
  738. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals: does low-level viremia cause non-AIDS comorbidities? - (10/21/10)
     
  739. Mixed Analysis Findings Adds to Evidence of Unusual Bone Fractures and Bisphosphonates - (10/21/10)
     
  740. Early Bone Loss Marker Predicts Fracture Risk Later - (10/21/10)
     
  741. Low-Carb Diets and Mortality - (10/20/10)
     
  742. Teriparatide for Bone Loss in the Jaw - Editorial - (10/19/10)
     
  743. "initiating HAART at higher CD4 cell counts for older individuals may be useful- NA-ACCORD Study" - pdf attached - (10/18/10)
     
  744. Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw - (10/18/10)
     
  745. Teriparatide and Osseous Regeneration in the Oral Cavity - (10/18/10)
     
  746. Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation - (10/18/10)
     
  747. Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation - (10/16/10)
     
  748. Boosting Dose Ritonavir Does Not Alter Peripheral Insulin Sensitivity in Healthy HIV-Seronegative Volunteers - (10/16/10)
     
  749. Biomarkers of impaired renal function - pdf attached - (10/16/10)
     
  750. Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort - pdf attached - (10/16/10)
     
  751. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey - pdf attached - (10/16/10)
     
  752. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study - pdf attached - (10/14/10)
     
  753. Aging Wrkshp: CD4 Counts Lower on Entry Into Care Among People 50 and Older: NA-ACCORD - (10/13/10)
     
  754. ICAAC: A Phase-Ib/IIa dose-escalation study for evaluation of the safety, tolerability, and pharmacokinetics of OBP-601 (4'-ethynyl-d4T, Festinavir) in treatment-experienced, HIV-1-infected patients - (10/13/10)
     
  755. Insulin Resistance a Possible Causal and Treatable Risk Factor for Ischemic Stroke - editorial - pdf attached - full text from original study below - (10/13/10)
     
  756. HCV Neurotoxicity & Inflammation Additive in Brain in HIV+ Person - pdf attached - (10/13/10)
     
  757. Aging Wrkshp: Low Vitamin D Not Linked to Bone Density or Liver Fibrosis in HIV/HCV Group - Written by Mark Mascolini - (10/08/10)
     
  758. Aging Wrkshp: Multiple non-AIDS Diseases More Frequent in Aging IDUs With Versus Without HIV - Written by Mark Mascolini - (10/08/10)
     
  759. Aging Wrkshp: Family History of Dementia Predicts Worse Neuropsych Function With HIV (dementia defined below) - Written by Mark Mascolini - (10/08/10)
     
  760. Severe Hypoglycemia and Risks of Vascular Events and Death - (10/07/10)
     
  761. Aging Wrkshp: Aging HIV+ Hospitalized More Often: Non-AIDS Infections, Heart and GI Disease Explain Most Hospitalizations in Over-50 People With HIV - Written by Mark Mascolini - (10/07/10)
     
  762. Aging Wrkshp: HIV-Infected in 40s Have Multiple Non-HIV Illnesses as Often as HIV-Negatives in 50s - Written by Mark Mascolini - (10/07/10)
     
  763. Aging Wrkshp: Comorbidity Rates Higher in Over-49 HIV Group Than in Matched HIV Negatives - Written by Mark Mascolini - (10/07/10)
     
  764. HIV and Premature Aging: A Field Still in Its Infancy - Editorial: "Age at Cancer Diagnosis Among Persons With AIDS in the United States" (pdf of published study attached) - (10/06/10)
     
  765. Aging Wrkshp: Sexual Function Worse With HIV Than Diabetes or No Chronic Illness in Older Men - Written by Mark Mascolini - (10/06/10)
     
  766. Aging Wrkshp: Older Age, HIV, and Antiretrovirals Linked to Neurodegenerative Marker - Written by Mark Mascolini - (10/06/10)
     
  767. Aging Wrkshp: More Non-HIV Illnesses With HIV Than Without, But Less Treatment; New HCV therapy will add to burden - Written by Mark Mascolini - (10/06/10)
     
  768. Aging Wrkshp: Older Women With HIV Report "Premature Aging" Strikingly More Often Than Men - Written by Mark Mascolini - (10/06/10)
     
  769. Aging Wrkshp: Higher Risk of Potential Drug-Drug Interactions in Toronto HIV Patients Over 60 - Written by Mark Mascolini - (10/05/10)
     
  770. Aging Wrkshp: Lipoatrophy and Efavirenz Tied to Vitamin D Deficiency in Ontario - Written by Mark Mascolini - (10/05/10)
     
  771. Aging Wrkshp: Pretreatment CD4s and CD4/CD8 Ratio Lower in Trial Participants Over 50 - Written by Mark Mascolini - (10/05/10)
     
  772. Aging Wrshp: Age Raises Fracture Risk More in People With Than Without HIV - Written by Mark Mascolini - (10/05/10)
     
  773. The new face of HIV/AIDS in Jacksonville (Black women): Rising disease rates strip away our stereotypes - (10/04/10)
     
  774. ICAAC: ICAAC 2010 Report by David Margolis MD University of North Carolina - (10/04/10)
     
  775. ICAAC: Associations between Protease Inhibitors (PIs) and QTc and PR Interval Durations in the Strategies for Management of Antiretroviral Therapy (SMART) Trial - poster pdf attached - (10/04/10)
     
  776. ICAAC: Association Between Early Virologic Response and Immunologic Outcomes in Raltegravir-treated Patients: "Early vRNA decay is significantly correlated with greater increases in CD4 (absolute and %) change from baseline at Wk 96" - (10/04/10)
     
  777. ICAAC: HIV At ICAAC 2010: Complications & Co-Infections - Written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (09/28/10)
     
  778. Early HAART, Within 6 Months of Infection Preserves Immunity Better Than HAART in Chronic Infection - (09/27/10)
     
  779. Osteoporosis: adherence needs to top two-thirds to cut fracture risk - (09/27/10)
     
  780. Long-term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes Mellitus (this can work in HIV for anyone) - pdf attached - (09/27/10)
     
  781. Diabetes, Alzheimer disease, and vascular dementia: Diabetes at baseline doubled the incidence of dementia, AD, and VaD, and increased mortality - pdf attached - (09/27/10)
     
  782. ICAAC: ICAAC PK Report - (09/26/10)
     
  783. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues - pdf attached - (09/25/10)
     
  784. Body Fat & Bone Loss: lipoatrophy & belly fat accumulation BOTH lead to bone loss - (09/25/10)
     
  785. Bisphosphonates and Reports of Unusual Broken Bones in the Femur (Thigh Bone) - (09/24/10)
     
  786. GRACE Study in HIV+ Women of Color: racial & gender health disparities in HIV - (09/24/10)
     
  787. GRACE Study: Sex-Based Outcomes (88% of women were women of color in the study, 67% black women, so results reflect on needs of black women with HIV in the USA) were of Darunavir-Ritonavir Therapy A Single-Group Trial - pdf attached - (09/24/10)
     
  788. Coronary Aging in HIV-Infected Patients - (09/23/10)
     
  789. Coronary Aging in HIV-Infected Patients: "Increased vascular age was observed in 162 patients (40.5%), with an average increase of 15 years"...."you are 50 years old but your heart's age is 65" - pdf attached - (09/23/10)
     
  790. Immune senescence in aged nonhuman primates Review - (09/23/10)
     
  791. Prevalence and Correlates of Sexual Behavior and Risk Management Among HIV-Positive Adults Over 50 - pdf attached - (09/23/10)
     
  792. Persistence of Racial Differences in Attitudes Toward Homosexuality in the United States.....may help to explain disparities in HIV-infection rates between black & white MSM - pdf attached - (09/23/10)
     
  793. ICAAC: Once-Daily Nevirapine XR Noninferior to Continued Twice-Daily Nevirapine - Written by Mark Mascolini - (09/19/10)
     
  794. ICAAC: Clinical, Virological and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 (09/19/10)
     
  795. ICAAC: Use of Genotypic and Maraviroc (MVC) Clinical Trial Data to Develop Statistical Models for Predicting Response in a Treatment-Naive (TN) Population (09/19/10)
     
  796. ICAAC: 48-week resistance and efficacy subgroup analysis of once- versus twice-daily darunavir/ritonavir in ODIN (09/19/10)
     
  797. ICAAC: Comparison of Quest Diagnostics to Trofile and Trofile-ES Coreceptor Tropism Assays for Predicting Virologic Response to Maraviroc (MVC), a CCR5 Antagonist (09/19/10)
     
  798. ICAAC: Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the MERIT Study (09/19/10)
     
  799. ICAAC: Raltegravir Pharmacokinetics during Pregnancy (09/16/10)
     
  800. ICAAC: Advanced Fibrosis Triples All-Cause Mortality With HCV and HIV - Written by Mark Mascolini - (09/16/10)
     
  801. ICAAC: CCR5 Antagonists Have No Special CD4-Boosting Power in Meta-Analysis (from Jules: I don't buy this) - Written by Mark Mascolini - (09/16/10)
     
  802. ICAAC: Once-Daily Nevirapine Noninferior to Twice-Daily Dose in Treatment Naive - Written by Mark Mascolini - (09/16/10)
     
  803. Ageing and HIV/AIDS (Aging/HIV Clinic in London): A dedicated clinical service for HIV-infected individuals over 50 years of age (09/16/10)
     
  804. Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers - pdf attached - "we recommend a DXA scan for all HIV-infected post-menopausal women and men >50 years" - (09/17/10)
     
  805. ICAAC: 48 Week Efficacy, Pharmacokinetics, and Safety of Once a Day 400 mg Nevirapine (Viramune) Extended Release Formulation for Treatment of Antiretroviral Naïve HIV-1 Infected Patients (09/15/10)
     
  806. ICAAC: Efficacy and Long-Term Safety of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, in Sub-Populations of HIV-Infected Patients with Excess Abdominal Fat (09/15/10)
     
  807. ICAAC: The Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF; "QUAD") Maintains a High Rate of Virologic Suppression, and Cobicistat (COBI) is an Effective Pharmacoenhancer Through 48 Weeks (09/15/10)
     
  808. Development of new HIV drug targeting a cofactor of the cell - Ledgins - Pfizer - pdf attached - (09/15/10)
     
  809. ICAAC: Insulin Resistance Correlates With HCV Load and SVR in HCV/HIV-Coinfected - Written by Mark Mascolini - (09/15/10)
     
  810. ICAAC: GSK New NNRTI Selects No Resistance Mutations in 7 Days of Monotherapy - Written by Mark Mascolini - (09/15/10)
     
  811. ICAAC: Atazanavir Without Ritonavir Sustains Virologic Suppression 120 Weeks in ARIES - Written by Mark Mascolini - (09/15/10)
     
  812. ICAAC: Lipids Drop After Switch From ABC/3TC/Efavirenz to Atripla - Written by Mark Mascolini - (09/15/10)
     
  813. ICAAC: Final Results from Stage 1 of a Double-Blind, Placebo-Controlled Trial with TMC207 in Patients with Multi-Drug Resistant (MDR) Tuberculosis (TB) (09/15/10)
     
  814. ICAAC: Switching from ABC/3TC + Efavirenz [EFV] to TDF/FTC/EFV [Atripla, ATR] Reduces Cholesterol in Hypercholesterolemic Subjects: 24-Week Final Results of a Randomised Study (09/15/10)
     
  815. ICAAC: New GSK761 NNRTI (09/15/10)
     
  816. ICAAC: GSK2248761, an NNRTI with Activity Against Common NNRTI Resistance Mutants, Did Not Select for NNRTI Resistance Mutations in Two 7-Day Monotherapy Studies (09/15/10)
     
  817. ICAAC: TMC-278 Phase 3 ECHO/THRIVE Studies Resistance Profile Rilpivirine - Written by Mark Mascolini - (09/15/10)
     
  818. ICAAC: Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study - press release (09/15/10)
     
  819. ICAAC: Four-Drug Single-Pill Antiretroviral Equivalent to Atripla at 48 Weeks - Written by Mark Mascolini - (09/15/10)
     
  820. ICAAC: High Rates of Bone Loss and Progression With HIV in Longitudinal Study - Written by Mark Mascolini - (09/15/10)
     
  821. ICAAC: Top Integrase Polymorphisms Do Not Confer Resistance to S/GSK1349572 or Raltegravir - Written by Mark Mascolini - (09/15/10)
     
  822. ICAAC: Raltegravir Re-Use Response After Failure Depends on Mutation Pattern - Written by Mark Mascolini - (09/15/10)
     
  823. ICAAC: Long-Term Outcomes Good After Coreceptor Switch in Maraviroc Failure - Written by Mark Mascolini - (09/15/10)
     
  824. ICAAC: Longer Antiretroviral Therapy Favors Return to Normal HDL-C - Written by Mark Mascolini - (09/15/10)
     
  825. ICAAC: Novel Mutations and Shifting Susceptibility to Darunavir and Tipranavir - Written by Mark Mascolini - (09/15/10)
     
  826. ICAAC: Characterization of the resistance profile of TMC278: 48-week analysis of the Phase III studies ECHO and THRIVE - (09/15/10)
     
  827. ICAAC: 24 Wk Efficacy and Safety of Transitioning Virologically Stable HIV-1 Patients from IR Nevirapine 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) - (09/15/10)
     
  828. ICAAC: Induction/Maintenance-Simplification: Sustained Virologic Efficacy of Atazanavir (ATV) Versus Atazanavir/Ritonavir (ATV/r), each in Combination with Abacavir/Lamivudine (ABC/3TC) over 120 Weeks: the ARIES Trial - (09/15/10)
     
  829. ICAAC: TMC-207 New TB Drug from Tibotec - New Drug Speeds Response in MDR TB - (09/15/10)
     
  830. ICAAC: Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study - press release - (09/14/10)
     
  831. ICAAC: Two Doses of Hep A Vaccine in HIV+ Men Equivalent to One Dose in HIV- Men - Written by Mark Mascolini - (09/14/10)
     
  832. ICAAC: Reduction in Visceral Adipose Tissue (VAT) with Tesamorelin Correlates with Changes in Anthropometric, and Patient-Reported Outcome (PRO) Parameters in HIV+ Patients with Excess Abdominal Fat - (09/14/10)
     
  833. ICAAC: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (09/14/10)
     
  834. ICAAC: Vitamin D Deficiency & Bone Loss in Europe - (09/14/10)
     
  835. Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid - published pdf attached - (09/13/10)
     
  836. Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells - (09/13/10)
     
  837. AIDS Cure Quest to Kill 'Sleeping' Viruses Enlists Merck Cancer Medicine - (09/13/10)
     
  838. PARKINSONISM IN HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY - (09/13/10)
     
  839. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort - (09/13/10)
     
  840. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection - pdf attached - (09/13/10)
     
  841. Aging Exacerbates Extrapyramidal Motor Signs in the Era of HAART - (09/13/10)
     
  842. ICAAC: ECG Abnormalities With PIs Versus NNRTIs in SMART Trial - Written by Mark Mascolini - (09/13/10)
     
  843. ICAAC: One Third on First-Line Antiretrovirals Have Clinically Significant Drug Interactions - Written by Mark Mascolini - (09/13/10)
     
  844. ICAAC: Maintenance With Raltegravir/Atazanavir Usually Effective for 48 Weeks (low troughs, a few viral rebounds) - Written by Mark Mascolini - (09/13/10)
     
  845. ICAAC: Staph Rate Falling in HIV+ Danes, But Still High vs General Population - Written by Mark Mascolini - (09/13/10)
     
  846. Microalbuminuria Is Associated With All-Cause and AIDS Mortality in Women With HIV Infection - pdf attached - (09/10/10)
     
  847. New UCSF Anal Cancer Information Website - (09/09/10)
     
  848. Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice - (09/09/10)
     
  849. Oral bisphosphonates and oesophageal cancer - 'evidence inconclusive' Editorial - (09/09/10)
     
  850. Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer - 2nd study 'no difference in risk' - (09/09/10)
     
  851. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers Free, Centralized Resource Designed to Help Overcome Some Barriers to Supportive Care - (09/07/10)
     
  852. Nevirapine Reuse Possible in Exposed Children With HIV - (09/07/10)
     
  853. IAC/Vienna AIDS Conference: Encouraging Advances Amid Funding Worries for Global Treatment - JAMA - (09/07/10)
     
  854. 'Low' viral load depletes CD4s: Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion - pdf attached - (09/07/10)
     
  855. 'hypercholesterol, hypertension, prior CVD associated with poor neurologic performance in SMART' factors: 'reported Increased vascular aging in HIV, inflammation, Hepatitis, immunosenescence, insulin resistance...... - (09/07/10)
     
  856. 'IL28B Predicts SVR in Coinfection, Associated With 2-Fold Higher Rate of SVR' - published pdf attached - (09/07/10)
     
  857. Is It Safe to Discontinue Primary Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/µL? - (08/30/10)
     
  858. High Rates of Asymptomatic Neurocognitive Impairment in Vertically Acquired HIV-1-Infected Adolescents Surviving to Adulthood - (08/29/10)
     
  859. High prevalence of reduced bone mineral density in primary HIV-1-infected men - (08/29/10)
     
  860. CD4 Predicts acute renal failure: Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure - (08/29/10)
     
  861. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses - (08/29/10)
     
  862. Opioid Use & Bone Loss: Prospective study of bone mineral density changes in aging men with or at risk for HIV infection - (08/29/10)
     
  863. IAC: Webcast Complications Plenary at IAC Vienna: The Double-Edged Sword: Long-Term Complications of ART and HIV - (08/29/10)
     
  864. Neurologic disease burden in treated HIV/AIDS predicts survival A population-based study - (08/26/10)
     
  865. Identification of a gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein as a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor - published pdf attached - (08/25/10)
     
  866. Potential HIV Drug Keeps Virus out of Cells: "PIE12-trimer is an entry-inhibitor, has the potential to work as a microbicide to prevent people from contracting HIV and as a treatment for HIV infected people." published study pdf attached - (08/25/10)
     
  867. Development of National and Multiagency HIV Care Quality Measures - (08/19/10)
     
  868. Quality of Care for Patients Infected with HIV - EDITORIAL COMMENTARY - (08/19/10)
     
  869. IAC: IAC Summary on New Drugs and New Combinations - How will They Change What We Do? - Written by Joe Eron, Univ of North Carolina - (08/16/10)
     
  870. IAC: A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Subjects: 48 Week Results - (08/15/10)
     
  871. IAC: Transmission of Integrase Strand-Transfer Inhibitor Multi-drug Resistant HIV: Case Report and Natural History of Response to Raltegravir-containing Antiretroviral Therapy - (08/15/10)
     
  872. IAC: Abacavir/Lamivudine with Fosamprenavir/Ritonavir or Efavirenz in Underrepresented, Antiretroviral-Naïve, HIV-Infected Subjects (SUPPORT): Tolerability, Safety, and Efficacy after 24 Weeks - (08/15/10)
     
  873. HIV and Low CD4 Increases Risk for Heart Disease - (08/13/10)
     
  874. After CAPRISA 004: time to re-evaluate the HIV lexicon - 'oral PrEP has greater likelihood for success' - (08/13/10)
     
  875. Cardiovascular effects of marine omega-3 fatty acids - Review - publication pdf attached - (08/13/10)
     
  876. Cognitive Decline Biomarkers-HIV Studies Needed !!!! - (08/13/10)
     
  877. Plasma β-Amyloid and Cognitive Decline - publication pdf attached - (08/12/10)
     
  878. Raltegravir Intensification Did Not Reduce Residual Viremia PLoS Medicine published - (08/11/10)
     
  879. IAC: SWITCH-EE Study (Swiss-Cohort): A Randomized Cross-over Study to Compare Etravirine and Efavirenz treatment - (08/10/10)
     
  880. IAC: The SENSE Trial: Etravirine (ETR) shows fewer Neuropsychiatric Adverse Events than Efavirenz (EFV) in Treatment-naïve HIV-1 Infected Patients - (08/10/10)
     
  881. Persistent Microbial Translocation and Immune Activation in HIV-1-Infected South Africans Receiving Combination Antiretroviral Therapy - (08/10/10)
     
  882. Can HIV be cured with stem cell therapy? commentary - (08/10/10)
     
  883. IAC: Efficacy of NGX-4010 (QUTENZA), an 8% capsaicin patch, in patients with HIV-associated distal sensory polyneuropathy: results of integrated analyses - (08/10/10)
     
  884. IAC: The SENSE trial: etravirine (ETR) QD shows fewer neuropsychiatric adverse events than efavirenz (EFV) in treatment-naïve HIV-1 infected patients - (08/10/10)
     
  885. IAC: Abacavir/lamivudine (ABC/3TC) with fosamprenavir/ritonavir (FPV/r) or efavirenz (EFV) in underrepresented, antiretroviral (ARV) naïve, HIV-infected subjects (SUPPORT): tolerability, safety, and efficacy after 24 weeks - (08/10/10)
     
  886. IAC: A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naive HIV-1 infected subjects: 48-week results - (08/10/10)
     
  887. IAC: HBV related complications in HIV positive patients during HAART therapy - LAM resistance and high serum HBV-DNA & advancd liver disease - (08/10/10)
     
  888. IAC: Vienna Declaration: 'decriminalize illicit drug use as an HIV prevention measure' - (08/10/10)
     
  889. High prevalence of reduced bone mineral density in primary HIV-1-infected men - publication pdf attached - (08/08/10)
     
  890. C-Reactive Protein Levels Increase During HIV-1 Disease Progression in Rakai, Uganda, Despite the Absence of Microbial Translocation - publication pdf attached - (08/07/10)
     
  891. HPV-associated head and neck cancer: a virus-related cancer epidemic Review - pdf attached - (08/07/10)
     
  892. Immune Exhaustion Occurs Concomitantly With Immune Activation and Decrease in Regulatory T Cells in Viremic Chronically HIV-1-Infected Patients - publication pdf attached - (08/07/10)
     
  893. Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy - publication pdf attached - (08/07/10)
     
  894. IAC: Highlights of the Vienna International AIDS Conference by Pablo Tebas, MD, University of Pennsylvania. - (08/07/10)
     
  895. IAC: High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10)
     
  896. Albuminuria and Estimated Glomerular Filtration Rate Independently Associate with Acute Kidney Injury - (08/04/10)
     
  897. Heart Disease in HIV: 64-slice multidetector row computed tomography coronary angiography predicts outcome, are we evaluating risk for heart disease in HIV correctly? - (08/04/10)
     
  898. Failing Heart Linked to Failing Brain - attached are both pdfs, the article & a commentary from the Jnl of the Am Heart Ass Epub - (08/04/10)
     
  899. Following is a statement by the National Osteoporosis Foundation on Bone Mineral Density Testing - (08/04/10)
     
  900. Kidney function and the risk of cardiovascular events in HIV-1-infected patients - (08/04/10)
     
  901. IAC: Bioequivalence of the Co-Formulation of Emtricitabine/Rilpivirine/Tenofovir DF - (08/04/10)
     
  902. IAC: Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (08/04/10)
     
  903. IAC: Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12 Week Randomized, Controlled Study (ROCKET II) - (08/04/10)
     
  904. IAC: Switching to Atripla (EFV/FTC/TDF) from ABC/3TC FDC (Kivexa/Epzicom) + Efavirenz (EFV) Improves Lipid Levels Towards NCEP Recommendations: Primary Endpoint Results of a 24-week Randomised Study - (08/04/10)
     
  905. IAC: The impact of switching to etravirine on efavirenz-related CNS toxicity - (08/04/10)
     
  906. IAC: Meta-analysis Shows Abacavir Has No Effect on Cardiovascular Adverse Events: Presented at AIDS 2010 - (08/04/10)
     
  907. IAC: Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting response to a MVC-containing regimen in a treatment-experienced (TE) population - (08/04/10)
     
  908. IAC: Low Risk of Malignancy With Maraviroc in Treatment-Experienced and Treatment-Naïve Patients Across the Maraviroc Clinical Development Program - (08/04/10)
     
  909. IAC: Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: "34% Reduction in Mortality in Early Arm" - (08/04/10)
     
  910. IAC: Abacavir Use and Cardiovascular Disease Events: A Meta-Analysis of Published & Unpublished Data - (08/04/10)
     
  911. IAC: Darunavir/Ritonavir Monotherapy Fails Primary Noninferiority Test at MONET Week 96 - written by Mark Mascolini - (07/29/10)
     
  912. IAC: HIV Prevention at AIDS 2010 Vienna - written by Jared Baeten, MD PhD and Connie Celum, MD MPH University of Washington (07/29/10)
     
  913. Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients - full text pdf attached - (07/27/10)
     
  914. IAC: Viral Control and Switch/Stop Rates Similar With ABC/3TC and TDF/FTC in Canada - written by Mark Mascolini - (07/27/10)
     
  915. IAC: Resistance and Bilirubin Derail Twice-Daily Raltegravir/Atazanavir - written by Mark Mascolini - (07/27/10)
     
  916. IAC: Tenofivir Once-Daily PrEP in MSM Friday Late Breaker - (07/27/10)
     
  917. IAC: The Monet Trial 96 Weeks: drunavir Monotherapy vs darunavir + 2 NRTIs inpatients with HIV RNA < 50 copies/ml at baseline - (07/27/10)
     
  918. IAC: Abacavir vs Tenofovir - Similar times to virologic suppression and switching or stopping for abacavir/3TC and tenofovir/FTC in naives in Canadian Observational Cohort Collaboration - (07/27/10)
     
  919. IAC: Coronary CT Sees Blockage in Half of HIV Group With No Heart Disease Symptoms - written by Mark Mascolini - (07/27/10)
     
  920. IAC: Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen - written by Mark Mascolini - (07/26/10)
     
  921. IAC: Metabolic Marker Changes Similar After 12 Weeks of Darunavir and Atazanavir - written by Mark Mascolini - (07/26/10)
     
  922. IAC: HIV Infection Tied to Lower Risk of Vitamin D Deficiency in US Women's Study - (07/26/10)
     
  923. IAC: Individual Antiretrovirals Not Tied to Vitamin D Deficiency in London HIV Clinic - (average age 48, 50% vit D low/deficient, 40% osteopenia, 13% oseoporosis) - (07/26/10)
     
  924. IAC: Infection With Resistant Virus More Than Doubles Risk of Virologic Failure - (07/26/10)
     
  925. IAC: HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients - (07/26/10)
     
  926. IAC: 80% Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients in Italy - (07/26/10)
     
  927. IAC: Oral Poster discussion: Shining Light on Vitamin D deficiency - (07/26/10)
     
  928. IOF position statement: vitamin D recommendations for older adults - Position Paper - (07/23/10)
     
  929. IAC: Benefits and Risks of Stepdown to Atazanavir/Ritonavir Plus Lamivudine - (07/23/10)
     
  930. IAC: HIV Raises Heart Disease Risk 60% in People Over 49 - (07/23/10)
     
  931. IAC: HAART Initiation and Clinical Outcomes: insights from the CASCADE Cohort on 'When To Start' - (07/23/10)
     
  932. IAC: Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10)
     
  933. IAC: Association of Antiretroviral Therapy, Immunologic and Virologic Factors with Myocardial Infarction Rates in a U.S. Health Care System - (07/23/10)
     
  934. IAC: Nadir CD4 is a Predictor of HIV Neurocognitive Impairment (NCI) in the era of Combination Antiretroviral Therapy (CART): Results from the CHARTER Study - (07/23/10)
     
  935. IAC: Increased Rate of HIV Neurocognitive Impairment (NCI) among non-AIDS Cases in the Post-CART versus Pre-CART era - (07/23/10)
     
  936. IAC: Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10)
     
  937. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats - pdf attached - (07/22/10)
     
  938. IAC: HPV Vaccine Prevents HPV Lesions and Infection in Men - written by Mark Mascolini - (07/22/10)
     
  939. IAC: Cognitive Impairment Rate Rising in HIV+ Without AIDS: CHARTER - written by Mark Mascolini - (07/22/10)
     
  940. IAC: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (07/22/10)
     
  941. IAC: Once-Daily Maraviroc (MVC) + Atazanavir/Ritonavir(ATV/r) vs. Emtricitabine/Tenofovir(TDF/FTC) + ATV/r in Treatment Naïve Patients: A Week 24 Planned Interim Analysis - (07/22/10)
     
  942. IAC: The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects - (07/22/10)
     
  943. IAC:VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune) extended release (NVP XR) formulation - BI press release - (07/22/10)
     
  944. IAC: Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients - (07/22/10)
     
  945. IAC: TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures - written by Mark Mascolini - (07/22/10)
     
  946. IAC: Once-Daily S/GSK1349572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING-1 (ING112276) - (07/22/10)
     
  947. IAC: S/GSK1349572 Works Fast in Phase 2 Study of Treatment Naive - written by Mark Mascolini - (07/22/10)
     
  948. IAC: Nadir CD4 Count Strongly Predicts Neurocognitive Impairment in CHARTER - written by Mark Mascolini - (07/22/10)
     
  949. IAC: Two to Three Times Higher Hodgkin Risk in First Months of ART - written by Mark Mascolini - (07/22/10)
     
  950. IAC: Five Times Higher Risk of Intracranial Hemorrhage With HIV - written by Mark Mascolini - (07/22/10)
     
  951. IAC: Types of Kidney Problems May Be Changing as HAART Era Matures - written by Mark Mascolini - (07/22/10)
     
  952. IAC: Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor (NRTI) Selection on 96 Week Bone Mineral Density (BMD): Results from ACTG 5142 - (07/22/10)
     
  953. IAC: Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients - (07/22/10)
     
  954. IAC: METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks - (07/22/10)
     
  955. IAC: Lipodystrophy and Inflammation Predict Grip Strength in HIV-Infected Men: the MACS Body Composition Sub-study - (07/22/10)
     
  956. IAC: New, Deadly, but Rare Encephalitis Described in 14 French HIV Patients - written by Mark Mascolini - (07/21/10)
     
  957. Tesamorelin FDA Briefing Document pdf attached - (07/21/10)
     
  958. IAC: Low CD4s Trump Other MI Risk Factors in 6500-Person US Analysis - written by Mark Mascolini - (07/21/10)
     
  959. IAC: CDC Study Confirms Rising Non-AIDS Cancer Rate in With HIV - written by Mark Mascolini - (07/21/10)
     
  960. IAC: Cancer Rates in HIV+ in Atlanta: 'Non-AIDS Cancers Found 10 to 15 Years Earlier in People With HIV' - written by Mark Mascolini - (07/21/10)
     
  961. IAC: A Year of ART Does Not Ease Anal Cancer Harbingers in Men - written by Mark Mascolini - (07/21/10)
     
  962. IAC: Higher CD4 Count at Lung Cancer Diagnosis Predicts Survival - written by Mark Mascolini - (07/21/10)
     
  963. IAC: HCV SVR Rate Higher With Nevirapine Than Lopinavir in Multicenter Study - written by Mark Mascolini - (07/21/10)
     
  964. IAC: Congresswoman Barbara Lee Calls for $6 Billion for Global Fund - (07/21/10)
     
  965. IAC: S/GSK1265744: A Next Generation Integrase Inhibitor (INI) with Activity Against Raltegravir-Resistant Clinical Isolates - (07/21/10)
     
  966. IAC: Activity of the Next Generation Integrase Inhibitor S/GSK1349572 and Two First Generation Inhibitors Across a Broad Panel of HIV Subtype Isolates in PBMCs and MDMs - (07/21/10)
     
  967. IAC: HIV Integrase Genotypic and Phenotypic Changes Between Day 1 and Day 11 in Subjects with Raltegravir Resistant HIV Treated with S/GSK1349572: Results of VIKING Study - (07/21/10)
     
  968. IAC: 'Start HIV Therapy Earlier, IAS-USA Panel Recommends' - (07/20/10)
     
  969. IAC: Bill Clinton on HIV/AIDS: Much More Needs to be Done - (07/20/10)
     
  970. IAC: Bill Clinton, Gates: Fight AIDS more efficiently - (07/20/10)
     
  971. IAC: Tenofovir AIDS gel protects women in study - (07/20/10)
     
  972. IAC: Tenofovir Gel found to reduce AIDS risk in women - (07/20/10)
     
  973. IAC: New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10)
     
  974. IAC: New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10)
     
  975. IAC: Number Globally of HIV-positive in treatment rose by a quarter last year - (07/20/10)
     
  976. IAC: Gays With Well-Controlled HIV Not Protected From Lymphogranuloma Venereum - written by Mark Mascolini - (07/20/10)
     
  977. IAC: Long-Term Nonprogression Rare and Transient in Large CASCADE Cohort Study - written by Mark Mascolini - (07/20/10)
     
  978. IAC: Liver Death Rate in Spain Similar With and Without HIV, But Only in HCV-Negative - written by Mark Mascolini - (07/20/10)
     
  979. IAC: Death Rate Has Not Dropped in Certain Disadvantaged HIV+ US Groups - written by Mark Mascolini - (07/20/10)
     
  980. IAC: Fatal Liver Failure Still 8 Times More Common With HIV in Large US Cohort - written by Mark Mascolini - (07/20/10)
     
  981. IAC: HCV in HIV-Positives Raises Osteoporotic Fracture Risk Over 40% - written by Mark Mascolini - (07/20/10)
     
  982. IAC: Once- Versus Twice-Daily Raltegravir When Switching From a PI - written by Mark Mascolini - (07/19/10)
     
  983. IAC: Antioxidants With ART Boost CD4s, Ease Mitochondrial Damage in 8-Week Trial - written by Mark Mascolini - (07/19/10)
     
  984. IAC: Trading a Ritonavir-Boosted PI for Twice-Daily Raltegravir in SPIRAL - written by Mark Mascolini - (07/19/10)
     
  985. IAC: Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint - Abbott Press Release - (07/19/10)
     
  986. IAC: Impact of prior NRTI failure in the ODIS trial, a study conducted in HIV+ patients with undetectable viremia on protease inhibitors who switched to raltegravir qd versus bid - (07/19/10)
     
  987. IAC: TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection - Inflammation - (07/19/10)
     
  988. IAC: Tenofovir Gel Reduced HIV Transmission - pdf of Science Mag publication attached - (07/19/10)
     
  989. IAC: First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive - written by Mark Mascolini - (07/19/10)
     
  990. IAC: Activity of Next Generation Integrase Inhibitor (INI) S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961) - (07/19/10)
     
  991. IAC: Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) Demonstrated Similar Antiviral Efficacy and Safety as LPV/r Combined with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naïve HIV-1-Infected Subjects: PROGRESS 48 week results (07/19/10)
     
  992. IAC: Raltegravir Resistance Pattern Critical in Early Response to S/GSK1349572 - written by Mark Mascolini - (07/19/10)
     
  993. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection - Editorial Review - (07/19/10)
     
  994. Untreated HIV: harmful even at high CD4 cell counts - Editorial - 'When To Begin HAART' - (07/19/10)
     
  995. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per µL in Europe and North America: a pooled cohort observational study - (07/19/10)
     
  996. IAC: New Guidelines Urge Earlier Therapy for HIV Patients - (07/19/10)
     
  997. IAC: Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study - (07/19/10)
     
  998. IAC: AIDS group fears annual HIV costs may hit $35 bln - (07/19/10)
     
  999. IAC: HIV/AIDS numbers from around the world - (07/19/10)
     
  1000. IAC: CDC Study Reports Poverty Among Minorities Doubles HIV Infection Rate - (07/19/10)
     
  1001. IAC: Julio Montaner AIDS Conference Chief Lashes Out At World Leaders for Not Funding Global HIV - (07/19/10)
     
  1002. IAC: 18th Int'l AIDS Conference opens in Vienna - (07/19/10)
     
  1003. IAC: World AIDS Conference (IAC) Opens -to hear progress on drugs, money worries - (07/19/10)
     
  1004. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes - (07/15/10)
     
  1005. Early vs Standard HAART Start in Haiti Randomized Study NEJM - pdf attached - (07/15/10)
     
  1006. Alzheimer disease and HIV A tangled story - Editorial - (07/15/10)
     
  1007. Geron Provides Update on Telomerase Anti-Aging Therapy Activation Program - (07/15/10)
     
  1008. HIV & Alzheimers: are HIV+ At Greater Risk for Alzheimers - pdf full text attached - (07/14/10)
     
  1009. HIV/Aging & Antiaging Therapy - (07/12/10)
     
  1010. CD4 Predicts Cardiovascular Disease (CVD), nadir cd4 too perhaps - (07/12/10)
     
  1011. Model Forecasting Test & Treat Impact - CID August 2010 - pdf attached - (07/12/10)
     
  1012. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients - pdf of full text attached - (07/12/10)
     
  1013. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors - (07/10/10)
     
  1014. NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells - 2 pdfs attaced of both Science mag published reports - (07/10/10)
     
  1015. HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals - Review - pdf attached - (07/10/10)
     
  1016. Advance in Quest for HIV Vaccine - (07/10/10)
     
  1017. Inflammation Predicts Mortality in FRAM - (07/08/10)
     
  1018. Telomere Length and Risk of Incident Cancer and Cancer Mortality - (07/08/10)
     
  1019. Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data - (07/07/10)
     
  1020. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment - (07/07/10)
     
  1021. Depressive symptoms and risk of dementia - The Framingham Heart Study - (07/07/10)
     
  1022. New Gene Therapy Zinc Fingers Research Published: 'doctors may someday control HIV virus using stem cells without using anti-retroviral drugs' - (07/07/10)
     
  1023. Raltegravir Switch from PI Effective - Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study - pdf attached - (07/05/10)
     
  1024. Long-term use of anabolic steroids associated with reduced LV ejection fraction - (07/04/10)
     
  1025. Neurological Symptoms-HIV ART Drug Resistance & Discordant CNS & Plasma Viral Load, Patients Suppressed on ART - pdf attached - (07/04/10)
     
  1026. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication - pdf of publication attached - (07/02/10)
     
  1027. Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia - (07/01/10)
     
  1028. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study - (06/30/10)
     
  1029. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy - (06/30/10)
     
  1030. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients - (06/30/10)
     
  1031. Immunosenescence and Vaccination - Commentary - (06/29/10)
     
  1032. Mechanisms of immunosenescence Short report - (06/29/10)
     
  1033. New Inhaled Insulin for Diabetes 2 - (06/25/10)
     
  1034. Hypertension Strongest Predictor of Stroke: and includes waist-to-hip ratio, regular exercise, smoking, diabetes, depression, stress - (06/23/10)
     
  1035. Diabetes & Liver Disease: does diabetes cause liver disease - pdf of article attached - (06/23/10)
     
  1036. Immunosenescence comes of age. Symposium on Aging Research in Immunology: The Impact of Genomics - (06/23/10)
     
  1037. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes' - (06/23/10)
     
  1038. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation - (06/23/10)
     
  1039. Diabetes & Liver Disease: does diabetes cause liver disease - pdf of article attached - (06/22/10)
     
  1040. HIV-associated lipodystrophy: from fat injury to premature aging - Review - pdf of article attached - (06/22/10)
     
  1041. Mitochondrial Dysfunction in HIV+ CNS/Muscular Organ Systems Disorders in HIV+ Children, and perhaps related to accelerated aging in older HIV+ adults - (06/20/10)
     
  1042. ResisWksp: Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - poster - (06/18/10)
     
  1043. ResisWksp: Analysis of the HIV-1 gp120 V3 Loop at Screening for Treatment-Experienced Patients in the MOTIVATE Studies With CCR5-Tropic Virologic Failure - poster - (06/18/10)
     
  1044. ResisWksp: Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment "Deep" Sequencing Results - poster - (06/18/10)
     
  1045. ResisWksp: Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the Merit Study - (06/18/10)
     
  1046. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era - (06/16/10)
     
  1047. ResisWksp: Intl Resistance Workshop Report by Mark Wainberg, PhD, McGill University, Montreal - (06/16/10)
     
  1048. Immunologic and Virologic Events in Early HIV Infection Predict Subsequent Rate of Progression - MAJOR ARTICLE - (06/11/10)
     
  1049. Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression - (06/11/10)
     
  1050. EACS: New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+
     
  1051. (Test & Treat) HIV Prevention, Diagnosis and Treatment A Best Practices Symposium at Albert Einstein School of Medicine, Bronx, NY -pdf attached
     
  1052. ResisWksp: Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572 - (06/15/10)
     
  1053. ResisWksp: Strong Inhibition of Wild-type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572, poster report: "S/GSK1349572 had stronger and faster binding to mutant IN than RAL" - (06/15/10)
     
  1054. ResisWksp: S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir when Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
     
  1055. ResisWksp: HIV Integrase Resistance Profiles and S/GSK1349572 Baseline Phenotypic Susceptibility for Subjects Experiencing Virologic Failure on Raltegravir (RAL) in the VIKING Study (ING112961) - (06/15/10)
     
  1056. ResisWksp: S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir When Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
     
  1057. ResisWksp: Structural Models of HIV-1 Integrase and DNA in Complex with S/GSK1349572, Raltegravir and Elvitegravir: Structure-based Rationale for INI Resistance Profiles - (06/15/10)
     
  1058. Study reveals promise for New/Improved HIV testing & Reporting Results on Internet - (06/15/10)
     
  1059. Common genetic determinants of vitamin D insufficiency: a genome-wide association study - (06/15/10)
     
  1060. A Finite Course of ART during Early HIV-1 Infection Modestly Delays Need for Subsequent ART Initiation: ACTG A5217, the SETPOINT Study - (06/12/10)
     
  1061. ResisWksp: Only Two Major PI Mutations (But No Resistance) in Darunavir Monotherapy Trial - written by Mark Mascolini - (06/12/10)
     
  1062. ResisWksp: US/Canadian HIV Transmission Clusters Largely Male, White, and Gay - written by Mark Mascolini - (06/12/10)
     
  1063. ResisWksp: Infection With 3TC/FTC Mutant Virus Favors Lower Pretreatment Viral Load - written by Mark Mascolini - (06/12/10)
     
  1064. ResisWksp: Treatment Success Rates High, Resistance Rates Lower, in France in 2009, but integrase resistance is present among failures - written by Mark Mascolini - (06/12/10)
     
  1065. ResisWksp: HIV CSF/Plasma Ratio and Genetic Distance in People With Neurologic Disorders - written by Mark Mascolini - (06/12/10)
     
  1066. ResisWksp: Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment Deep Sequencing Results - (06/11/10)
     
  1067. ResisWksp: Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - (06/11/10)
     
  1068. ResisWksp: Use of the Enhanced Sensitivity Tropism Assay (ESTA) to Predict On-Treatment Detection of CXCR4-using Virus and Impact on Virologic Outcomes in a Vicriviroc (VCV) Phase 2 Treatment Experienced Study (VICTOR-E1) - (06/11/10)
     
  1069. ResisWksp: Mutation Rate in Antiretroviral-Naive Falling in One US Patient Population (GSK studies in USA) - written by Mark Mascolini - (06/11/10)
     
  1070. ResisWksp: Are Single Transmitted Mutants the Tip of a Resistance Iceberg? - written by Mark Mascolini - (06/11/10)
     
  1071. ResisWksp: New Mutations Found in 43% of People With Low But Detectable Viral Loads - written by Mark Mascolini - (06/11/10)
     
  1072. ResisWksp: Study Clarifies Risk of Switch to Raltegravir From Suppressive PI - written by Mark Mascolini - (06/11/10)
     
  1073. ResisWksp: Truvada Protects Macaques From Rectal Exposure to FTC-Resistant Virus - written by Mark Mascolini - (06/11/10)
     
  1074. ResisWksp: Transmitted Resistance Imperils First-Line Response in 10,000-Person Study - written by Mark Mascolini - (06/11/10)
     
  1075. ResisWksp: "Deep" Sequencing Finds X4 Virus in Screening Samples of Maraviroc Failures - written by Mark Mascolini - (06/10/10)
     
  1076. ResisWksp: Pairwise Comparison of genotypic tropism prediction between one reference center and 10 European laboratories - (06/10/10)
     
  1077. ResisWksp: Better Etravirine Response Predicted After Efavirenz Than Nevirapine - written by Mark Mascolini - (06/10/10)
     
  1078. ResisWksp: Over Half of European Raltegravir Failures Without Apparent Integrase Mutations - written by Mark Mascolini - (06/10/10)
     
  1079. ResisWksp: GSK Integrase Following Raltergavir Use: When Is It Risky to Use S/GSK1349572 After Raltegravir? - written by Mark Mascolini - (06/10/10)
     
  1080. ResisWksp: Debate Follows Data on Genotypic Predictions of HIV Tropism - written by Mark Mascolini - (06/10/10)
     
  1081. Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1-Infected Subjects at 48 Weeks - (06/10/10)
     
  1082. The Effects of Opiate Use and Hepatitis C Virus Infection on Risk of Diabetes Mellitus in the Women's Interagency HIV Study: history of opiate use & HCV both increase risk for diabetes - (06/10/10)
     
  1083. Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials - (06/10/10)
     
  1084. ResisWksp: Resistance Emergence With Raltegravir Versus Efavirenz in Treatment Naive - written by Mark Mascolini - (06/10/10)
     
  1085. ResisWksp: Temporal Order of Resistance Emergence for Lamivudine/Emtricitabine, Efavirenz, and Raltegravir in Treatment-Naïve Patients - (06/10/10)
     
  1086. ResisWksp: Differing Integrase Dissociation Rates With S/GSK1349572 and Raltegravir - written by Mark Mascolini - (06/10/10)
     
  1087. Beyond Hemoglobin A1c-Need for Additional Markers of Risk for Diabetic Microvascular Complications - commentary - (06/08/10)
     
  1088. Does Lipoatrophy Persist ? - Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy - pdf attached (I suggest reading the pdf closely) - (06/07/10)
     
  1089. Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria - pdf full text attached - (06/07/10)
     
  1090. Circulating mitochondrial DAMPs cause inflammatory responses to injury - (06/07/10)
     
  1091. "mitochondria.....might initiate inflammation....mitochondria are probably released in patients with infectious disease" - (06/07/10)
     
  1092. Immunology & Mitochondria - Clinical immunology: Culprits with evolutionary ties - (06/07/10)
     
  1093. The Mitochondrion - A Trojan Horse That Kicks Off Inflammation? - (06/07/10)
     
  1094. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study - (06/03/10)
     
  1095. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia - (06/03/10)
     
  1096. HIV-associated neurocognitive disorders: is there a hidden epidemic? - Editorial Comment - (06/03/10)
     
  1097. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening - (06/03/10)
     
  1098. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens - (06/03/10)
     
  1099. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers Free, Centralized Resource Designed to Help Overcome Some Barriers to Supportive Care - (05/30/10)
     
  1100. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada - (05/30/10)
     
  1101. The Gap between Human Immunodeficiency Virus (HIV) Infection and Advances in HIV Treatment - EDITORIAL - (05/30/10)
     
  1102. HPV and Therapeutic Vaccines: Where are We in 2010? - pdf attached - (05/29/10)
     
  1103. M2010: Press briefings at International Microbicides Conference, May 22-25 - (05/28/10)
     
  1104. M2010: Using ARVs to Prevent HIV Could Result in Drug Resistance if Routine Screening is Not Done New Research Presented at International Microbicides Conference - (05/28/10)
     
  1105. M2010: Researchers Searching For New Ways (micobicides: tablets, gel, film, vaginal rings) To Protect Women Against HIV - (05/28/10)
     
  1106. M2010: Lubricant Use May Raise HIV Infection Risk During Anal Sex - (05/28/10)
     
  1107. M2010: Vaginal gel with integrase inhibitor shows promise in monkeys; Darunavir/Maraviroc/NNRTis/Fusion - (05/28/10)
     
  1108. M2010: New ARTs Research Takes The Lead: HIV Microbicides Conference Report - (05/28/10)
     
  1109. In this analysis of almost 3400 HIV-1 serodiscordant heterosexual couples from seven African countries, ART use by the infected person was accompanied by a 92% reduction in risk of HIV-1 transmission to their partner - (05/28/10)
     
  1110. HIV drugs for treatment, and for prevention Editorial - (05/28/10)
     
  1111. Tesamorelin & IGF-1 Levels - (05/28/10)
     
  1112. Tesamorelin Reduces VAT: FDA Hearing - (05/28/10)
     
  1113. VOTE: 16-0 to recommend approval for tesamorelin - 'benefit outweighs risk' - (05/28/10)
     
  1114. FDA: Possible Fracture Risk with High Dose, Long-term Use of Proton Pump Inhibitors - (05/26/10)
     
  1115. New CVD Anti-Inflammation Drug: Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome - pdf full text attached - (05/26/10)
     
  1116. People with AIDS more likely to develop cancers, research says - (05/26/10)
     
  1117. Tesamorelin FDA Briefing Document pdf attached - (05/26/10)
     
  1118. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation - pdf attached - (05/25/10)
     
  1119. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals - (05/25/10)
     
  1120. Cholesterol Crystals Incite Inflammation in Coronary Arteries, Research Finds - (05/25/10)
     
  1121. Cholesterol crystals incite inflammation in coronary arteries - (05/25/10)
     
  1122. 11th Wrkshp Adverse Drug Reactions Omega-3 fatty acids supplementation may improve inflammation and endothelial activation in HIV-infected adults on stable antiretroviral therapy - (05/24/10)
     
  1123. 11th Wrkshp Adverse Drug Reactions Vitamin D and Efavirenz - (05/24/10)
     
  1124. 11th Wrkshp Adverse Drug ReactionsAssociation between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D - (05/24/10)
     
  1125. Study pinpoints how a normally defensive immune response can help HIV - journal commentary included - (05/24/10)
     
  1126. New Aging/HIV Study-blocking inflammation: Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease - (05/24/10)
     
  1127. Visceral fat is associated with lower brain volume in healthy middle-aged adults - (05/20/10)
     
  1128. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis - (05/18/10)
     
  1129. Low Vitamin D Levels Associated with Genotype 1, Fibrosis, Inflammation, with SVR, with waist circumference, Low HDL - (05/18/10)
     
  1130. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men - (05/17/10)
     
  1131. "A higher 25(OH)D (vit D) was associated with better dietary quality, lower %BF (body fat, central obesity), and lower number of MetD (metabolic disturbances including CRP, glucose)"...dairy in diet helped vit D levels - pdf attached - (05/13/10)
     
  1132. Denosumab Inhibits Bone Loss in RA - (05/13/10)
     
  1133. High Dose Vitamin D Increased Fall & Fracture Rate - (05/13/10)
     
  1134. High-Dose Vitamin D Supplementation, Too Much of a Good Thing? - (05/12/10)
     
  1135. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model - (05/12/10)
     
  1136. HPV, Genital wart virus may raise men's risk of HIV - link to free full text JID article - (05/12/10)
     
  1137. Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection - (05/07/10)
     
  1138. Inflammation and Complications of HIV Disease - EDITORIAL COMMENTARY - (05/07/10)
     
  1139. Pre-HAART Immune Activation Associated with Developing Cancers & Death - (05/07/10)
     
  1140. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection (and HCV) - (05/07/10)
     
  1141. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy - (05/05/10)
     
  1142. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations - (05/05/10)
     
  1143. Experimental NYC HIV Anal Cancer Screening Clinic - (05/05/10)
     
  1144. An aged T cell phenotype: A prognostic indicator in liver transplant recipients? Editorial - (05/03/10)
     
  1145. Features of immune senescence in liver transplant recipients with established grafts - (05/03/10)
     
  1146. ACCORD Glycemia (intensive control <6% A1C) Results Continue to Puzzle Editorial - (05/03/10)
     
  1147. Intensive Sugar Control HbA1C <6% Is Beneficial; Unsuccessful intensive therapy the culprit in ACCORD - (05/03/10)
     
  1148. (Low A1C <6% Reduces Death) Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial - (05/03/10)
     
  1149. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients - (04/29/10)
     
  1150. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis - (04/29/10)
     
  1151. PK Workshop: 11th International Workshop on Clinical Pharmacology of HIV Therapy (April 2010) Report - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (04/27/10)
     
  1152. Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial - (04/26/10)
     
  1153. Statins for Primary Prevention in Older Adults: Who Is High Risk, Who Is Old, and What Denotes Primary Prevention? Editorial - (04/26/10)
     
  1154. PK Workshop: Evaluation of Ritonavir-boosted Elvitegravir PK upon Co-administration with a Second Potent CYP3A inhibitor, Ketoconazole - (04/23/10)
     
  1155. PK Workshop: Metabolism and Excretion in Humans of the Pharmacoenhancer GS-9350 - (04/22/10)
     
  1156. Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody - (04/22/10)
     
  1157. PK Workshop: Relative Bioavailability and Pharmacokinetics of Darunavir when boosted with the Pharmacoenhancer GS-9350 versus Ritonavir - (04/21/10)
     
  1158. Sequential Acquisition of Human Papillomavirus (HPV) Infection of the Anus and Cervix: The Hawaii HPV Cohort Study. - (04/13/10)
     
  1159. HAART Reduces HPV - Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women - (04/13/10)
     
  1160. The role of secondary lymphatic tissue in immune deficiency of HIV infection, and aging - (04/13/10)
     
  1161. HIV Drug Resistance over the Long Haul - EDITORIAL COMMENTARY - (04/13/10)
     
  1162. PK Workshop: GRACE PK Study: Median (range) AUC12h and C0h were similar between women and men, and across black, Hispanic and white patients; Pharmacokinetic results from GRACE demonstrated no clinically relevant differences in exposure to DRV across a range of covariates, including sex, race/ethnicity, use of ETR, use of TDF, age, body weight and hepatitis B co-infection status - (04/13/10)
     
  1163. PK Workshop: Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (04/13/10)
     
  1164. PK Workshop: Higher Darunavir and Raltegravir Levels in Small Study of People With Liver Disease - written by Mark Mascolini - (04/13/10)
     
  1165. PK Workshop: Limited Risk of Serious Interaction Between TMC278 and Methadone - written by Mark Mascolini - (04/13/10)
     
  1166. PK Workshop: More Than Half in Barcelona HIV Clinic Use Alternative Therapies - written by Mark Mascolini - (04/13/10)
     
  1167. PK Workshop: Cell Levels of Once-Daily Raltegravir Adequate in Pilot Study - written by Mark Mascolini - (04/13/10)
     
  1168. PK Workshop: Older Age Impairs Kidney Function During Tenofovir Therapy - written by Mark Mascolini - (04/13/10)
     
  1169. PK Workshop: Etravirine Lowers Levels of S/GSK Integrase Inhibitor, But PIs Counter Effect - written by Mark Mascolini - (04/13/10)
     
  1170. PK Workshop: Darunavir Boosting with GS-9350 (Cobicistat) or Ritonavir in Healthy Volunteers - written by Mark Mascolini - (04/13/10)
     
  1171. PK Workshop: Extra CYP3A Inhibitor Has Modest Impact on Already-Boosted Elvitegravir - written by Mark Mascolini - (04/13/10)
     
  1172. PK Workshop: What Will It Take To Replace Ritonavir as the Prime PK Booster? ...Debate Ritonavir v GS9350 - written by Mark Mascolini - (04/13/10)
     
  1173. PK Workshop: Higher Atazanavir Levels Sync With Higher Raltegravir Levels in Dual Combo - written by Mark Mascolini - (04/13/10)
     
  1174. PK Workshop: The Effect of Food Intake on Reyataz Blood Levels - written by Mark Mascolini - (04/13/10)
     
  1175. PK Workshop: Darunavir Levels Not Tied to Detectable HIV RNA in MONET Monotherapy Trial - written by Mark Mascolini - (04/13/10)
     
  1176. PK Workshop: Darunavir Levels Not Affected by Gender, Race, or Age in GRACE Trial - written by Mark Mascolini - (04/13/10)
     
  1177. PK Workshop: Impact of Pravastatin on Raltegravir Levels in Healthy Volunteers - written by Mark Mascolini - (04/13/10)
     
  1178. PK Workshop: Efavirenz Troughs Higher in People Over 50 Years Old - written by Mark Mascolini - (04/13/10)
     
  1179. PK Workshop: Women With Tight HIV Control Have Higher Antiretroviral Troughs Than General Population - written by Mark Mascolini - (04/13/10)
     
  1180. Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials - (04/06/10)
     
  1181. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management - (04/06/10)
     
  1182. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients - (04/06/10)
     
  1183. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy - (04/06/10)
     
  1184. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience - (04/06/10)
     
  1185. CROI: HAART Reduces New Infections - Decreases in Community Viral Load Are Associated with a Reduction in New HIV Diagnoses in San Francisco (CROI) - (04/05/10)
     
  1186. Conspiracy Beliefs About HIV Are Related to Antiretroviral Treatment Nonadherence Among African American Men With HIV - (04/05/10)
     
  1187. 45% of Eligible Patients Receive HIV Drug Resistance Testing - (04/05/10)
     
  1188. The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART) - (04/05/10)
     
  1189. Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States - (04/05/10)
     
  1190. CROI: Prolonged Control of Viremia After Transfer of Autologous CD4 T Cells Genetically Modified with a Lentiviral Vector Expressing Long Antisense to HIV env (VRX496) - (04/04/10)
     
  1191. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function - (04/03/10)
     
  1192. Inflammation, CRP & new test (DTI, difussion tensor imaging) - Are white matter signal abnormalities clinically relevant? Editorial - (04/03/10)
     
  1193. Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome - (04/03/10)
     
  1194. Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis - (03/28/10)
     
  1195. Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss - (03/28/10)
     
  1196. Evolving Data about Subtrochanteric Fractures and Bisphosphonates-EDITORIAL - (03/25/10)
     
  1197. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur - (03/25/10)
     
  1198. NYS Guidelines recommendations on anal pap smears - (03/25/10)
     
  1199. CROI: HIV Persistence, Raltegravir/Maravoric Intensification, Immunology: Some Impressions from San Francisco: CROI 2010 - written by David Margolis MD University of North Carolina - (03/24/10)
     
  1200. MRSA Risk 6-Fold Higher in HIV+: Community-Associated Methicillin-Resistant Staphylococcus aureus and HIV: Intersecting Epidemics - (03/24/10)
     
  1201. CROI: Management of Treatment-Experienced Patients: darunavir, raltegravir, raltegravir intensification, maraviroc, vicriviroc - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida - (03/23/10)
     
  1202. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects - pdf attached - (03/22//10)
     
  1203. Short-Course Raltegravir Intensification Does Not Reduce Persistent Low-Level Viremia in Patients with HIV-1 Suppression during Receipt of Combination Antiretroviral Therapy - (03/22/10)
     
  1204. Benefit or Toxicity from Neurologically Targeted Antiretroviral Therapy? EDITORIAL COMMENTARY - (03/22/10)
     
  1205. Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1-Infected Individuals Commencing cART? A Randomized, Controlled Study - (03/22/10)
     
  1206. CROI: Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)
     
  1207. CROI: Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)
     
  1208. CROI: No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of Raltegravir-containing Therapy in Patients with Controlled Viremia: A Sub-study of the Randomized EASIER-ANRS 138 Trial - (03/22/10)
     
  1209. CROI: Effect of the Intensification with a CCR5 Antagonist on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - (03/22/10)
     
  1210. CROI: No Decrease in Intrathecal Immunoactivation or Residual CSF Viremiaduring Treatment Intensification in Patients on Stable ART - (03/22/10)
     
  1211. CROI: Quantification of Persistent Viremia in Cerebrospinal Fluid and Plasma: Initial Experience in a Raltegravir Intensification Study - (03/22/10)
     
  1212. CROI: Differences in HIV Burden throughout the Gut of Patients on Suppressive ART: Implications for HIV Persistence - (03/21/10)
     
  1213. CROI: HIV-1 Replication and Immune Dynamics Are Impacted by Raltegravir Intensification of HAART-suppressed Patients - (03/21/10)
     
  1214. CROI: Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response - (03/21/10)
     
  1215. Test & Treat-what is the impact? Can antiretroviral therapy eliminate HIV transmission? The lancet 2009 - (03/20//10)
     
  1216. Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection - (03/19//10)
     
  1217. CROI: Efficacy of Intermittent Prophylaxis with Tenofovir and Emtricitabine against Rectal SHIV Transmission in Macaques and Relationship to Systemic and Mucosal Drug Levels - (03/19/10)
     
  1218. CROI: Protection of Rhesus Macaques from Vaginal Infection by Maraviroc (solution), an Inhibitor of HIV-1 Entry via the CCR5 Co-receptor - (03/19/10)
     
  1219. CROI: Clinical Pharmacology at CROI 2010: Advances in Antiretroviral Discovery, Drug Interactions, Compartmental Penetration, and Adverse Reactions - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center- (03/14/10)
     
  1220. CROI: CROI: Inflammation/activation linked to diseases of organ systems (heart, kidney, liver) & death in USA and now reported as well in Africa - HIV accelerated aging will be bigger problem in undeveloped countries - (03/18/10)
     
  1221. CROI: INFLAMMATORY MARKERS DURING TREATMENT OF OIs ARE PREDICTIVE OF LATE VIROLOGIC AND IMMUNOLOGIC RESPONSES: Sub-study of A5164 - (03/16/10)
     
  1222. CROI:Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large italian cohort - (03/15/10)
     
  1223. CROI: Bone/Osteoporosis/Vitamin D CROI 2010 Update - written by Michael Yin, MD MS Assistant Professor of Clinical Medicine Columbia University Medical Center New York, NY- (03/14/10)
     
  1224. Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study - (03/11/10)
     
  1225. CROI: Longitudinal Analysis of Bone Mineral Density in Aging Men With or at Risk for HIV Infection: heroin causes bone loss; accelerated bone loss progressed over 3 years in HIV+ - (03/10/10)
     
  1226. CROI: Changes in Bone Mineral Density: two-years follow-up of the ANRS CO3 Aquitaine Cohort - Bone Metabolism Evolves- in 11% from osteopenia to osteoporosis and to osteopenia, bone markers worsen in 41% - (03/10/10)
     
  1227. Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate - (03/09/10)
     
  1228. Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy - (03/09/10)
     
  1229. CROI: Non-AIDS-defining Events among HAART-treated Adults in an Urban US vs an Urban Sub-Saharan African Setting: 'high non-AIDS events rate in Africa' - (03/09/10)
     
  1230. CROI: Low CD4 Cell Count and Impaired Renal Function (eGFR) Are Independent Risk Factors for ARF (acute renal failure) in HIV-infected Patients - (03/09/10)
     
  1231. CROI: Prevalence of Hepatitis Coinfection among HIV-Infected Nigerian Children in the Harvard PEPFAR ART Program - (03/09/10)
     
  1232. CROI: Persistent Low-level Viremia Is Associated with Increased Risk of Virologic Failure and Mortality - (03/09/10)
     
  1233. CROI: Association of IL28B Haplotypes with Chronic HCV Infection in HIV/HCV Co-infected Individuals - (03/09/10)
     
  1234. CROI: Genetic Variation in IL28B and Treatment-induced Clearance of HCV in HCV/HIV Co-infected Patients - (03/09/10)
     
  1235. CROI: Sustained Virological Response to Interferon plus Ribavirin Reduces HIV Progression and Non-liver-related Mortality in Patients Co-infected with HIV and HCV - (03/09/10)
     
  1236. CROI: HIV Prevention at CROI 2010 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/07/10)
     
  1237. CROI: 5-Year Tenofovir Therapy Is Associated with Maintained HBV Response and Renal Toxicity in HIV/HBV Co-infected Patients - (03/06/10)
     
  1238. CROI: Determinants of Incident Chronic Kidney Disease in a Cohort of HIV-infected Patients with Free Access to Care - (03/06/10)
     
  1239. CROI: Predictors for Change in Estimated Glomerular Filtration Rate in HIV-infected Individuals with or without cART: The Swiss HIV Cohort Study - (03/06/10)
     
  1240. CROI: Improved Correlation of Coronary Atherosclerosis with Estimated Glomerular Filtration Rate Assessed with Chronic Kidney Disease Epidemiology Collaboration Equation than with MDRD and Cockcroft-Gault in HIV-infected Patients - (03/06/10)
     
  1241. CROI: HAART Is Associated with Improved Kidney Function in Patients with Impaired Kidney Function at Baseline but Was Associated with Slight Worsening of Kidney Function in Patients with Normal Baseline Kidney Function - (03/06/10)
     
  1242. CROI: Chronic Renal Failure in HIV-Infected Patients: Incidence and Risk Factors (ANRS CO3 Aquitaine Cohort, France) - (03/06/10)
     
  1243. CROI: Episodes of HIV Viremia and the Risk of Non-AIDS Events among Successfully Treated Patients (503) - (03/06/10)
     
  1244. HbA1C Predicts Diabetes & CVD: Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults - (03/05/10)
     
  1245. CROI: DNA Damage and p16-mediated Growth Arrest in HIV-1-specific CD8+ T Cells - (03/05/10)
     
  1246. CROI: Ritonavir and Lopinavir Boosted with Ritonavir Induce Endothelial dysfunction and Premature Senescence in Cultured Human Coronary Artery Endothelial Cells - (03/05/10)
     
  1247. CROI: In vitro Effect of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages and Dendritic Cells - (03/05/10)
     
  1248. CROI: Vicriviroc Phase 3 at CROI 2010 - (03/05/10)
     
  1249. CROI: Plasma Levels of Soluble CD14 (activation marker) Predict Mortality in HIV Infection - (03/05/10)
     
  1250. CROI: Short-Term Raltegravir Monotherapy Does Not Predispose Patients to Develop RAL Resistance During Subsequent Combination Therapy: Analysis of Samples From Protocol 004 - (03/05/10)
     
  1251. CROI:Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth - (03/05/10)
     
  1252. CROI:Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patient - (03/04/10)
     
  1253. CROI: Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus - (03/04/10)
     
  1254. CROI: A Pharmacokinetic Comparison of Adult and Pediatric Formulations of Raltegravir (RAL) in Healthy Adults - (03/04/10)
     
  1255. CROI: Screening for Hepatocellular Carcinoma (HCC) in HIV/HCV-Coinfected Patients: Impact on Staging, Therapy, and Survival - (03/04/10)
     
  1256. CROI: Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes - (03/04/10)
     
  1257. CROI: Determining HIV-1 Coreceptor Tropism Using PBMC Proviral DNA Derived from Aviremic Blood Samples, for Patients with Undetectable Viral Load - (03/04/10)
     
  1258. CROI: The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK - (03/04/10)
     
  1259. CROI: Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/04/10)
     
  1260. CROI: Effect of the Intensification with a CCR5 Antagonist Maraviroc on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - reduced activation - (03/04/10)
     
  1261. CROI:Effect of CCL3L1 Copy Number Variation on CD4+ Cell Recovery in Treatment-Naïve Patients: 96-Week Results from the Maraviroc in Treatment-Naïve Patients (MERIT) Study - (03/04/10)
     
  1262. CROI: Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-Experienced Patients Enrolled Into the MOTIVATE Studies and Who Received Maraviroc + Optimized Background Therapy - (03/03/10)
     
  1263. CROI:Population-based Sequencing of the V3-loop is Comparable to the Enhanced Sensitivity Trofile Assay (ESTA) in Predicting Virologic Response to Maraviroc of Treatment-naïve Patients in the MERIT Trial - (03/03/10)
     
  1264. CROI:Mechanisms of Virologic Failure With Maraviroc in Treatment-Naïve HIV-1-Infected Patients Through 96 Weeks - (03/03/10)
     
  1265. CROI:Large-Scale Application of "Deep" Sequencing Using 454 Technology to HIV Tropism Screening - (03/03/10)
     
  1266. CROI:HIV Did Not Worsen H1N1 Severity in Spanish Case-Control Study - written by Mark Mascolini - (03/03/10)
     
  1267. CROI:Failure to Respond to HBV Vaccine Linked to Higher Cancer Risk With HIV - written by Mark Mascolini - (03/03/10)
     
  1268. CROI:Prediction of X4-tropic Human Immunodeficiency Virus from Proviral Envelope Sequence in Patients with Suppressed Viral Load on Antiretroviral Therapy (ART). - (03/03/10)
     
  1269. CROI: Four Non-AIDS Cancers on the Rise With HIV in Big North American Cohort - written by Mark Mascolini - (03/03/10)
     
  1270. CROI:Correlation of Inflammatory Biomarkers with the Framingham Coronary Risk Score in Antiretroviral-naïve HIV-1 Infected Patients - (03/03/10)
     
  1271. CROI:Trends in Cumulative Incidence of Cancer among HIV-infected Patients in North America: high cancer rates in HIV+ - (03/03/10)
     
  1272. CROI: Prevalence (59%) and Correlates of Minor Neurocognitive Disorders in Asymptomatic HIV-infected Outpatients - (03/03/10)
     
  1273. CROI: Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve management of Hepatitis coinfection in HIV-Infected Patients? - written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/03/10)
     
  1274. CROI: The Kidney at CROI - written by Christina M. Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY - (03/03/10)
     
  1275. CROI: Chronic Inflammation in HIV: CROI 2010 - written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (03/03/10)
     
  1276. CROI: Modest Lipid and Body Fat Changes With Raltegravir vs Efavirenz in 96-Week Trial - written by Mark Mascolini - - (03/02/10)
     
  1277. CROI: CDC Finds 1 in 6 Newly Diagnosed With HIV Had Resistant Virus in 2007 - written by Mark Mascolini - - (03/02/10)
     
  1278. CROI: Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study - abstract 107LB - (03/02/10)
     
  1279. CROI: Higher Levels of Heart Cell Peptide Tied to Cardiovascular Disease in SMART Study Patients - written by Mark Mascolini - (03/01/10)
     
  1280. CROI: D-Dimer But Not hsCRP Predicts Impending Cardiovascular Disease in Case-Control Study - written by Mark Mascolini - (03/01/10)
     
  1281. CROI:Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)
     
  1282. CROI:Risk of Non-AIDS Death in HIV/HCV-Coinfected People in SMART - written by Mark Mascolini - (03/01/10)
     
  1283. CROI: T cell Senescence and Proliferation Defects Persist in Treated HIV-infected Individuals Maintaining Viral Suppression and Are Associated with Poor CD4+ T Cell Recovery - (03/01/10)
     
  1284. CROI: Impact of CD8+ T Cell Activation on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating Antiretroviral Therapy - (03/01/10)
     
  1285. CROI: Valganciclovir Reduces CD8+ T Cell Activation among HIV-infected Patients with Suboptimal CD4+ T cell Recovery During Antiretroviral Therapy - (03/01/10)
     
  1286. CROI:CD4 at HAART Initiation Predicts Long Term CD4 Responses and Mortality from AIDS and non-AIDS Causes in the HIV Outpatient Study (HOPS) - (03/01/10)
     
  1287. CROI: Improved Genotypic Algorithm for Predicting Etravirine Susceptibility: Comprehensive List of Mutations Identified Through Correlation with Matched Phenotype - (03/01/10)
     
  1288. CROI:Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir when Combined in Treatment Experienced Patients: a Substudy of the ANRS 139 TRIO Trial - (03/01/10)
     
  1289. CROI: Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)
     
  1290. CROI: Antiretrovirals For Prevention: tenofovir, FTC, maraviroc; rectal, vaginal, semen. - (03/01/10)
     
  1291. CROI:Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/01/10)
     
  1292. CROI: Effect of Raltegravir-containing Intensification on HIV burden and T cell Activation in the Gut of HIV+ Adults on Suppressive Antiretroviral Therapy (ART) - reduced activation - (03/01/10)
     
  1293. CROI:Nadir CD4 Count Under 350 Predicts Arterial Stiffness in Case-Control Study - written by Mark Mascolini - (02/28/10)
     
  1294. CROI: Sociobehavioral Factors Affect Clinical Outcomes Apart From HIV Factors in Swiss Cohort - written by Mark Mascolini - (02/28/10)
     
  1295. CROI:Darunavir Penetrates Semen Well With High Levels Through 24 Hours - written by Mark Mascolini - (02/28/10)
     
  1296. CROI: Darunavir Concentrations in Seminal Plasma in patients receiving Darunavir/ritonavir(DRV/r) monotherapy: a MONOI-ANRS 136 substudy - (02/28/10)
     
  1297. CROI: Darunavir Monotherapy Increased Limb Fat - Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial : Results at 48 weeks - (02/28/10)
     
  1298. CROI: Maraviroc Levels in Cerebrospinal Fluid (CSF) and Seminal Plasma from HIV-Infected Patients - (02/28/10)
     
  1299. CROI: Correlates of Time-to-Loss-of-Viral-Response in CSF and Plasma in the CHARTER Cohort: CPE Score predicts CSF suppression (02/27/10)
     
  1300. CROI: Neuropsychological Performance is Better in HIV-Infected Subjects Treated with Neuroactive HAART (02/27/10)
     
  1301. CROI: Plasma HIV Load Strongest Predictor of CSF Load in CHARTER Cohort - written by Mark Mascolini - (02/26/10)
     
  1302. CROI: Early Initiation of Antiretroviral Therapy in HIV-Infected Individuals Is Associated with Reduced Arterial Stiffness: a low nadir CD4+ T-cell counts are associated with arterial stiffness as assessed by Aix and PWV - (02/26/10)
     
  1303. CROI:Inflammation Is Associated with Endothelial Dysfunction Among Individuals with Treated and Suppressed HIV Infection - (02/26/10)
     
  1304. CROI:High Prevalence of Severe Vitamin D Deficiency in cART Naïve and Successfully Treated Swiss HIV Patients - (02/26/10)
     
  1305. CROI: Vitamin D Deficiency and Bacterial Vaginosis among HIV-infected and -uninfected Women in the United States - (02/26/10)
     
  1306. CROI:Assessment of Vitamin D Levels Among HIV-infected Persons in the Study To Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) - (02/26/10)
     
  1307. CROI: The Discovery of S/GSK1349572: A Once Daily Next Generation Integrase Inhibitor with a Superior Resistance Profile - (02/25/10)
     
  1308. CROI: Positive HBV Vaccine Response Halves HIV Progression and Death Risk in US Military - written by Mark Mascolini - (02/25/10)
     
  1309. CROI: Cell Studies Point to Antiinflammatory Activity of Maraviroc - written by Mark Mascolini - (02/25/10)
     
  1310. CROI: Elvucitabine Versus 3TC in First-Line Regimens for 96 Weeks - see slides from poster below - written by Mark Mascolini - (02/25/10)
     
  1311. CROI:Early Antiretrovirals in People Diagnosed With AIDS May Quell Inflammation Faster - written by Mark Mascolini - (02/25/10)
     
  1312. CROI: The US Epidemic - Disparities in HIV Disease for African-Americans (02/25/10)
     
  1313. CROI:Maraviroc (MVC) Intensification for Suboptimal CD4+ Response Despite Sustained Virologic Suppression: ACTG 5256 (02/25/10)
     
  1314. CROI:CNS Toxicity of Antiretroviral Drugs (02/25/10)
     
  1315. CROI:Inflammation and Mortality in HIV-infected Adults: Analysis of the FRAM Study Cohort (02/25/10)
     
  1316. CROI:Effect of Atazanavir and Atazanavir/Ritonavir on the Pharmacokinetics of the Next Generation Integrase Inhibitor, S/GSK1349572 (02/25/10)
     
  1317. CROI:S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a Superior Resistance Profile Substantiated with 60 Integrase Mutant Molecular Clones (02/23/10)
     
  1318. CROI:Worse Neuropsych Scores Tied to Viral Rebounds in CSF and Plasma; CPE Score Tied to CSF Rebound - written by Mark Mascolini - (02/23/10)
     
  1319. CROI:Low CD4 Nadir Predicts Neurocognitive Problems Despite Good CD4 Gains - written by Mark Mascolini - (02/23/10)
     
  1320. CROI: Metabolic complications of HIV infection at CROI 2010 (Feb 16-19) -Pablo Tebas, University of Pennsylvania. Philadelphia.- (02/23/10)
     
  1321. CROI:Standard First Regimens Less Effective in US Blacks Than Others - written by Mark Mascolini - (02/23/10)
     
  1322. Activation of CD8 T Cells Predicts Progression of HIV Infection in Women Coinfected with Hepatitis C Virus - (02/24/10)
     
  1323. Can the further clinical development of bevirimat be justified? editorial - (02/24/10)
     
  1324. CROI:ART Improves Cerebral Blood Flow--But Not to Levels in HIV-Negatives - written by Mark Mascolini - (02/23/10)
     
  1325. CROI: Bone & Limb Fat Outcomes in ACTG5202- More Bone Loss With TDF/FTC Than ABC/3TC - written by Mark Mascolini - (02/23/10)
     
  1326. CROI:Bone Fractures at CROI 2010 - see slides below - (02/23/10)
     
  1327. CROI:Elevated Cancer Risks Remains in HAART Era: increasing mortality risk due to non-AIDS cancers- increased risk for these no-AIDS cancers - anal, liver, Hodgkin lymphoma, lung - (02/23/10)
     
  1328. CROI:Recent CD4 Predicts Risk for Cancers; Increased Risk for Anal/liver/Hodgkin Lymphoma/oral cavity pharynx cancers in HIV+ - (02/23/10)
     
  1329. CROI: Mixed Findings on Value of Brain-Penetrating Antiretroviral Scores - written by Mark Mascolini - (02/22/10)
     
  1330. CROI: Bone Disease: Risk Factors - (02/22/10)
     
  1331. CROI: Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen: DIVA 01 Study - (02/22/10)
     
  1332. CROI: Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients - (02/22/10)
     
  1333. CROI: Rapid Progression of Atherosclerosis at the Carotid Bifurcation Is Linked to Inflammation in HIV-infected Patients - "These data strongly suggest that inflammation contributes to the higher risk of atherosclerosis noted in HIV-infected persons." - (02/22/10)
     
  1334. CROI: CROI (2010 Feb 16-19) Selected Neurocognitive Abstracts - (02/22/10)
     
  1335. CROI: Vitamin D Deficiency Prevalence and Associations - (02/22/10)
     
  1336. CROI: A 48 week randomized study of uridine supplementation versus switch to tenofovir on limb fat, mitochondrial function, inflammation, and bone mineral density in HIV lipoatrophy - (02/22/10)
     
  1337. CROI: Uridine supplementation in the management of HIV lipoatrophy: Results of ACTG 5229 - (02/22/10)
     
  1338. CROI: Safety and Efficacy of TBR-652, a Chemokine Receptor 5 (CCR5) Antagonist, in HIV-1-Infected, Antiretroviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients - (02/22/10)
     
  1339. CROI: Discovery of Potent HIV-1 Capsid Assembly Inhibitors - (02/22/10)
     
  1340. CROI: T-cell Senescence and T-cell Activation Predict Carotid Atherosclerosis in HIV-infected Women - (02/22/10)
     
  1341. CROI: T-Cell Activation and Senescence Linked to Carotid Lesions in HIV+ Women - written by Mark Mascolini - (02/21/10)
     
  1342. CROI: Heart Risk Factors Tied to Neurocognitive Skills in SMART Substudy - written by Mark Mascolini - (02/21/10)
     
  1343. CROI:Baseline Liver Disease is Independently Associated with Risk of Death among HIV/HCV co-infected Adults with Histologic Staging - (02/20/10)
     
  1344. CROI:Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6-11 Years - (02/20/10)
     
  1345. CROI:High Triglycerides Independently Raise MI Risk in DAD Study - written by Mark Mascolini - (02/20/10)
     
  1346. CROI: Three Years With More Than 500 CD4s Normalizes Mortality in HIV+ Men - written by Mark Mascolini - (02/20/10)
     
  1347. CROI:Life Expectancy Approaches Normal in Dutch Without HIV Symptoms - written by Mark Mascolini - (02/20/10)
     
  1348. CROI: Chronic HIV and HCV Swell Stroke Risk in Veterans Aging Cohort - written by Mark Mascolini - (02/20/10)
     
  1349. CROI: Fast ART in Late Disease Means Slower Progression in Europe and Canada - written by Mark Mascolini - (02/20/10)
     
  1350. CROI:Heart Risk Falls With Time Since Quitting Smoking in DAD - written by Mark Mascolini - (02/20/10)
     
  1351. CROI: Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up - (02/20/10)
     
  1352. CROI:Chronic kidney disease and exposure to ARTs in a large cohrt with long-term follow-up: EuroSida - (02/20/10)
     
  1353. CROI: Bone & Limb Fat Outcomes in ACTG5202 Substudy: abacavir/3TC, tenofivir/FTC, efavirenz, atazanavir/r - (02/20/10)
     
  1354. CROI: Inflammation and Fibrosis Markers Tied to AIDS or Death After Good Virologic Response - written by Mark Mascolini - (02/19/10)
     
  1355. CROI:Inflammation Tied to Endothelial Dysfunction Despite Tight HIV Control - written by Mark Mascolini - (02/19/10)
     
  1356. CROI:Antiretroviral Risk Factors for Kidney Disease in EuroSIDA: Tenofovir Is Not Alone - written by Mark Mascolini - (02/19/10)
     
  1357. CROI:Most Non-AIDS Cancers Not Diagnosed at Earlier Age in People With AIDS - written by Mark Mascolini - (02/19/10)
     
  1358. CROI:HIV Load Tied to Fibrosis Signal in Women Without Hepatitis or Alcohol Abuse - written by Mark Mascolini - (02/19/10)
     
  1359. CROI: QUAD Four-in-One Pill as Strong as Atripla, But a Kidney Concern Arises - written by Mark Mascolini - (02/18/10)
     
  1360. CROI: Maraviroc Does Not Boost Stalled CD4s in Virologically Suppressed People - written by Mark Mascolini - (02/18/10)
     
  1361. CROI: Vicriviroc Does Not Outdo Placebo Regimen in Phase 3 Trials - written by Mark Mascolini - (02/18/10)
     
  1362. CROI: Older Age, Lower CD4 Nadir, NNRTI Use Predict Slow CD4 Recovery in ATHENA - written by Mark Mascolini - (02/18/10)
     
  1363. CROI: High Rate of Coronary Artery Problems in Young People Tied to TDF/FTC - written by Mark Mascolini - (02/18/10)
     
  1364. CROI: Low-Level Viremia Quadruples Death Risk in Canadian Cohort Study - written by Mark Mascolini - (02/18/10)
     
  1365. CROI: Side Effect and CD4 Differences in Four ACTG 5202 Arms at 96 Weeks - written by Mark Mascolini - (02/18/10)
     
  1366. CROI: RNA Spikes Predict Heart Disease, CD4s Predict Liver and Kidney Disease - written by Mark Mascolini - (02/18/10)
     
  1367. CROI: ODIN: efficacy and safety at 48 weeks of once-daily versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients with no darunavir resistance-associated mutations - (02/18/10)
     
  1368. CROI: Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)
     
  1369. CROI: ACTG5202 - (02/11/10)
     
  1370. CROI: New Data on ISENTRESS (raltegravir) Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) - Merck announcement - (02/18/10)
     
  1371. CROI: Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)
     
  1372. CROI: The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of Virologic Suppression and GS-9350 is an Effective Booster - (02/18/10)
     
  1373. Aciclovir reduced risk of HIV-1 disease progression by 16% - (02/15/10)
     
  1374. Treating HIV infection with drugs for HSV-2 infection? Commentary - (02/15/10)
     
  1375. Early Immune Senescence in HIV Disease - (02/15/10)
     
  1376. Barriers To Retention in Care in HIV and HCV - (02/10/10)
     
  1377. FDA approves expanded rosuvastatin label, Includes CRP - (02/10/10)
     
  1378. Neurologic Disease Despite Undetectable Viral Load & The Use of Drugs That Penetrate Well the CSF - pdf of full article attached - (02/08/10)
     
  1379. Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension - pdf attached - (02/08/10)
     
  1380. HIV Brain Impairment - (02/08/10)
     
  1381. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis - (02/08/10)
     
  1382. C-reactive protein and cardiovascular risk: more fuel to the fire - Comment - (02/08/10)
     
  1383. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero - (02/08/10)
     
  1384. Immunosupportive therapies in aging - pdf attached - (02/05/10)
     
  1385. The rate of mother-to-child HIV transmission among infants is 23 times higher for blacks than whites, the CDC reported. - (02/05/10)
     
  1386. Bone Loss in HIV+ Premenopausal Women & Fracture Risk - (02/04/10)
     
  1387. Protein in Urine Presages More Severe Problems - free full text link below - (02/04/10)
     
  1388. Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV: "veterans coinfected with HCV have significantly higher rates of CKD and mortality" - (02/04/10)
     
  1389. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women (and men) - (01/29/10)
     
  1390. NYS AIDS Institute guidelines on Acute HIV Seroconversion Updated Jan 2010 - (01/28/09)
     
  1391. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV - Workshop report - (01/28/10)
     
  1392. Life Expectancy & Comorbidities in HIV: - (01/27/09)
     
  1393. Diagnosis and management of vitamin D deficiency - (01/27/09)
     
  1394. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study - (01/27/09)
     
  1395. Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings - (01/27/09)
     
  1396. The anal Pap test as a screening tool- EDITORIAL - (01/27/09)
     
  1397. Kidney function and the risk of cardiovascular events in HIV-1-infected patients - (01/27/09)
     
  1398. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor and HIV protease inhibitors - (01/27/09)
     
  1399. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users - (01/27/09)
     
  1400. Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection - (01/27/09)
     
  1401. Vicriviroc Effective in Treatment-Experienced Patients in Phase 2 Study VICTOR-E1 - (01/26/09)
     
  1402. Proinflammatory IL-18 Increased in HIV+ Despite HAART - (01/26/09)
     
  1403. Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection - (01/26/09)
     
  1404. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters in SMART - (01/25/09)
     
  1405. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction - (01/25/09)
     
  1406. HIV Infection and Aging Independently Affect Brain Function as Measured by Functional Magnetic Resonance Imaging - BRIEF REPORT - (01/25/09)
     
  1407. Estimating the proportion of patients infected with HIV who will die of comorbid diseases - pdf attached - (01/20/09)
     
  1408. Fish Oil Slows Telomere Aging - (01/20/09)
     
  1409. Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection - (01/19/09)
     
  1410. HIV Life Expectancy Study Published - pdf attached - (01/19/09)
     
  1411. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies - (01/19/09)
     
  1412. Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years - (01/17/09)
     
  1413. Aerobic Exercise Improved Cognitive Function in Older Adults with Mild Cognitive Impairment - (01/17/09)
     
  1414. Moderate Mid-Life Exercise Prevents Mild Cognitive Impairment - (01/17/09)
     
  1415. Will HIV Drug Resistance Rates Increase? Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection - (01/17/09)
     
  1416. Treatment of HIV-Related Inflammatory Cerebral Cryptococcoma with Adalimumab - brief report - (01/17/09)
     
  1417. Quality-Of-Life Predicts Survival in HIV: HIV & aging - (01/17/09)
     
  1418. The MONET trial: darunavir/ritonavir (monotherapy) with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml - (01/16/09)
     
  1419. Visceral Fat Causes Inflammation and Cytokines Leading To Bone Loss - (01/16/09)
     
  1420. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men - (01/15/09)
     
  1421. Antihypertensive agents and prevention of dementia - Editorial - (01/14/09)
     
  1422. Hypertension Medications Use To Prevent Dementia & Alzheimer's - (01/14/09)
     
  1423. Study: Certain hypertension drugs may reduce Alzheimer's risk - (01/14/09)
     
  1424. Raltegravir SWITCHMRK Study Published in The Lancet jan 13 2010 - publication pdf attached - (01/14/09)
     
  1425. Association of C-Reactive Protein With Cognitive Impairment - (01/13/09)
     
  1426. GS-9148 Nucleotide Active Against Resistance - (01/13/09)
     
  1427. Chloroquine To Block Immune Activation - pdf attached - (01/13/09)
     
  1428. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study - BMJ Jan 2010 - (01/12/09)
     
  1429. Update on HIV Eradication.... Report from the 4th HIV Persistence Intl Wksp (Dec 8-11 2009, David Margolis, MD - written by David Margolis MD, University of North Carolina at Chapel Hill - (01/12/09)
     
  1430. Investigational HIV agents for salvage - (01/11/09)
     
  1431. HIV-Infected Postmenopausal Women at High Risk for Bone Fractures - pdf publication attached - (01/11/09)
     
  1432. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/10/09)
     
  1433. Cardiac Risk: Not So Simple - EDITORIAL COMMENTARY D.A.D Study - (01/10/09)
     
  1434. Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitus - (01/10/09)
     
  1435. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes - publication pdf attached - (01/10/09)
     
  1436. Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients - (01/10/09)
     
  1437. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/07/09)
     
  1438. Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy - (01/07/09)
     
  1439. hsCRP/inflammation & CVD in Patients with with low Framingham risk score & median CD4 of 500 & <50 HIV RNA - (01/07/09)
     
  1440. (EPO) Erythropoiesis-Stimulating Agents - Time for a Reevaluation - (01/07/09)
     
  1441. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/05/09)
     
  1442. Many Americans Have Pre-Diabetes and Should Be Considered for Metformin Therapy - (01/05/09)
     
  1443. Delay in Diagnosis of Diabetes Is Not the Patient's Fault - (01/05/09)
     
  1444. Comparison of A1C and Fasting Glucose Criteria to Diagnose Diabetes Among U.S. Adults - (01/05/09)
     
  1445. CD4 Recovery Severely Blunted After HAART Treatment Interruption - (01/05/09)
     
  1446. CCR5 Deficiency Is a Risk Factor for Early Clinical Manifestations of West Nile Virus Infection but not for Viral Transmission - (12/29/09)
     
  1447. Double-Edged Genetic Swords and Immunity: Lesson from CCR5 and Beyond EDITORIAL COMMENTARY - (12/29/09)
     
  1448. Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients - (12/29/09)
     
  1449. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (12/29/09)
     
  1450. Bypass Anemia Drugs in Chronic Kidney Disease, Expert Says - (12/29/09)
     
  1451. Treatment of Anemia in Chronic Kidney Disease - Strategies Based on Evidence EDITORIAL - (12/29/09)
     
  1452. Gender & Racial Differences in Discontinuation of HAART JAIDS Nov 2009 - (12/23/09)
     
  1453. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
     
  1454. Enhanced Reyataz & Efavirenz Co-Pay Benefit Program - (12/21/09)
     
  1455. Testosterone: More Is Not Always Better - EDITORIAL - (12/21/09)
     
  1456. Thyroid Function and Longevity: New Insights into an Old Dilemma - EDITORIAL - (12/21/09)
     
  1457. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals - (12/17/09)
     
  1458. White House Community Discussions in 14 Cities Videos - (12/17/09)
     
  1459. EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne (2) - (11/20/09)
     
  1460. Paying the Price for Late Starts and Early Stops: Racial and Sex Disparities in HIV-Related Mortality - EDITORIAL COMMENTARY - (12/15/09)
     
  1461. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy - (12/15/09)
     
  1462. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men (AIDS Dec 7 2009)-- pdf full text attached for you to download - (12/14/09)
     
  1463. EACS: The Impact of Maraviroc on Insulin Sensitivity, Lipids and Adipokines after 2 weeks in HIV Negative Male Volunteers - (12/10/09)
     
  1464. EACS: Pros and Cons of Boosted PI Monotherapy - (12/10/09)
     
  1465. Mediterranean Diet and Late-Life Cognitive Impairment -Editorial - (12/09/09)
     
  1466. Physical Activity, Diet, and Risk of Alzheimer Disease: In this study, both higher Mediterranean-type diet adherence and higher physical activity were independently associated with reduced risk for AD. - (12/09/09)
     
  1467. New Changes in DHHS Guidelines- HAART Recommended Earlier in HIV; new What To Start; DHHS Reasons for Changes - (12/04/09)
     
  1468. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial - (12/04/09)
     
  1469. Updated European (EACS) & USA Treatment Guidelines (DHHS) - (12/04/09)
     
  1470. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (12/03/09)
     
  1471. Physical Exercise Prevents Cellular Senescence in Circulating Leukocytes and in the Vessel Wall - (12/01/09)
     
  1472. When and how to use maraviroc in HIV-infected patients - (12/01/09)
     
  1473. New WHO HIV recommendations on HIV ART treatment, prevention & infant feeding to improve health, reduce infections and save lives - (12/01/09)
     
  1474. Long-Term Evolution and Determinants of Renal Function in HIV-Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE - BRIEF REPORT - (11/30/09)
     
  1475. Low Bone Mineral Density, Renal Dysfunction, and Fracture Risk in HIV Infection: A Cross-Sectional Study - (11/30/09)
     
  1476. EACS: New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+
     
  1477. IAS: HIV-1 INFECTION IN SUBJECTS OLDER THAN 70: A MULTICENTER CROSS-SECTIONAL ASSESSMENT IN CATALONIA, SPAIN - (11/29/09)
     
  1478. EACS: The ARTEN study: 48 week efficacy data stratified by screening viral load and CD4+ cell count - (11/30/09)
     
  1479. EACS: Pharmacokinetic interaction study between TMC278,an NNRTI, and the contraceptives norethindrone plus ethinylestradiol - (11/30/09)
     
  1480. EACS: Absorption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150mg in healthy male volunteers - (11/30/09)
     
  1481. EACS: Absence of a teratogenic potential from a novel next-generation NNRTI, TMC278 - (11/24/09)
     
  1482. EACS: TMC278 25mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers - (11/24/09)
     
  1483. EACS: Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (11/30/09)
     
  1484. EACS: A Pilot Study of Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral Naive HIV-1 Infected Subjects - (11/30/09)
     
  1485. EACS: Detrimental effect of current patient-reported drug holidays on long-term sub-optimal treatment out-come in advanced naive subjects initiating cART - (11/30/09)
     
  1486. EACS: Association of effectiveness and adherence of antiretroviral treatment - (11/30/09)
     
  1487. EACS: Impact of different types of adherence behaviours and of cART characteristics on plasma HIV-1 RNA detection under lower limit of quantification at real-time assay - (11/30/09)
     
  1488. EACS: Moving from risk factor assessment to atherosclerosis imaging to select the most appropriate patient for primary prevention: CVD algorithms underestimate risk in HIV+ - (11/30/09)
     
  1489. Oral Gonorrhea for Men & Women: pharynx a reservoir for gonorrhea - (11/24/09)
     
  1490. Chlamydia trachomatis and Neisseria gonorrhoeae Transmission from the Oropharynx to the Urethra among Men Who Have Sex with Men - (11/24/09)
     
  1491. FDA Approves Expanded Use of Selzentry for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time - (11/24/09)
     
  1492. EACS: Adherence to and quality of life of a one-pill once-a-day HAART (Atripla). Results of the ADONE study - (11/24/09)
     
  1493. EACS: The Effect of Antiretroviral Therapy Without CCR5-Antagonists on HIV-1 Tropism in the MOTIVATE Studies of Maraviroc in Treatment-Experienced Patients With R5 HIV-1 - (11/24/09)
     
  1494. EACS: Safety Profile of HIV-1 Patients Co-Infected With Hepatitis B or C in the Maraviroc Expanded Access Program - (11/24/09)
     
  1495. EACS: ASSESSMENT OF THE STEADY STATE PK PARAMETERS OF TWO EXTENDED RELEASE (XR) NEVIRAPINE (NVP) TABLETS 400 MG AND 300 MG QD COMPARED WITH IMMEDIATE RELEASE (IR) NVP TABLETS 200 MG BID IN HIV-1 INFECTED PATIENTS - THE ERVIR STUDY - (11/24/09)
     
  1496. EACS: Gender-Based Differences in Antiretroviral-Naïve Patients Treated With Ritonavir-Boosted Protease Inhibitors: Results From the CASTLE Study Through 96 Weeks - (11/24/09)
     
  1497. EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne - (11/20/09)
     
  1498. EACS: Viral Load Over 50 and Low CD4/CD8 Ratio Hoist MI Risk in French Cohort - Written Mark Mascolini - (11/20/09)
     
  1499. EACS: Risk of Cardiovascular Disease in ART-Naive People Without Heart Symptoms, Carotid Artery Ultrasonography May Be Useful - Written Mark Mascolini - (11/20/09)
     
  1500. EACS: Abdominal Adiposity Not Waning With Newer Antiretrovirals in France - Written Mark Mascolini - (11/20/09)
     
  1501. EACS: Metabolic Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV-infected Patients with Excess Abdominal Fat over a Period of 52 Weeks. A Pooled Analysis of 2 Multicenter, Double- blind, Placebo-controlled Phase 3 Trials with 816 Randomized Patients - (11/20/09)
     
  1502. EACS: "Deep" Sequencing to Identify Treatment-Experienced Patients Who Respond to Maraviroc (MVC) - (11/20/09)
     
  1503. EACS: Optimization of Clinically Relevant Cutpoints for the Determination of HIV Co-Receptor Usage to Predict Maraviroc Responses in Treatment Experienced (TE) Patients Using Population V3 Genotyping - (11/20/09)
     
  1504. EACS: Improved Treatment Compliance with Once-Daily (QD) Compared to Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) in HIV-1-Infected, Antiretroviral-Experienced Subjects - (11/20/09)
     
  1505. EACS: Impact of Baseline Resistance on Virologic Outcome with Once-Daily (QD) or Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) through 48 Weeks of Combination Antiretroviral Therapy in Treatment-Experienced, HIV-1-Infected Subjects - (11/20/09)
     
  1506. EACS: Diagnosis and management of cognitive disorders during successful HIV treatment - (11/20/09)
     
  1507. EACS: Simplified Antiretroviral Therapy in Special Populations: Clinical Outcomes at Week 48 of Lopinavir/ritonavir (LPV/r) Tablet Dosed Once Daily (QD) or Twice Daily (BID), Administered with ≥2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-experienced Subjects, Analyzed by Gender, Age, Race, Ethnicity, and Hepatitis Co-infection Status (Study M06-802) - (11/18/09)
     
  1508. EACS: Etravirine demonstrates a favourable safety and tolerability profile versus placebo irrespective of hepatitis co-infection: Week 96 analysis from the DUET trials - (11/24/09)
     
  1509. EACS: Kaletra QD Resistance Report: Lopinavir/ritonavir (LPV/r) with Tenofovir DF (TDF) and Emtricitabine (FTC) in Antiretroviral (ARV)-naïve Subjects - (11/18/09)
     
  1510. EACS: Etravirine demonstrates a favourable safety and tolerability profile: pooled 96-week results from the Phase III DUET trials - (11/18/09)
     
  1511. EACS: Safety and pharmacokinetics of etravirine in pregnant HIV-infected women - (11/18/09)
     
  1512. EACS: Tesamorelin Health-Related Quality of Life in HIV+ regarding belly and weight image - (11/18/09)
     
  1513. EACS: MIs, Cocaine/IVDUs French Database - (11/17/09)
     
  1514. EACS: S/GSK1349572 Integrase Inhibitor Resistance Profile - (11/17/09)
     
  1515. EACS: Potent Antiviral Activity of GSK Integrase S/GSK1349572 - (11/17/09)
     
  1516. EACS: A Phase II, open-label trial in treatment-naive, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/17/09)
     
  1517. EACS: Twice Daily Darunavir to Replace Dual Boosted Protease Inhibitors in Virologically Suppressed Patients - (11/17/09)
     
  1518. EACS: Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with HIV infection: meta-analysis of two randomised, non-inferiority trials BICOMBO and STEAL - (11/17/09)
     
  1519. EACS: Fatty Liver in HIV & HCV - (11/17/09)
     
  1520. EACS: A Phase II, open-label trial in treatment-naïve, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/15/09)
     
  1521. EACS: Darunavir Maintenance Monotherapy - (11/15/09)
     
  1522. EACS: Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naïve HIV-1 infected patients: ARTEN Study Week 48 results - (11/15/09)
     
  1523. EACS: Body Composition Changes in Treatment-Naive Patients Treated with Boosted Protease Inhibitors Plus Tenofovir/Emtricitabine: Results From the CASTLE Study Through 96 Weeks - (11/15/09)
     
  1524. EACS: Assessment of Safety and Efficacy of Abacavir/Lamivudine and Tenofovir/Emtricitabine in Treatment-Naïve HIV-1 Infected Subjects ASSERT: 48-Week Result - (11/15/09)
     
  1525. EACS: Once-Daily Dosing Ups Risk of Stopping Antiretrovirals in Single-Clinic Study - written by Mark Mascolini - (11/15/09)
     
  1526. EACS: Lower Intracellular Carbovir (Abacavir) Levels With Darunavir/Ritonavir - written by Mark Mascolini - (11/15/09)
     
  1527. EACS: Darunavir Troughs Lower With Raltegravir in Cross-Sectional Study - written by Mark Mascolini - (11/15/09)
     
  1528. EACS: More Evidence of Low Vitamin D in People Taking Antiretrovirals - written by Mark Mascolini - (11/15/09)
     
  1529. EACS: Study of Once-Daily Boosted Darunavir Monotherapy as First-Line Therapy Had Difficulty - written by Mark Mascolini - (11/15/09)
     
  1530. EACS: Multicohort Study Confirms Continuing Hodgkin Lymphoma Risk With HAART - written by Mark Mascolini - (11/15/09)
     
  1531. EACS: Good 4-Year HIV Response in People Over 60, But High Cancer and Heart Disease Rates - written by Mark Mascolini - (11/15/09)
     
  1532. EACS: Later Year and Age Over 50 Tied to Better Response After Triple-Class Failure - written by Mark Mascolini - (11/15/09)
     
  1533. EACS: Hodgkin Lymphoma, Liver Cancer, Anal Cancer More Common With HIV - written by Mark Mascolini - (11/13/09)
     
  1534. EACS: Mortality High With Non-AIDS Cancers in EuroSIDA Despite HAART - written by Mark Mascolini - (11/13/09)
     
  1535. EACS: More Than Half in HIV Patient Series Carry High-Risk Human Papillomavirus - written by Mark Mascolini - (11/13/09)
     
  1536. EACS: Rough Group Sex--Not Just Anal Sex--May Explain HCV Epidemic in HIV+ Gays - written by Mark Mascolini - (11/13/09)
     
  1537. EACS: MONET Paints Noninferiority Picture With Darunavir/Ritonavir Monotherapy - written by Mark Mascolini - (11/13/09)
     
  1538. EACS: Twice-Daily Darunavir/Ritonavir to Replace Double-Boosted PIs - written by Mark Mascolini - (11/13/09)
     
  1539. Aging is a significant risk factor for cognitive impairment. As the HIV cohort ages, further investigation is needed into the effects of aging on HIV cognitive impairment. - (11/10/09)
     
  1540. ViiV Healthcare Launches: GSK/Pfizer New HIV Company - (11/10/09)
     
  1541. AASLD: HCV/MSM Sex Transmission in HIV+ in New York City - (11/05/09)
     
  1542. IDSA: 144Week Efficacy & Safety of Raltegravir in TreatmentExperienced Patients, TripleClass Resistant - (11/01/09)
     
  1543. IDSA: (IDSA) TMC278 25mg qd has no effect on corrected QT interval in HIV-negative volunteers - (11/01/09)
     
  1544. IDSA: (IDSA) Predictors of Response in GRACE (Gender, Race And Clinical Experience) - (11/01/09)
     
  1545. IDSA: (IDSA) Darunavir, Ritonavir, and Etravirine Steady-state Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-infected Women Enrolled in the GRACE Study - (11/01/09)
     
  1546. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study - (11/01/09)
     
  1547. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials - (11/01/09)
     
  1548. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials - (11/01/09)
     
  1549. Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication - (11/01/09)
     
  1550. Role of metabolic syndrome components in HIV-associated sensory neuropathy - (11/01/09)
     
  1551. HIV infection and the risk of cancers with and without a known infectious cause - (11/01/09)
     
  1552. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Both once-daily saquinavir / ritonavir and atazanavir / ritonavir, when combined with tenofovir / emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reductions in glomerular filtration rate over 48 weeks: the BASIC trial - (10/28/09)
     
  1553. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naive HIV-1 infected patients: ARTEN Study Week 48 results - (10/28/09)
     
  1554. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Neuropsychiatric adverse events in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 copies/mL at screening - (10/27/09)
     
  1555. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Correlation between laboratory parameters and use or discontinuation of nucleoside analogues in the MONET trial - (10/27/09)
     
  1556. 11th Wrkshp Adverse Drug Reactions Co-morbidities: 48 week changes in Quality of Life and adherence in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 at screening - (10/27/09)
     
  1557. Cardiovascular Diseases and Risk of Hip Fracture - (10/27/09)
     
  1558. ACG: ACE Inhibitor Use Linked to Liver Toxicity - (10/27/09)
     
  1559. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America - (10/27/09)
     
  1560. Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe - BRIEF REPORT - (10/27/09)
     
  1561. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy - (10/25/09)
     
  1562. CDC Updated Oct 21 Interim Recommendations for H1N1 Influenza for HIV-Infected Adults and Adolescents - (10/25/09)
     
  1563. Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection - (10/25/09)
     
  1564. Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection - (10/25/09)
     
  1565. Increased Peripheral Proinflammatory Cytokines in HIV-1-Infected Patients With Prolonged Viral Suppression Suffering From High Psychological Stress - (10/25/09)
     
  1566. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand - (10/20/09)
     
  1567. HIV Vaccine Trial Results - An Opening for Further Research EDITORIAL - (10/20/09)
     
  1568. Adverse health effects of non-medical cannabis use - (10/17/09)
     
  1569. High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial - (10/16/09)
     
  1570. IL-2 in HIV: associated with vascular events, inflammation, and no clinical benefit despite CD4 increase - (10/16/09)
     
  1571. New Approach To Targeting The Hidden Reservoir Of HIV: Siliciano Can Screen Compounds with new system - (10/16/09)
     
  1572. Bone Loss in HCV/HIV Coinfection - (10/16/09)
     
  1573. ICAAC:TBR-652, A CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST, DEMONSTRATES GOOD ORAL BIOAVAILABILITY AND DESIRABLE PHARMACOKINETIC (PK) AND SAFETY PROFILES IN HEALTHY VOLUNTEERS - (10/13/09)
     
  1574. ICAAC: IN VITRO ANTI-HIV EFFICACY OF THE CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST TBR-652 IN COMBINATION WITH FOUR OTHER CLASSES OF ANTIRETROVIRAL AGENTS - (10/13/09)
     
  1575. Target HbA1c levels still the subject of much debate, but tailored therapy should be the aim - (10/12/09)
     
  1576. Clumsy FDA Antiviral Advisory Committee (Maraviroc hearing) for both HIV & HCV in the future - (10/12/09)
     
  1577. Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects: more colon lesions in HIV+ - (10/09/09)
     
  1578. FDA Antivirals Advisory Panel Recommends Maraviroc for Naives Approval 10-4 - (10/09/09)
     
  1579. "Current CD4 cell count was the most predictive risk factor for all malignancies apart from anal cancer" - - (10/09/09)
     
  1580. Diabetes Can Impair Exercise Capacity: Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus - (10/07/09)
     
  1581. Subcutaneous (lipoatrophy) Rather than Visceral Adipose Tissue Is Associated with Adiponectin Levels and Insulin Resistance in Young Men - (10/07/09)
     
  1582. Sex Hormones and Frailty in Older Men: The Osteoporotic Fractures in Men (MrOS) Study - (10/07/09)
     
  1583. Frontostriatal fiber bundle compromise in HIV infection without dementia - (10/06/09)
     
  1584. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels - (10/06/09)
     
  1585. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy - (10/06/09)
     
  1586. New Approach To Targeting The Hidden Reservoir Of HIV - (10/05/09)
     
  1587. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
     
  1588. Fall Prevention: how much vitamin D do you need? - (10/04/09)
     
  1589. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
     
  1590. Doctors Prescribe Caution With Insulin's Cancer Ties - (10/04/09)
     
  1591. ICAAC: HIV-Associated Neurocognitive Disorders in the Era of Potent Antiretroviral Therapy: risk factors/prevalence, CSF HIV-RNA, HCV, ART PK/penetration, assessment tools - (10/04/09)
     
  1592. Lipoatrophy & Mortality, CVD - (09/30/09)
     
  1593. A1C Underestimates Glycemia in HIV Infection - (09/30/09)
     
  1594. Diabetes 2 Caused Brain Atrophy in Older Individuals - (09/30/09)
     
  1595. Vitamin D Improves Muscle Function - (09/29/09)
     
  1596. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells (HIV eradication) - (09/29/09)
     
  1597. Renal function with use of a tenofovir-containing initial antiretroviral regimen - (09/29/09)
     
  1598. CCR5 antagonism in HIV infection: ways, effects, and side effects - (09/29/09)
     
  1599. Evaluation of Adherence and Factors Affecting Adherence to Combination Antiretroviral Therapy Among White, Hispanic, and Black Men in the MACS Cohort - (09/29/09)
     
  1600. Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations - (09/29/09)
     
  1601. Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers - (09/29/09)
     
  1602. Incidence of Non-AIDS-Defining Malignancies Higher in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression - (09/26/09)
     
  1603. ICAAC: Acute HBV & HCV Infection Among MSM: CDC Data from Population-Based Surveillance, 2006-2008 - (09/25/09)
     
  1604. Serum Immune Activation Markers Are Persistently Increased in Patients with HIV Infection after 6 Years of Antiretroviral Therapy despite Suppression of Viral Replication and Reconstitution of CD4+ T Cells - (09/25/09)
     
  1605. ICAAC: Differential Effects of Maraviroc (MVC) and Efavirenz (EFV) on Markers of Immune Activation (IA) and Inflammation and Their Association with CD4 Cell Rises: A Sub-analysis of the MERIT (09/21/09)
     
  1606. ICAAC: MERIT: Week 96 Virologic Response and Tropism at Virologic Failure by Baseline CD4+ Cell Count (09/21/09)
     
  1607. ICAAC: Maraviroc (MVC) is Similar to Efavirenz (EFV) for Virologic Response (VR) Across Subgroups: MERIT 96-Week (09/21/09)
     
  1608. Tenofovir Gel & Tablets PrEP Study: Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under Way (study in 5,000 women) - (09/21/09)
     
  1609. ICAAC:Renal Disease in Diabetics with HIV: "higher rate of microalbuminuria than either HIV-positive patients without diabetes or diabetics without HIV infection" - (09/21/09)
     
  1610. National HIV/AIDS and Aging Awareness Day (09/20/09)
     
  1611. ICAAC: Safety and Effectiveness of Raltegravir-based HAART in HIV-Subjects after Solid Organ Transplantation (09/20/09)
     
  1612. ICAAC: 24 Week Safety and Efficacy from IMPAACT P1066: A Phase I/II, Multicenter, Open-Label, Noncomparative Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth (09/20/09)
     
  1613. National HIV/AIDS and Aging Awareness Day (09/20/09)
     
  1614. ICAAC: Phenotypic Screening for HIV Tropism versus both Population-based and "Deep" Sequencing (09/20/09)
     
  1615. ICAAC: Direct comparison with 454 pyrosequencing validates V3-loop based genotyping in patients eligible for Maraviroc initiation (09/20/09)
     
  1616. ICAAC: Prediction of HIV Disease Progression Using a Modification of the Enhanced Sensitivity (ES) Trofile Assay (09/20/09)
     
  1617. ICAAC:Prevalence of HIV-1 CCR5 Co-Receptor Tropism Differs by Env (gp41) Subtype in a Large Commercial Dataset (09/20/09)
     
  1618. ICAAC: The composition of dual-mixed HIV-1 populations can be discerned from the level of CXCR4-mediated infectivity (09/20/09)
     
  1619. ICAAC: Incorporation of Optimized Primers into the Trofile Assay Substantially Improves Determination of Viral Tropism in Genetically Diverse HIV Subtypes (09/20/09)
     
  1620. ICAAC: "Deep" Sequencing to Quantify in vivo Viral Fitness after Transmission of Resistant HIV (09/20/09)
     
  1621. ICAAC:Raltegravir in CSF: "Raltegravir Concentrations in CSF Exceed The Median Inhibitory Concentration" (09/20/09)
     
  1622. ICAAC: Darunavir in the CSF: "Darunavir Concentrations in CSF Exceed The Median Inhibitory Concentration" (09/20/09)
     
  1623. ICAAC: ART Helps Bring Lungs Up to Par in Nonsmokers, But Not Smokers - written by Mark Mascolini - (09/19/09)
     
  1624. ICAAC: Pharmacokinetics and Safety of a Novel 100 mg Tablet Formulation of MPC-4326 in Subjects with HIV-1 Infection (09/19/09)
     
  1625. ICAAC: The Effect of Ritonavir-Boosted Protease Inhibitors on the HIV Integrase Inhibitor, S/GSK1349572, in Healthy Subjects (09/19/09)
     
  1626. ICAAC: Lack of Interaction between the HIV Integrase Inhibitor, S/GSK1349572, and Tenofovir Disoproxil Fumarate (TDF) in Healthy Subjects (09/19/09)
     
  1627. ICAAC: Meta-Analysis of Safety for Short-term Dosing of an HIV Integrase Inhibitor, S/GSK1349572, from Seven Clinical Studies (09/19/09)
     
  1628. ICAAC: In Vitro Passage of Drug Resistant HIV-1 against a Next Generation Integrase Inhibitor (INI), S/GSK1349572 (09/19/09)
     
  1629. ICAAC: Evaluation of Antacid and Multivitamin (MVI) Effects on S/GSK1349572 Pharmacokinetics (PK) in Healthy Subjects (09/19/09)
     
  1630. ICAAC: Endothelial Function Drops in First Month of Antiretroviral Therapy - written by Mark Mascolini - (09/18/09)
     
  1631. ICAAC: Peripheral Endothelial Function is Reduced after Initiation of Antiretroviral Therapy in Treatment Naïve HIV Patients: A Prospective Longitudinal Study (09/18/09)
     
  1632. ICAAC: Steady State Evaluation of Two Extended Release (XR) Nevirapine (NVP) Tablets 400 mg QD Compared with Immediate Release (IR) NVP Tablets 200 mg BID in HIV-1 Infected Patients (09/18/09)
     
  1633. ICAAC: Pharmacokinetic interaction between etravirine and lopinavir/ritonavir (09/18/09)
     
  1634. ICAAC: Bevirimat Antiviral Activity & Safety, 14-Day Monotherapy Study (09/18/09)
     
  1635. ICAAC: GRACE (Gender, Race And Clinical Experience): Outcomes by Race at Week 48 (09/17/09)
     
  1636. Eradication Drug Research: Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors - (09/17/09)
     
  1637. ICAAC: Sharp Drop in ICU Mortality After Introduction of HAART in Netherlands - written by Mark Mascolini - (09/17/09)
     
  1638. ICAAC: Vicriviroc Long-term Safety and Efficacy: 96-Week Results from the Extension of VICTOR-E1 Stud - (09/17/09)
     
  1639. ICAAC: INSPIRE Study: Effects of r-hIL-7 on T Cell Recovery and Thymic Output in HIV-infected Patients Receiving c-ART - Interim Analysis of a Phase I/IIa Multicenter Study - (09/17/09)
     
  1640. ICAAC: Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer GS-9350 versus Ritonavir - (09/17/09)
     
  1641. ICAAC: Effect of Food on Pharmacokinetics of Elvitegravir, Emtricitabine, Tenofovir DF and the Pharmacoenhancer GS-9350 as a Fixed- Dose Combination Tablet - (09/17/09)
     
  1642. ICAAC: Fasted Lipid Changes after Administration of Maraviroc or Efavirenz, both with Zidovudine and Lamivudine, to Treatment-Naive HIV-Infected Patients: 96-Week Results from MERIT - (09/17/09)
     
  1643. ICAAC: Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects GSK press release - (09/17/09)
     
  1644. ICAAC: Improvement in Fasting Lipids but Minimal Recovery of Limb Fat Were Seen 96 Weeks After Switching from Lamivudine/Zidovudine Plus Efavirenz to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-Infected Patients - (09/17/09)
     
  1645. ICAAC: Phase 2a Study of PRO 140 in HIV-Infected Adults - (09/17/09)
     
  1646. ICAAC: Can IL-7 Succeed Where IL-2 Failed in People With HIV? - written by Mark Mascolini - (09/17/09)
     
  1647. ICAAC: Once-Daily Replacement Raltegravir as Good as Twice-Daily in Pilot Trial - written by Mark Mascolini - (09/17/09)
     
  1648. ICAAC: Another Small Study Suggests Viability of Unboosted Atazanavir/Raltegravir Maintenance - written by Mark Mascolini - (09/17/09)
     
  1649. ICAAC: Faster Viral Decay With Nevirapine Than Atazanavir/Ritonavir in ARTEN Trial - written by Mark Mascolini - (09/17/09)
     
  1650. ICAAC: Gut-Shielding Mix Slows CD4 Drop in People Not Taking Antiretrovirals - written by Mark Mascolini - (09/17/09)
     
  1651. ICAAC: Gilead GS-9350 Protease Inhibitor Booster - written by Mark Mascolini - (09/17/09)
     
  1652. ICAAC: Raltegravir Reaches Good Nervous System Levels 4.3 Fold x EC50 - written by Mark Mascolini - (09/17/09)
     
  1653. ICAAC: GSK "Backup" Integrase Inhibitor Looks Strong in People With HIV: 10-day monotherapy study - written by Mark Mascolini - (09/17/09)
     
  1654. ICAAC: Early Virological and Immunological Response is Comparable between Nevirapine and RTV-boosted Atazanavir: An ARTEN Sub-analysis - (09/17/09)
     
  1655. ICAAC: A Pilot Study assessing Raltegravir QD versus BID in HIV patients included in a Simplification Trial - (09/17/09)
     
  1656. ICAAC: Dual Maintenance Therapy with Raltegravir 400 mg BID with Atazanavir 400 mg qD in Patients with no Prior PI Resistance and Intolerance to Other ARV Regimens: Preliminary Report - (09/17/09)
     
  1657. ICAAC: SCHERING-PLOUGH REPORTS LONG-TERM VICRIVIROC DATA FROM PHASE II OPEN-LABEL EXTENSION STUDY IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS - Schering-Plough press releaser - (09/17/09)
     
  1658. ICAAC: Discovery of GS-9350: A Novel Pharmacoenhancer without Anti-HIV Activity - (09/17/09)
     
  1659. ICAAC: Pharmacokinetics (PK) and Safety in Healthy and HIV-Infected Subjects and Short-Term Antiviral Efficacy of S/GSK1265744, a Next Generation Once Daily HIV Integrase Inhibitor - (09/17/09)
     
  1660. ICAAC: Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 48-Week Data - (09/17/09)
     
  1661. ICAAC: Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects - (09/14/09)
     
  1662. Gardasil HPV vaccine for boys - FDA Hearing Oct 21 - (09/11/09)
     
  1663. ICAAC: Weighted Antiretroviral Sensitivity Score May Be Better Predictor of Short-Term Response - written by Mark Mascolini - (09/14/09)
     
  1664. ICAAC: Seven Short Studies Suggest Good Safety Profile of New Integrase Inhibitor - written by Mark Mascolini - (09/14/09)
     
  1665. ICAAC: Merck's ISENTRESS (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients - Merck press release - (09/14/09)
     
  1666. ICAAC: Raltegravir Demonstrates Durable Efficacy Through 96 Weeks: Results from STARTMRK, A Phase III Study of Raltegravir-based vs. Efavirenz-based Therapy in Treatment-Naïve HIV+ Patients - (09/14/09)
     
  1667. ICAAC: Effects of CYP2B6 Single Nucleotide Polymorphisms (SNPs) and Substance Abuse on Efavirenz (EFV) Pharmacokinetics - (09/14/09)
     
  1668. ICAAC: Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals - (09/14/09)
     
  1669. ICAAC: Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and buprenorphine/naloxone - (09/14/09)
     
  1670. ICAAC: Early Changes in HCV Viral Load During the First 24 Hours of Treatment Exhibit a Very High Negative Predictive Value of Sustained Virological Response in HCV/HIV Coinfected Patients - (09/14/09)
     
  1671. ICAAC:Role for Short-Term Enfuvirtide to Boost CD4s After Late Diagnosis? - written by Mark Mascolini - (09/14/09)
     
  1672. ICAAC: Lab Study Suggests High Barrier to Resistance With New Integrase Inhibitor - written by Mark Mascolini - (09/14/09)
     
  1673. ICAAC: Smoking and Drinking Alcohol Linked to Lower Efavirenz Levels - written by Mark Mascolini - (09/14/09)
     
  1674. ICAAC: Tobacco and Marijuana Tied to Lower Atazanavir Concentrations - written by Mark Mascolini - (09/14/09)
     
  1675. ICAAC: DC Emergency Patients Who Decline HIV Test Have Twice Higher HIV Rate - written by Mark Mascolini - (09/14/09)
     
  1676. ICAAC: Impact of One-Time or Annual HIV Screening on Life Expectancy in France - written by Mark Mascolini - (09/14/09)
     
  1677. ICAAC: HCV Load Decay in First Day of PegIFN Treatment Predicts Long-Term Failure - written by Mark Mascolini - (09/14/09)
     
  1678. HIV and Aging: The Long-term Consequences of Successful Antiretroviral Therapy - (09/11/09)
     
  1679. HIV, HAART & Brain Damage & Repair - (09/11/09)
     
  1680. Effect of HAART on Risk of Sexual Transmission of HIV & Superinfection - CDC Report - (09/11/09)
     
  1681. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients - (09/11/09)
     
  1682. Sex Steroids & Fracture Risk in Men - (09/06/09)
     
  1683. Lipodystrophy & Bone Loss - (09/06/09)
     
  1684. Vitamin D, Diabetes & Bone in African-Americans - (09/06/09)
     
  1685. Inflammation & Diabetes, Interventions - (09/06/09)
     
  1686. The model for end-stage liver disease score (MELD) is the best prognostic factor in HIV 1-infected patients with end-stage liver disease: A prospective cohort study - (09/03/09)
     
  1687. Viable strategies to facilitate liver transplantation for HIV/HCV coinfection - Editorial - (09/03/09)
     
  1688. A Potential Role for Vitamin D on HIV Infection? - (09/03/09)
     
  1689. Vitamin D Immunomodulator EDITORIAL - (09/03/09)
     
  1690. Low Vitamin D Levels Increased Risk for HIV MTCT: Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania - (09/03/09)
     
  1691. Resting cerebral blood flow A potential biomarker of the effects of HIV in the brain - (09/03/09)
     
  1692. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients in TITAN - (09/03/09)
     
  1693. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people - (08/29/09)
     
  1694. Neurological Impairment Persists Despite HAART: "adjunctive therapies needed" - (08/29/09)
     
  1695. Insulin Resistance Is Associated With Cognition Among HIV-1-Infected Patients: The Hawaii Aging With HIV Cohort - (08/29/09)
     
  1696. HCV Coinfection & Neurologic Impairment - (08/29/09)
     
  1697. 5th IAS: Association between activation of inflammatory and coagulation pathways and mortality during long-term follow up in SMART - (08/29/09)
     
  1698. 5th IAS: HAART Interruption Increased Inflammation - IMPACT OF HAART INTERRUPTION ON PLASMA INFLAMMATORY MARKERS ASSOCIATED WITH CARDIOVASCULAR DISEASE FINAL 36-MONTH RESULTS FROM A RANDOMIZED STUDY - (08/29/09)
     
  1699. 5th IAS: HAART Did Not Control Immune Activation - (08/29/09)
     
  1700. 5th IAS: HAART Interruption Increases Immune Activation - (08/29/09)
     
  1701. 5th IAS: Kaletra Protects Mitochondria - (08/29/09)
     
  1702. Untreated HIV Infection and Large and Small Artery Elasticity - "Untreated HIV infection is associated with impaired arterial elasticity" - (08/28/09)
     
  1703. Higher CPE Score Improved Cognition, Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders - (08/28/09)
     
  1704. 5th IAS: Prevalence of HIV-1-Associated Neurocognitive Disorders in Argentina - (08/28/09)
     
  1705. Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss - pdf attached - (08/27/09)
     
  1706. Mild Glucose Intolerance In Pregnancy May Be Associated With Cardiovascular Risk - (08/26/09)
     
  1707. The clot thickens-oxidized lipids and thrombosis - (08/26/09)
     
  1708. Oxidized lipids: a key to heart disease? - (08/26/09)
     
  1709. Aging/HIV Clinical Care & Research - New IDSA Guidelines - (08/26/09)
     
  1710. Thyroid Dysfunction, Hypogonadism, Testosterone, Bone, Prostate Cancer, HIV & HAART - (08/26/09)
     
  1711. Aging & HIV Recognized as a Serious Concern But No Real Discussion, Still Ignored. 2007 NIH Workshop recommendations - (08/26/09)
     
  1712. Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse-Transcriptase Inhibitor-Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA) - (08/21/09)
     
  1713. Vitamin D Deficiency/Muscle Function/Frailty - (08/21/09)
     
  1714. GSK says latest Avandia findings are flawed: new pio vs rosiglitazone study - (08/20/09)
     
  1715. Diagnosis and management of neuropathic pain - Clinical Review - (08/20/09)
     
  1716. NIH Workshop on HIV in Older Adults Oct 20 2007 - (08/18/09)
     
  1717. A serum 25-hydroxyvitamin D level below 50 nmol/l has been associated with increased body sway and a level below 30 nmol/l with decreased muscle strength. - (08/18/09)
     
  1718. Vitamin D deficiency, muscle function, and falls in elderly people1,2 Review Article - (08/18/09)
     
  1719. 5th IAS: IAS: darunavir & etravirine studies - (08/16/09)
     
  1720. New IDSA HIV Guidelines Push 'Adherence to Care' - (08/17/09)
     
  1721. FDA Approves Generic Fixed Dose Efavirenz/FTC/Tenofovir - (08/14/09)
     
  1722. 5th IAS: Kaletra Once-Daily Dosing, IAS Summary - (08/14/09)
     
  1723. 5th IAS: Reyataz Studies at IAS - (08/14/09)
     
  1724. 5th IAS: Maraviroc IAS Reports: MERIT (naives), Genotype vs Tropism (MOTIVATE), Malignancies Report (MOTIVATE) - (08/14/09)
     
  1725. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a - (08/14/09)
     
  1726. Coinfection with Hepatitis C Virus and HIV: More than Double Trouble - EDITORIAL COMMENTARY - (08/14/09)
     
  1727. 5th IAS: Abacavir & MIs - IAS Summary - (08/12/09)
     
  1728. 5th IAS: Cancers & HIV at IAS Summary Report - (08/12/09)
     
  1729. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy (HCV, IVDU) - (08/12/09)
     
  1730. New Expanded Access Rules to Investigational Drugs for Treatment Use and Charging for Investigational Drugs - (08/12/09)
     
  1731. FDA Expands Access to Investigational Drugs - (08/12/09)
     
  1732. Lipoatrophy and lipohypertrophy are independently associated with hypertension - (08/12/09)
     
  1733. Physical Activity, Diet, and Risk of Alzheimer Disease (65% reduction in risk) - (08/12/09)
     
  1734. Mediterranean Diet and Late-Life Cognitive Impairment EDITORIAL - (08/12/09)
     
  1735. tenofovir & abacavir - Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients  - (08/12/09)
     
  1736. Study Suggests Immune Systems of Untreated HIV-Infected Individuals May Deteriorate Faster than Previously Thought - NIH BULLETIN - (08/12/09)
     
  1737. Midlife Serum Cholesterol and Increased Risk of Alzheimer's and Vascular Dementia Three Decades Later- pdf attached - (08/12/09)
     
  1738. Structural biology: Aerial view of the HIV genome - (08/12/09)
     
  1739. Oral Cancer In Men Associated With HPV - (08/12/09)
     
  1740. Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir - New UK CHIC Study BRIEF REPORT - (08/12/09)
     
  1741. Thiazolidinediones and Fractures in Men and Women - (08/12/09)
     
  1742. Bone Guidelines Excerpted From New IDSA Guidelines- pdf of full paper attached  - (08/12/09)
     
  1743. Prevalence and Associations of 25-Hydroxyvitamin D Deficiency in US Children: NHANES 2001-2004 - pdf of published report attached - (08/12/09)
     
  1744. 5th IAS: New Drugs, New strategies - written by Joe Eron MD - (08/12/09)
     
  1745. WHO May Recommend HAART for PMTCT: IAS - (08/07/09)
     
  1746. Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission - (08/07/09)
     
  1747. WHO may change ARV guidelines for pregnant mothers: HAART reduces HIV transmission while breastfeeding - (08/07/09)
     
  1748. New review endorses CV benefits of fish oil - (08/06/09)
     
  1749. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases - (08/06/09)
     
  1750. HIV-associated brain dysfunction in the era of HAART - Editorials, Reasons for hope, but continued concern - (08/06/09)
     
  1751. The Pathogenetic Role of Cortisol in the Metabolic Syndrome (and lipodystrophy): A Hypothesis - (08/06/09)
     
  1752. Continuous antiretroviral therapy decreases bone mineral density in SMART - (08/06/09)
     
  1753. 5th IAS: Similar Declines in HIV-1 RNA (Viral load, VL) from Baseline (BL) to 96 Weeks Observed in Subjects Randomized to ABC/3TC or TDF/FTC each with Lopinavir/Ritonavir (LPV/r) in the HEAT Trial (EPZ104057) - (08/04/09)
     
  1754. 5th IAS: Efficacy, safety and tolerability of dual therapy with raltegravir 400mg bid and atazanavir 200mg bid in antiretroviral experienced patients. - (08/04/09)
     
  1755. 5th IAS: 91% Have Low Vitamin D Levels in UK Cohort, 34% Severely Deficient; Efavirenz use is associated with severe Vitamin D deficiency in a large, ethnically diverse, urban UK HIV cohort - (08/04/09)
     
  1756. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women - it accumulated at high levels quickly in CVF & vaginal tissue - (08/04/09)
     
  1757. Bone mineral density and disorders of mineral metabolism in chronic liver disease: Cirrhotics Have Low Bone Density & Low Vitamin D Levels - (08/04/09)
     
  1758. -2.5% Bone Loss Over 96 Weeks on PI or NNRTI in study reported - (08/04/09)
     
  1759. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial -- attached is pdf and appendix with adverse events - (08/04/09)
     
  1760. Scientists learn why even treated genital herpes sores boost the risk of HIV infection - (08/04/09)
     
  1761. 5th IAS: Earlier HAART at 350 CD4 Instead of Current 200 in Developing World Recommended - (08/01/09)
     
  1762. 5th IAS: Preliminary analyses suggest a higher rate of HIV seroconversion among men who were HPV positive at baseline - (08/01/09)
     
  1763. 5th IAS: Virologic Suppression on Maraviroc in Treatment-Naive Patients With R5 HIV-1 is Similar to Efavirenz at High Baseline Viral Load, and Maraviroc Discontinuations for Adverse Events are Less Likely to Show Drug Resistance: 48-Week Results From the MERIT Study - (08/01/09)
     
  1764. 5th IAS: Duration of Viral Suppression Strongly Modifies the Adherence-Viral Rebound Relationship - (08/01/09)
     
  1765. Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure - (07/31/09)
     
  1766. 5th IAS: Neurocognitive Disorders Despite Undetectable HIV RNA - (07/31/09)
     
  1767. 5th IAS: Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida (07/31/09)
     
  1768. 5th IAS: 48 week lipid- and glucose-related safety profile of darunavir/ritonavir in treatment-experienced, paediatric patients in DELPHI - (07/31/09)
     
  1769. 5th IAS: HIV Infection Modulates Cellular Proteins Associated With Cardiovascular Disorders - (07/31/09)
     
  1770. 5th IAS: Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1 Infected Patients: Final Results of the Randomized ANRS 138 Trial (EASIER). - (07/31/09)
     
  1771. CROI: Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and association with low nadir CD4 count in the MOST study - (06/02/09)
     
  1772. 5th IAS: HIV Prevention at IAS 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (07/30/09)
     
  1773. 5th IAS: Genital HIV-1 RNA Concentrations and Heterosexual HIV-1 Transmission Risk: 'higher genital HIV levels increase HIV sex transmission risk' - (07/30/09)
     
  1774. 5th IAS: MIs & ARTs: Nested Control Study in Quebec Cohort - (07/30/09)
     
  1775. 5th IAS: Predictive factors of serious vascular events in HIV patients in LATINA (LATInamerican Network on AIDS) - (07/30/09)
     
  1776. 5th IAS: Influence of patient baseline clinical and demographic characteristics on choice of initial antiretroviral therapy regimen: evidence of channeling bias in HIV clinical care - (07/30/09)
     
  1777. 5th IAS: Metabolic Complications of HIV infection Update form the 5th IAS Conference in Cape Town - Pablo Tebas MD, University of Pennsylvania - (07/30/09)
     
  1778. 5th IAS: Persistence and Progression of HIV-associated Neurocognitive Impairment (NCI) in the Era of Combination Antiretroviral Therapy (CART) and the Role of Comorbidities: The CHARTER Study - (07/30/09)
     
  1779. Bioavailability of Efavirenz Capsule Contents (Sprinkles) Mixed with a Small Amount of Food Compared with Intact Capsules in Healthy Adults - (07/29/09)
     
  1780. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  1781. 5th IAS: Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV Infection in Africa in the DART trial - (07/30/09)
     
  1782. 5th IAS: Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring - press release - (07/30/09)
     
  1783. 5th IAS: DART Study Slide Presentation at IAS - (07/30/09)
     
  1784. 5th IAS: Omega-3 polyunsaturated fatty acids inhibit the release of matrix metalloproteinases: therapeutic implications for HIV-associated immune activation - (07/30/09)
     
  1785. CHMP Recommends Expanded Use of ISENTRESS® (raltegravir), from MSD, in Treatment-Naïve Adult Patients with HIV-1 Infection - (07/29/09)
     
  1786. 5th IAS: Efavirenz Linked to Severe Vitamin D Deficit in Diverse London Clinic - written by Mark Mascolini - (07/29/09)
     
  1787. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz - (07/29/09)
     
  1788. HIV Can Kill Chimps; Infectious diseases: An ill wind for wild chimps? - (07/29/09)
     
  1789. 5th IAS: What CD4 Cell Count Levels are Associated With a Reduced Risk of Cancer? 'When To Begin HAART' - (07/29/09)
     
  1790. 5th IAS: HIV Regimens Lacking Nucleosides Tied to Higher SVR Rate With HCV Therapy - written by Mark Mascolini - (07/29/09)
     
  1791. 5th IAS: Varying Risk of AIDS and Non-AIDS Cancers in Diverse CD4 Brackets - written by Mark Mascolini - (07/29/09)
     
  1792. 5th IAS: Half in US HIV Group Have Neurocognitive Impairment, Which Improves With NNRTIs - written by Mark Mascolini - (07/29/09)
     
  1793. 5th IAS: Two Triple PEP Regimens With Truvada Look Safer Than Older PEPs - written by Mark Mascolini - (07/29/09)
     
  1794. 5th IAS: TB Rate in South African Township Plummets After Antiretrovirals Arrive - written by Mark Mascolini - (07/29/09)
     
  1795. 5th IAS: Anal Cancer Rates Keep Climbing in US HIV Group Despite HAART - written by Mark Mascolini - (07/29/09)
     
  1796. 5th IAS: Triple Antiretrovirals Cut Breastfeeding HIV Transmission Rate Below 1% - written by Mark Mascolini - (07/29/09)
     
  1797. 5th IAS: Adding Raltegravir to Suppressive Regimen Does Not Cut Low-Level Viremia - written by Mark Mascolini - (07/29/09)
     
  1798. 5th IAS: More Time With Low CD4 Count Boosts Non-AIDS Cancer Risk - written by Mark Mascolini - (07/29/09)
     
  1799. 5th IAS: THE FOTOSTUDY 48 week Results to assess durability of the strategy of taking Efavirenz, Tenofovir and Emtricitabine Five-days-On, Two-days-Off each week in virologically suppressed patients - (07/29/09)
     
  1800. 5th IAS: ARTEMIS: Week 96 safety and efficacy of darunavir/r by gender, age and race - (07/29/09)
     
  1801. 5th IAS: Efficacy and Safety of Atazanavir/RTV vs. Lopinavir/RTV in Treatment-Naïve Patients with Advanced Disease: CASTLE Study 96-Week Results - (07/29/09)
     
  1802. 5th IAS: Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)
     
  1803. 5th IAS: Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results - (07/29/09)
     
  1804. 5th IAS: Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)
     
  1805. 5th IAS: Efficacy and Safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial - (07/29/09)
     
  1806. 5th IAS: Comparable Safety and Efficacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730 - (07/28/09)
     
  1807. 5th IAS: Highly prevalent vitamin D deficiency and insufficiency among an urban cohort of human immunodeficiency virus (HIV)-infected men under care - (07/28/09)
     
  1808. 5th IAS: ARTs Cause Bone Loss - (07/28/09)
     
  1809. 5th IAS: Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana - (07/28/09)
     
  1810. 5th IAS: Cumulative & Current Viral Replication & Low CD4 Increases NHL Risk: Immune deficiency, uncontrolled HIV replication and non-Hodgkin's lymphoma, ANRS CO3 Aquitaine Cohort, 1998-2006. - (07/28/09)
     
  1811. 5th IAS: ISENTRESS (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy - (07/23/09)
     
  1812. Tight Glucose Control Raises Mortality Risk in Heart Failure in a New Study - (07/23/09)
     
  1813. HIV & Kidney Disease: African-Americans with HIV are more susceptible to type of kidney disease known as HIVAN - (07/23/09)
     
  1814. 5th IAS: Screening for HIV Tropism using Population-based V3 Genotypic Analysis: a Retrospective Virologic Outcome Analysis Using Stored Plasma Screening Samples from the MOTIVATE Studies of Maraviroc in Treatment Experienced Patients - (07/23/09)
     
  1815. 5th IAS: Abacavir Not Associated with MIs, 2 Studies Report at IAS - (07/23/09)
     
  1816. 5th IAS: Swiss Suicide Risk Still High With HIV, But HAART Made a Difference - written by Mark Mascolini - (07/22/09)
     
  1817. 5th IAS: Atazanavir Effective After Atazanavir/Ritonavir Induction in Naive Patients - written by Mark Mascolini - (07/22/09)
     
  1818. 5th IAS: Kaletra Once vs Twice Daily - (07/22/09)
     
  1819. 5th IAS: Once- and Twice-Daily Lopinavir/Ritonavir Equivalent in Antiretroviral Experienced - written by Mark Mascolini - (07/22/09)
     
  1820. 5th IAS: Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study - written by Mark Mascolini - (07/22/09)
     
  1821. 5th IAS: Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study; HCV Therapy Quadrupled Chance For Fibrosis Regression - written by Mark Mascolini - (07/22/09)
     
  1822. 5th IAS: Second Trial of Darunavir Monotherapy Seems Less Convincing - written by Mark Mascolini - (07/22/09)
     
  1823. 5th IAS: Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive, HIV-1-infected ARTEMIS patients at Week 96 - (07/22/09)
     
  1824. 5th IAS: Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/22/09)
     
  1825. 5th IAS: Reyataz Induction/Maintenance From Boosted to Unboosted: Similar Efficacy and Tolerability of Atazanavir (ATV) Compared to Atazanavir/Ritonavir (ATV/r), each with Abacavir/Lamivudine (ABC/3TC) after Initial Suppression with ABC/3TC + ATV/r: 84 Week Results of the ARIES Trial - (07/22/09)
     
  1826. 5th IAS: Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients - press release - (07/22/09)
     
  1827. 5th IAS: EPZICOM + atazanavir regimen provided comparable efficacy to EPZICOM + atazanavir/ritonavir regimen in treatment-naive HIV-infected patients - press release - (07/22/09)
     
  1828. 5th IAS:Incidence and Risk Factors for Malignancies in Treatment-experienced (TE) Patients in the MOTIVATE Studies of Maraviroc (MVC) + Optimized Background Therapy (OBT): 96-Week Follow-up - (07/22/09)
     
  1829. 5th IAS: A randomized multicenter study to compare the efficacy of a monotherapy of darunavir to a triple therapy with 2 nucleosides analogues combined to darunavir/r in HIV infected patients with full viral suppression: MONOI ANRS 136 - (07/22/09)
     
  1830. 5th IAS: Long-Term Bone Loss Similar With PI- and NRTI-Sparing Regimens - written by Mark Mascolini - (07/21/09)
     
  1831. 5th IAS: Blacks and Women Have Worse Virologic Response in Trial of ABC/3TC vs TDF/FTC - written by Mark Mascolini - (07/21/09)
     
  1832. 5th IAS: Raltegravir Rescue Regimens Do Well With or Without a PI - written by Mark Mascolini - (07/21/09)
     
  1833. 5th IAS: Nevirapine Combo May Work for Some Kids Exposed to Single-Dose Nevirapine - written by Mark Mascolini - (07/21/09)
     
  1834. 5th IAS: Adding More NRTIs to Salvage May Lower Chance of Response - written by Mark Mascolini - (07/21/09)
     
  1835. 5th IAS: Once-Daily Darunavir Monotherapy Effective for 48 Weeks After Viral Control - written by Mark Mascolini - (07/21/09)
     
  1836. 5th IAS: New Once-Daily Integrase Inhibitor Looks Strong in Early Trial - written by Mark Mascolini - (07/21/09)
     
  1837. 5th IAS: Attacking LDL Cholesterol in People on ARVs Has Mixed Results - written by Mark Mascolini - (07/21/09)
     
  1838. 5th IAS: Recovery of Functional Immunity over 48 Weeks with Darunavir-based Therapy in the GRACE Immunology Substudy - (07/21/09)
     
  1839. 5th IAS: The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline - (07/21/09)
     
  1840. 5th IAS: Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/21/09)
     
  1841. 5th IAS: The MERIT Study of Maraviroc in Antiretroviral-Naive Patients With R5 HIV-1: 96-Week Results - (07/21/09)
     
  1842. 5th IAS: 96-Week Merit Es Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naive HIV Patients; Results Consistent With 48-Week Analysis - Pfizer press release - (07/21/09)
     
  1843. 5th IAS: Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol - (07/21/09)
     
  1844. 5th IAS: Sustained Antiretroviral Efficacy of Raltegravir as part of Combination ART in Treatment-Naive HIV-1 infected patients: 144-week data - (07/21/09)
     
  1845. 5th IAS: Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients - (07/21/09)
     
  1846. 5th IAS: Pharmacokinetics (PK) and Safety in Healthy Subjects of S/GSK1349572, a Next Generation, Once-Daily HIV Integrase Inhibitor (INI) - (07/21/09)
     
  1847. 5th IAS: GRACE: New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies - (07/21/09)
     
  1848. 5th IAS: African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09)
     
  1849. 5th IAS: Differences in Virologic Response Among African Americans and Females Regardless of Therapy in the HEAT Study: African-Americans Have Lower Viral Response Rates - (07/21/09)
     
  1850. Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1-Infected Individuals - (07/20/09)
     
  1851. 5th IAS: One Third With Undetectable HIV RNA Have Asymptomatic Neurocognitive Impairment - written by Mark Mascolini - (07/20/09)
     
  1852. 5th IAS: Raltegravir and Unboosted Atazanavir as Simple Maintenance Regimen - written by Mark Mascolini - (07/20/09)
     
  1853. 5th IAS: Abacavir Heart Attack Controversy: Kidney Disease Appears to Matter - written by Mark Mascolini - (07/20/09)
     
  1854. 5th IAS: New results from ARTEN study of nevirapine plus tenofovir and emtricitabine (TDF/FTC) versus boosted protease inhibitor regimen of atazanavir/ritonavir plus TDF/FTC revealed - BI Press Release For U.S. Media Only - (07/20/09)
     
  1855. 5th IAS: S/GSK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy - (07/20/09)
     
  1856. 5th IAS: 96-WEEK SAFETY AND EFFICACY FINDINGS PRESENTED FOR INTELENCETM (ETRAVIRINE) AS PART OF HIV COMBINATION THERAPY - Tibotec press release - (07/20/09)
     
  1857. 5th IAS: S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor - (07/20/09)
     
  1858. 5th IAS: Prospective randomised comparison of Nevirapine and Atazanavir/ritonavir both combined with Tenofovir DF/Emtricitabine in treatment-naive HIV-1 infected patients: ARTEN Study week 48 results - (07/20/09)
     
  1859. 5th IAS: NEW HIV STUDY SHOWS THAT LARGE NUMBERS OF WOMEN AND PEOPLE OF COLOR CAN BE SUCCESSFULLY ENROLLED IN U.S. HIV CLINICAL STUDIES - Tibtec press release - (07/20/09)
     
  1860. 5th IAS: IAS Opening Session - Recession Impact - (07/20/09)
     
  1861. 5th IAS: Thinking Through the CNS: The Importance of Considering the Blood-Brain Barrier. Slide talk by Scott Letende, GSK satellite meeting at IAS 2009 - (07/19/09)
     
  1862. 5th IAS: European Researchers Issuing Guidelines on Bone Disease - (07/19/09)
     
  1863. HIV-1 Infection Is Associated With an Earlier Occurrence of Frailty....in MACS - (07/18/09)
     
  1864. Male Circumcision Didn't Reduce HIV Transmission To Women in African Study - (07/18/09)
     
  1865. Male circumcision and HIV risks and benefits for women - EDITORIAL - (07/18/09)
     
  1866. Mortality in WIHS, Women of Color: non-AIDS Events, Viral Replication & low CD4, Depression, Violence, HCV/HBV, Drug Use: Federal AIDS funding neglects inner-city women of color - (07/17/09)
     
  1867. HIV Viral Replication Causes Non-AIDS Events - (07/17/09)
     
  1868. TMC278+Truvada Coformulation Announced by Gilead & Tibotec - (07/17/09)
     
  1869. Lopinavir/Ritonavir in Pregnancy - (07/16/09)
     
  1870. Vicriviroc/Reyataz Nuke-Sparing HAART: Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV - (07/16/09)
     
  1871. Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study - (07/16/09)
     
  1872. Growth Hormone and Sex Steroid Effects on Serum Glucose, Insulin, and Lipid Concentrations in Healthy Older Women and Men - (07/16/09)
     
  1873. MRI Findings May Track Risk of Cognitive Impairment in Healthy Seniors - (07/16/09)
     
  1874. Lower Testosterone Levels Predict Incident Stroke and Transient Ischemic Attack in Older Men - (07/16/09)
     
  1875. Low Serum Testosterone and Estradiol Predict Mortality in Elderly Men - (07/16/09)
     
  1876. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population - (07/15/09)
     
  1877. DDI Associated with NonCirrhotic Portal Hypertension - (07/14/09)
     
  1878. Grinding to a Halt: The Effects of the Increasing Regulatory Burden on Research and Quality Improvement Efforts - IDSA POLICY PRINCIPLES - (07/10/09)
     
  1879. FDA: Isentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients - (07/10/09)
     
  1880. Glutamic Acid (Vegetables) May Lower Blood Pressure - (07/10/09)
     
  1881. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women - A preliminary study - (07/10/09)
     
  1882. New HIV Research Finds Early Disabled Immune Response - (07/09/09)
     
  1883. Independent effects of physical activity in patients with nonalcoholic fatty liver disease: exercise improves fatty liver & metabolics - (07/08/09)
     
  1884. Nitrates May Be Environmental Trigger For Alzheimer's, Diabetes And Parkinson's Disease - (07/08/09)
     
  1885. Global Consequences of the Future of Aging with HIV - (07/08/09)
     
  1886. Stepped-Dose vs. Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events A Randomized Trial - (07/08/09)
     
  1887. Study finds no increased progression of retinopathy with sanofi-aventis' Lantus - (07/08/09)
     
  1888. Epidemilogical Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis - (07/08/09)
     
  1889. A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection - full text pdf attached - (07/07/09)
     
  1890. IL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection - pdf full text attached - (07/07/09)
     
  1891. IL-21 Is Required to Control Chronic Viral Infection - pdf full text attached - (07/07/09)
     
  1892. Immunology Controlling Chronic Viral Infections, EDITORS' CHOICE - (07/07/09)
     
  1893. A Chronic Need for IL-21 EDITORIAL - (07/07/09)
     
  1894. Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy - (07/04/09)
     
  1895. Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat EDITORIAL - (07/04/09)
     
  1896. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy - (07/04/09)
     
  1897. Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events? - (07/03/09)
     
  1898. IL-7 Increased T-Cells CD4/CD8/Naive/Memory: In HIV, Cytokine Boosts Immune System  - (07/03/09)
     
  1899. Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study - (07/03/09)
     
  1900. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance - (07/03/09)
     
  1901. Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapy EDITORIAL - (07/03/09)
     
  1902. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients - (07/03/09)
     
  1903. Metabolic bone disease in HIV infection: HIV, ART Implicated EDITORIAL - (07/02/09)
     
  1904. First line AZT/3TC/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir - (07/02/09)
     
  1905. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (07/02/09)
     
  1906. Inflammation Marker hsCRP & CVD- Cause or Effect: Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease - (07/02/09)
     
  1907. Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community: "Minimal Benefit In Predicting CVD Compared To Traditional Risk Factors" - (07/02/09)
     
  1908. Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment - Editorial - (07/02/09)
     
  1909. CRP, other biomarkers, not clinically useful to predict CVD risk - (07/02/09)
     
  1910. New meta-analysis: Statins of benefit in primary prevention: improved survival & CVD risk in patients with only risk factors - (07/02/09)
     
  1911. HIV Resistance Wksp: Bulk sequence-detectable resistance mutations in peripheral RNA following single-dose nevirapine are associated with poorer treatment responses but do not adequately explain treatment failure (06/26/09)
     
  1912. HIV Resistance Wksp: Addition of extended zidovudine to extended nevirapine prophylaxis reduces resistance in infants who were HIV-infected in utero: the PEPI- Malawi Study - (06/28/09)
     
  1913. HIV Resistance Wksp: Resistance mutations detected by OLA of HIV-1 DNA at the initiation of nevirapine containing ART are associated with virologic failure - (06/28/09)
     
  1914. HIV Resistance Wksp: Pre-Existing Low-Levels of the K103N HIV-1 RT Mutation Above a Threshold is Associated with Virological Failure in Treatment-Naïve Patients Undergoing EFV-Containing Antiretroviral Treatment (06/16/09)
     
  1915. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants - (06/27/09)
     
  1916. Monitoring bone mineral density during antiresorptive treatment for osteoporosis - Editorial - (06/27/09)
     
  1917. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data - (06/27/09)
     
  1918. The Value of Bone Density Testing - (06/27/09)
     
  1919. Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study - (06/27/09)
     
  1920. Head-to-head 96-week study shows EPZICOM® was comparable to Truvada® -- in efficacy and safety measures -- for HIV treatment-naïve patients - (06/27/09)
     
  1921. HIV Resistance Wksp: Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants - (06/27/09)
     
  1922. HIV Resistance Wksp: CCR5 Tropism Genotype vs Trofile - (06/27/09)
     
  1923. HIV Resistance Wksp: Virco: Population and clonal tropism phenotyping of clinical isolates and comparison with next generation sequencing and prediction tools - (06/27/09)
     
  1924. HIV Resistance Wksp:Quest Tropism Assay: Performance of an HIV-1 Co-receptor Tropism Assay Utilizing Replicate V3 Loop Sequencing and Heteroduplex Analysis with Capillary Electrophoresis - (06/27/09)
     
  1925. HIV Resistance Wksp: Virco: Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays - (06/27/09)
     
  1926. HIV infection and the risk of diabetes mellitus in Vets - (06/26/09)
     
  1927. Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction - (06/26/09)
     
  1928. Analysis of HIV-1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy - (06/26/09)
     
  1929. New HIV Eradication Theory: 2nd reservoir identified, HAART + IL-7 Inhibition - (06/26/09)
     
  1930. HIV Resistance Wksp: HIV Reservoirs and Potential Eradication - Written by Mark A. Wainberg, Ph.D. Professor and Director, McGill University AIDS Centre - (06/26/09)
     
  1931. HIV Resistance Wksp: PERSISTENCE, RESERVOIRS AND ELIMINATION STRATEGIES - Reported by David Margolis, University of North Carolina (06/26/09)
     
  1932. New Anti-Inflammation Modulator Improves Kidney/Diabetes Functions; for CNS disease too - (06/21/09)
     
  1933. Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys - (06/19/09)
     
  1934. HIV Resistance Wksp: Phenotypic Resistance and Response to Tipranavir, evidence for Hypersusceptibility (06/19/09)
     
  1935. HIV Resistance Wksp: Emergence of mutations and phenotypic resistance with tipranavir treatment in protease inhibitor experienced patients (06/19/09)
     
  1936. HIV Resistance Wksp: Tipranavir & Darunavir, Prevalences of mutations in patients with discordant phenotypic resistance from Monogram Biosciences database of routine clinical samples from 2006 - 2008 (06/19/09)
     
  1937. HIV Resistance Wksp: Tipranavir - Phenotypic protease inhibitor resistance in the clinic from 2006 to 2008: available treatment options (06/19/09)
     
  1938. Interleukin-2: Trials and Tribulations; IL-2 Fails Again, EDITORIAL COMMENTARY - (06/17/09)
     
  1939. HIV Resistance Wksp: Genotypic, Phenotypic and Virtual Phenotypic Resistance Patterns for Darunavir and Tipranavir: An Independent Analysis of a Quebec HIV-1 Cohort Highly Resistant to all Other Protease Inhibitors (06/17/09)
     
  1940. HIV Resistance Wksp: Amino Acid Changes in gp41 of HIV-1 Associated with Coreceptor Tropism (06/17/09)
     
  1941. HIV Resistance Wksp: Transitions from CCR5 to CXCR4 use in the absence of antiretroviral drug pressure proceed incrementally and may occur through a multitude of genetic pathways: Monogram Report, Vs loop changes vary (06/17/09)
     
  1942. HIV Resistance Wksp: PI-Resistant Virus Seems More Prone to Emergence of Bevirimat Mutations - written by Mark Mascolini (06/16/09)
     
  1943. HIV Resistance Wksp: Genotypic and Phenotypic Weighted Optimized Background Therapy Susceptibility Scores Are Similarly Strong Predictors of Virologic Response <50 Copies/mL at Week 48 in MOTIVATE 1 and 2 (06/16/09)
     
  1944. HIV Resistance Wksp: 48-Week Results From the Phase 3 Study A4001026 (MERIT) -"Time to Loss of Virologic Response" Virology Analysis of Failures in the Enhanced Trofile®-Censored Subpopulation (06/16/09)
     
  1945. 7th Euro HIV Drug Resis Wrkshp: Ultradeep pyrosequencing and phenotypic analysis to characterize the V3 genetic diversity among HIV-1 primary isolates and their responses to maraviroc - (06/16/09)
     
  1946. HIV Resistance Wksp: High -Prevalence of bevirimat resistance mutations in non-B subtypes and in PI resistant HIV isolates (06/16/09)
     
  1947. HIV Resistance Wksp: Resistance Mutations in the Viral Protease Alter Bevirimat Resistance Patterns in vitro (06/16/09)
     
  1948. HIV Resistance Wksp: Prevalence and Clinical Significance of Transmitted Drug Resistant HIV Mutations by Ultra-Deep Sequencing in HIV-Infected ARV-Naïve Subjects in the CASTLE Study (06/16/09)
     
  1949. HIV Resistance Wksp: Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir (06/16/09)
     
  1950. HIV Resistance Wksp: Swiss Cohort Analysis Reveals Clusters of Transmitted Resistant HIV: "make sure patient names remain unlinked to transmission analyses" - written by Mark Mascolini - (06/16/09)
     
  1951. HIV Resistance Wksp: Low-Level K103N in Primary Infection Can Reappear After Suppressive Therapy - written by Mark Mascolini - (06/16/09)
     
  1952. HIV Resistance Wksp: CCR5 and CCR5 Screening Assays Comparisons: genotype, 454 Ultra-Deep Sequencing and Trofile (06/15/09)
     
  1953. HIV Resistance Wksp: Screening for HIV Tropism Using Population-Based V3 Genotypic Analysis: A Retrospective Virological Outcome Analysis Using Stored Plasma Screening Samples From MOTIVATE 1 (06/15/09)
     
  1954. HIV Resistance Wksp: In-vitro resistance profile of TMC278, a next-generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first-generation NNRTIs (06/15/09)
     
  1955. HIV Resistance Wksp: Weighted Genotype and Phenotypic Scores Predict Response to Maraviroc - written by Mark Mascolini - (06/15/09)
     
  1956. HIV Resistance Wksp: Key Etravirine Mutations Also Render HIV Resistant to Rilpivirine - written by Mark Mascolini - (06/15/09)
     
  1957. HIV Resistance Wksp: STD History Tied to Infection With Resistant HIV in San Francisco - written by Mark Mascolini - (06/15/09)
     
  1958. HIV Resistance Wksp: Low-Level Etravirine Mutations With K103N After NNRTI Failure - written by Mark Mascolini - (06/15/09)
     
  1959. HIV Resistance Wksp: Low-Level Q148R in People Without Integrase Inhibitor Experience - written by Mark Mascolini - (06/15/09)
     
  1960. HIV Resistance Wksp: Evolving Mutation Patterns Traced During Elvitegravir Failure - written by Mark Mascolini - (06/15/09)
     
  1961. HIV Resistance Wksp: Rising Rates of 3-Class Exposure But Falling Failure Rate in US Cities - written by Mark Mascolini - (06/15/09)
     
  1962. HIV Resistance Wksp: Transmitted Multidrug-Resistant HIV Persists in PBMC DNA for Years - written by Mark Mascolini - (06/15/09)
     
  1963. HIV Resistance Wksp: The HIV-1 RT Mutant Q151L Shows Decreased Replication Capacity, Selective High-Level Resistance to GS-9148 and Hypersusceptibility to Tenofovir and Zidovudine - (06/15/09)
     
  1964. HIV Resistance Wksp: HBV Resistance to Lamivudine at Undetectable and Low Levels of Viremia - written by Mark Mascolini - (06/15/09)
     
  1965. HIV Resistance Wksp: Early Response to Maraviroc Equivalent With Coreceptor Genotyping and Trofile Phenotyping - written by Mark Mascolini - (06/15/09)
     
  1966. HIV Resistance Wksp: Most Low-Level Pretreatment Mutations Did Not Affect Outcome in PI Trial - written by Mark Mascolini - (06/15/09)
     
  1967. HIV Resistance Wksp: Cutoffs Suggested for Predicting Efavirenz Failure With Low-Level K103N - written by Mark Mascolini - (06/15/09)
     
  1968. HIV Resistance Wksp: Regimens Lacking CCR5 Antagonists Have Minimal Impact on Coreceptor Use - written by Mark Mascolini - (06/12/09)
     
  1969. HIV Resistance Wksp: Lower M184V Rates With FTC/TDF Than With 3TC/TDF - written by Mark Mascolini - (06/12/09)
     
  1970. HIV Resistance Wksp: Raltegravir Did Not Lower HIV DNA Levels in Cell Reservoirs in Salvage Patients in 24 Weeks - written by Mark Mascolini - (06/12/09)
     
  1971. HIV Resistance Wksp: Intensification of Already Suppressive Therapy with Raltegravir Had No Impact on Low-Level (sub-50-copy) Viremia - written by Mark Mascolini - (06/12/09)
     
  1972. HIV Resistance Wksp: HIV Genetic Diversity Does Not Change Much After Complete Viral Control - written by Mark Mascolini - (06/12/09)
     
  1973. HIV Resistance Wksp: NNRTI/PI Regimen More Prone to Resistance Than Standard Triple Combos - written by Mark Mascolini - (06/12/09)
     
  1974. HIV Resistance Wksp: Success Rate With Genotype-Guided First Regimen Near 90% in California - written by Mark Mascolini - (06/12/09)
     
  1975. Thiazolidinediones and clinical outcomes in type 2 diabetes Comment - (06/09/09)
     
  1976. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial - (06/09/09)
     
  1977. PPI Use & Risk For Hip Fracture (Tagamet & Zantac to) - (06/09/09)
     
  1978. Drug Interactions with New and Investigational Antiretrovirals: darunavir, etravirine, rilpivirine (TMC278), maraviroc, vicriviroc, raltegravir, elvitegravir, INCB 9471 (CCR5), bevirimat [Review Articles] - (06/09/09)
     
  1979. Can HIV Be Eradicated? - (06/08/09)
     
  1980. Study in Neurology journal (Aug 2008) Reports Alzheimers Appears to Precede Frailty and Study in Jnl of Geronotology (2007) in the MACS Cohort Reports Risk of Frailty Higher in HIV+ vs HIV-; is early onset of Alzheimers or some other brain or cognitive dysfunction related to early onset and higher rates of frailty among HIV+? - (06/08/09)
     
  1981. DATA ON INVESTIGATIONAL DRUG TMC207 FOR TREATMENT OF MDR-TUBERCULOSIS, PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE - Tibotec announcement - (06/05/09)
     
  1982. TMC207, New Drug for TB MultiDrug Resistant (MDR) & XDR (extensively drug resistant) - (06/05/09)
     
  1983. Aspirin in CVD primary prevention: sex and baseline risk matter - (06/04/09)
     
  1984. Gardasil in Older Women Aged 24-45 Years - (06/04/09)
     
  1985. FDA Approves Zoledronic Acid - Reclast(R) - to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing, Once Every 2 Years - (06/03/09)
     
  1986. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy - (06/03/09)
     
  1987. Maraviroc Safety/CD4 - A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1 - (06/03/09)
     
  1988. HIV Viremia and the Development of AIDS-Related Lymphoma in Patients Treated with Highly Active Antiretroviral Therapy - EDITORIAL COMMENTARY - (06/03/09)
     
  1989. Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictor of AIDS-Related Lymphoma - (06/03/09)
     
  1990. CROI: Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (06/02/09)
     
  1991. Antiaging Therapy with TAT2: Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD8+ T Lymphocytes - (06/02/09)
     
  1992. Modulation of T Lymphocyte Replicative Senescence via TNF-{alpha} Inhibition: Role of Caspase-31 - (06/01/09)
     
  1993. Duration of antihypertensive drug use and risk of dementia: "Antihypertensive drug use was associated with 8% risk reduction of dementia per year of use for persons <75 years." - (05/29/09)
     
  1994. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons - (05/29/09)
     
  1995. Hypertension and late-life dementia - Editorial - (05/29/09)
     
  1996. Routine Use of Antihypertensive Medications Recommended For All Older People Even Those Who Do Not Have High Blood Pressure - (05/29/09)
     
  1997. Give blood pressure drugs to all - Criticism/Commentary - (05/29/09)
     
  1998. Editorials Management of blood pressure in primary care - (05/29/09)
     
  1999. In NFL, Higher Rates of Hypertension/Prehypertension & BMI (large size) Associated with Increased Cardiovascular Risk - (05/28/09)
     
  2000. Review of Prostate Cancer Treatment A 64-Year-Old Man With Low-Risk Prostate Cancer - (05/28/09)
     
  2001. Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients - (05/28/09)
     
  2002. Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir - (05/28/09)
     
  2003. Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis - (05/28/09)
     
  2004. Lipoatrophy Influenced by Genetics - (05/28/09)
     
  2005. Lipoatrophy and lipohypertrophy (belly fat not associated after BMI factored in) are independently associated with hypertension - (05/27/09)
     
  2006. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? - (05/27/09)
     
  2007. Hyperglycaemia and coronary heart disease: the meta picture - EDITORIAL - (05/27/09)
     
  2008. It is "premature to conclude that glucose control has no part to play." - (05/27/09)
     
  2009. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials - (05/27/09)
     
  2010. The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals - (05/27/09)
     
  2011. Sustained release of microbicides by newly engineered vaginal rings - TMC120/tenofovir/AZT - (05/26/09)
     
  2012. Interaction of Ginkgo biloba with efavirenz - (05/26/09)
     
  2013. Efavirenz and bone health - (05/22/09)
     
  2014. Maturation Inhibitor Bevirimat, now called MPC-4326, Starting Phase 2b in 2nd Half 2009 - (05/22/09)
     
  2015. Efavirenz and bone health - (05/22/09)
     
  2016. Maturation Inhibitor Bevirimat, now called MPC-4326, Starting Phase 2b in 2nd Half 2009 - (05/22/09)
     
  2017. Does HIV Increase Prostate Cancer Risk? - (05/21/09)
     
  2018. Effects of Oxidation and Inflammation, Cancer, Prostate Cancer - (05/21/09)
     
  2019. ACTG 5142 Published: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment - (05/21/09)
     
  2020. HIV viremia and changes in kidney function - (05/21/09)
     
  2021. ACTG 5164 Published: Early HAART Reduces AIDS/Death in Individuals with Acute OIs - (05/21/09)
     
  2022. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men - (05/21/09)
     
  2023. Immune Exhaustion in Aging and AIDS: Parallel Mechanisms and Possible Solutions - (05/21/09)
     
  2024. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis - (05/20/09)
     
  2025. Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men - (05/18/09)
     
  2026. Kidney Damage in Metabolic Syndrome: Nip It in the Bud - EDITORIAL - (05/18/09)
     
  2027. Kidney Pathological Changes in Metabolic Syndrome: A Cross-sectional Study - (05/18/09)
     
  2028. C-Reactive Protein, Statins, and Cardiovascular Risk: What Can JUPITER Teach Us? - (05/18/09)
     
  2029. 10th Int PK Wrkshp: 10th International Workshop on Clinical Pharmacology of HIV Therapy Written by Courtney V. Fletcher, Pharm.D. - (05/18/09)
     
  2030. Predicting risk of dementia in older adults. The late-life dementia risk index - Aging !!!! - (05/15/09)
     
  2031. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence - REVIEW ARTICLE - (05/15/09)
     
  2032. Ejaculation Frequency and Subsequent Risk of Prostate Cancer - "high ejaculation frequency was related to decreased risk of total prostate cancer." - (05/15/09)
     
  2033. Data on the Use of GARDASIL in Men Presented at the 25th Annual International Papillomavirus Conference - (05/15/09)
     
  2034. THE EFFFICACY OF QUADRIVALENT HPV (TYPES 6/11/16/18) VACCINE AGAINST HPV-RELATED GENITAL DISEASE AND INFECTION IN YOUNG MEN - (05/15/09)
     
  2035. Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects - (05/14/09)
     
  2036. Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States; Increased Hypothyroidism Reported un HIV+ - (05/14/09)
     
  2037. Elevated A1C in Adults Without a History of Diabetes in the U.S. - (05/14/09)
     
  2038. Tenative approval of lamivudine/zidovudine fixed dose combination tablets plus nevirapine tablets - (05/14/09)
     
  2039. Raltegravir+Etravirine - Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort - (05/14/09)
     
  2040. Increased Reporting of Detectable Plasma HIV-1 RNA Levels at the Critical Threshold of 50 Copies per Milliliter With the Taqman Assay in Comparison to the Amplicor Assay - (05/14/09)
     
  2041. Implementation of HIV Testing at 2 New York City Bathhouses: From Pilot to Clinical Service (4% HIV+) - (05/14/09)
     
  2042. Availability of HIV Postexposure Prophylaxis Services in Los Angeles County - (05/14/09)
     
  2043. RNA Testing for HIV Instead of Antibody Testing Could Detect Early Stage of HIV Infection And Would Likely Improve Prevention AND Allow for Early HAART' Could it Prevent Accelerated Aging? - (05/13/09)
     
  2044. Dementia with features of Alzheimer's disease and HIV-associated dementia in an elderly man with AIDS (case study) - (05/13/09)
     
  2045. Cancers in HIV Review in AIDS May 15 2009 - (05/13/09)
     
  2046. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial - (05/13/09)
     
  2047. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival (NA-ACCORD): deferring HAART til <500 CD4s increased risk of death 94% - (05/11/09)
     
  2048. WHO Guidance for HIV Patient Care & Swine Flu - (05/11/09)
     
  2049. HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials - (05/11/09)
     
  2050. Hypoglycemia Increased Risk for Death in Diabetics with Chronic Kidney Disease: - (05/11/09)
     
  2051. 10th Int PK Wrkshp: First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Negative Women - (04/30/09)
     
  2052. Interim Results of Abbott's PROGRESS Study Show Rapid Viral Decline in Dual-Therapy Regimen of Kaletra® (lopinavir/ritonavir) and Raltegravir - Abbott press release - (04/30/09)
     
  2053. Sunlight and Vitamin D Both Good for Cardiovascular Health - (04/22/09)
     
  2054. Tight Glycemic Control NOT Recommended for Diabetics in Annals Review - (04/22/09)
     
  2055. A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease - (04/22/09)
     
  2056. 10th Int PK Wrkshp: Raltegravir Levels in Cervicovaginal Fluid May Prompt PEP and PrEP Studies - written by Mark Mascolini - (04/21/09)
     
  2057. 10th Int PK Wrkshp: Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor - written by Mark Mascolini - (04/20/09)
     
  2058. 10th Int PK Wrkshp: Differing Darunavir Troughs With Once- and Twice-Daily Dosing in Practice - written by Mark Mascolini - (04/20/09)
     
  2059. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial - (04/20/09)
     
  2060. Glucocorticoid-induced osteoporosis: hope on the HORIZON-COMMENT once yearly infusion therapy better than once weekly - (04/20/09)
     
  2061. Reversing HIV T-Cell Aging - (04/20/09)
     
  2062. HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty: HIV+ men in MACS 10-Times More Likely to Exhibit Frailty than HIV-negative Men. - (04/20/09)
     
  2063. MACS Frailty/HIV/CD4 Study Misses The Point - (04/20/09)
     
  2064. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance - (04/20/09)
     
  2065. PrEP, Microbicides and IL-2 - (04/20/09)
     
  2066. 15th Annual British HIV Conference April 1-3 2009 Abstracts/Presentations - (04/20/09)
     
  2067. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up - (04/20/09)
     
  2068. Lopinavir/Ritonavir (LPV/r) Combined With Raltegravir (RAL) Provides More Rapid Viral Decline Than LPV/r Combined With Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-naïve HIV-1 Infected Subjects - (04/20/09)
     
  2069. Ignoring Addiction in Prison/Jails Increases HIV & HCV Infections - (04/20/09)
     
  2070. Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus - (04/20/09)
     
  2071. the REYATAZ and SUSTIVA Co-pay Benefit Program - (04/20/09)
     
  2072. Treatment Interruption Revisited with LOTTI Study: authors reported interruptions were not inferior to continuous HAART in this study - (04/20/09)
     
  2073. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases - (04/20/09)
     
  2074. 10th Int PK Wrkshp: Unboosted Atazanavir Plus Raltegravir Analyzed as Two-Drug Replacement Regimen - written by Mark Mascolini - (04/20/09)
     
  2075. 10th Int PK Wrkshp: Etravirine Levels Higher When Added After Darunavir vs With Darunavir - written by Mark Mascolini - (04/20/09)
     
  2076. 10th Int PK Wrkshp: Enfuvirtide-to-Raltegravir Switch Lowers Levels of Darunavir and Tipranavir - written by Mark Mascolini - (04/20/09)
     
  2077. CROI: Prevention of Rectal Simian HIV Transmission in Macaques by Intermittent Pre-exposure Prophylaxis with Oral Truvada - (04/17/09)
     
  2078. 10th Int PK Wrkshp: Efavirenz Lowers Levels of Darunavir Given as 900/100 mg Once Daily With Ritonavir - (04/16/09)
     
  2079. 10th Int PK Wrkshp: Early Look at Once-Daily Darunavir/Ritonavir for Treatment-Experienced Patients - written by Mark Mascolini - (04/16/09)
     
  2080. 10th Int PK Wrkshp: How Much (or How Little) Ritonavir Do You Need to Boost Another PI? - written by Mark Mascolini - (04/16/09)
     
  2081. 10th Int PK Wrkshp: Lopinavir/Ritonavir Monotherapy as an Antiretroviral Stopping Strategy - written by Mark Mascolini - (04/16/09)
     
  2082. 10th Int PK Wrkshp: Genetic Markers Tied to Early Discontinuation of Three Antiretrovirals - (04/16/09)
     
  2083. IDUs Risky Behavior: < 32% share syringes/63% have unprotected vaginal sex, CDC Study - (04/10/09)
     
  2084. Screening for Albuminuria Identifies Individuals at Increased Renal Risk - (04/10/09)
     
  2085. Should the CD4 threshold for starting ART be raised? Commentary - (04/10/09)
     
  2086. Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints - (04/10/09)
     
  2087. Vitamin D Deficiency in Older Men - (04/09/09)
     
  2088. Relationships of Serum 25-Hydroxyvitamin D to Bone Mineral Density and Serum Parathyroid Hormone and Markers of Bone Turnover in Older Persons - (04/09/09)
     
  2089. The Relationship Between Prolonged Antiretroviral Therapy and Cryptogenic Liver Disease - (04/09/09)
     
  2090. Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome? EDITORIAL - (04/09/09)
     
  2091. Leptin Improved Belly Fat/Dyslipidemia - The Effects of Recombinant Human Leptin on Visceral Fat, Dyslipidemia, and Insulin Resistance in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy and Hypoleptinemia - Pilot Study - (04/09/09)
     
  2092. Belly Fat & Women. Adipokines, Inflammation, and Visceral Adiposity across the Menopausal Transition: A Prospective Study - (04/09/09)
     
  2093. Broccoli sprouts appear to reduce risk for stomach cancer, reduced inflammation in stomach. - (04/08/09)
     
  2094. End-Stage Liver Disease in HIV+ in France A Leading Cause of Death - (04/03/09)
     
  2095. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study - (04/03/09)
     
  2096. 'When to Start HAART' Experts Disagree-NEJM Study - (04/03/09)
     
  2097. Does Inflammation Fuel the Fire in CKD? - (04/03/09)
     
  2098. HPV Test vs Cytologic Testing or Visual Inspection: HPV Screening for Cervical Cancer in Rural India - (04/03/09)
     
  2099. When to Start Antiretroviral Therapy - Ready When You Are? EDITORIAL (NA-ACCORD) - (04/03/09)
     
  2100. Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes - (04/02/09)
     
  2101. Aspirin, salicylates, and cancer - (03/31/09)
     
  2102. JUPITER Study Reports Reducing hsCRP & LDL to Low Levels with Statin rosuvastatin Further Reduced Cardiovascular Risk - (03/31/09)
     
  2103. JUPITER: Rosuvastatin reduces risk of VTE in healthy subjects - (03/31/09)
     
  2104. EHDRW: Comparison of two etravirine weighted genotypic scores with phenotypic susceptibility and virological response data (03/31/09)
     
  2105. EHDRW: No Darunavir & Kaletra Major PI Mutations in ARTEMIS 96 Weeks (03/31/09)
     
  2106. EHDRW: Low-Level Transmitted K103N Mutation Predicts Virologic Failure - Written by Mark Mascolini (03/31/09)
     
  2107. EHDRW: No Resistance to Darunavir or Lopinavir After 96 Weeks in ARTEMIS - Written by Mark Mascolini (03/31/09)
     
  2108. EHDRW: Weighted Genotyping Scores Work Equally Well in Predicting Response to Etravirine - Written by Mark Mascolini (03/31/09)
     
  2109. EHDRW: Weighted Genotypic Score Predicts Response to Maraviroc in MOTIVATE Trials - Written by Mark Mascolini (03/30/09)
     
  2110. ART Interruption in Pregnancy Increases MTCT - (03/30/09)
     
  2111. Tight glucose control may increase mortality in critically ill patients - (03/30/09)
     
  2112. Intensive versus Conventional Glucose Control in Critically Ill Patients The NICE-SUGAR Study Investigators - (03/30/09)
     
  2113. Glucose Control in the ICU - How Tight Is Too Tight? EDITORIAL - (03/30/09)
     
  2114. Transfer of HIV between T Cells Captured on Video - (03/30/09)
     
  2115. Application of Lower Sodium Intake Recommendations to Adults --- United States, 1999--2006 - (03/30/09)
     
  2116. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study - (03/30/09)
     
  2117. Prevalence and Pathogenesis of Diabetes Mellitus in HIV-1 Infection Treated With Combined Antiretroviral Therapy - (03/30/09)
     
  2118. EHDRW: Genotyping for Coreceptor Use Concordant With Trofile in PBMCs and Plasma: from Jules- genotyping this falls short - Written by Mark Mascolini - (03/27/09)
     
  2119. EHDRW: HIV-Induced CD4 Declines Affect Immune Response to HBV in Untreated People - Written by Mark Mascolini - (03/27/09)
     
  2120. Prevention of Viral Sexually Transmitted Infections - Foreskin at the Forefront (male circumcision) EDITORIAL - (03/27/09)
     
  2121. Midlife Patients With HIV or AIDS Require Care for Chronic Conditions: "HIV simulates aging" - (03/27/09)
     
  2122. Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV-Infected Men: The HIPVIRG Cohort Study - (03/27/09)
     
  2123. Avexa Reaches First Critical Evaluation Point for new NRTI ATC's Phase III Trial - (03/27/09)
     
  2124. Tight glucose control may increase mortality in critically ill patients - (03/27/09)
     
  2125. Male Circumcision for the Prevention of HSV-2 and HPV Infections and Syphilis: circumcision prevents HSV-2 and HPV - (03/27/09)
     
  2126. EHDRW: Viral Loads--But Not Transmission of Resistant Virus--Falling in Italian Cohort - Written by Mark Mascolini - (03/27/09)
     
  2127. EHDRW: Resistance Testing Is Not Standard-of-Care After Antiretroviral Failure in Europe - Written by Mark Mascolini - (03/27/09)
     
  2128. EHDRW: Cumulative Resistance Score Gives Broader View of Potential Antiretroviral Activity - Written by Mark Mascolini - (03/27/09)
     
  2129. CROI: Non-HIV Markers Add to HIV Signals in Predicting VA Cohort Deaths - written by Mark Mascolini - (03/25/09)
     
  2130. CROI: US and Canadian Studies Trace Impact of Resistance Results on Mortality - written by Mark Mascolini - (03/25/09)
     
  2131. CROI: Higher Rate of Non-AIDS Infection-Related Cancers With HIV May Be Waning in HAART Era - written by Mark Mascolini - (03/25/09)
     
  2132. ISHLVD: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) - (03/25/09)
     
  2133. ISHLVD: Developing HBV/HCV Associated Liver Cancer At A Young Age < 40 Yrs Old - (03/25/09)
     
  2134. ISHLVD: Estimated Prevalence of Chronic Hepatitis B (CHB) in Foreign-Born (FB) Persons Living in the United States (U.S.) by Country/Region of Origin - (03/23/09)
     
  2135. ISHLVD: Federal Government's Response to Viral Hepatitis - (03/23/09)
     
  2136. ISHLVD: Key Health Care Provisions in Stimulus Legislation - (03/23/09)
     
  2137. ISHLVD: HCV Burden of Disease and Associated Costs: An Overview - (03/23/09)
     
  2138. ISHLVD: Barriers to HCV Care - (03/23/09)
     
  2139. Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-Treated HIV Infection - (03/24/09)
     
  2140. Is HIV Eradication Feasible? - (03/20/09)
     
  2141. CROI: Neurologic Complications of HIV Disease and Their Treatment - written by Scott L. Letendre, M.D. et al - (03/19/09)
     
  2142. HIV-Specific IgG in Cervicovaginal Secretions of Exposed HIV-Uninfected Female Sexual Partners of HIV-Infected Men - (03/19/09)
     
  2143. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants: ART before age 3 months dramatically reduces AIDS/death - (03/19/09)
     
  2144. Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhbitor - (03/19/09)
     
  2145. Vicriviroc Does Not Increase Epstein-Barr Virus Replication: CCR5 and lymphoma - (03/19/09)
     
  2146. Changes in Cancer Mortality among HIV-infected Patients: The Mortalite 2005 Survey - (03/19/09)
     
  2147. Malignancy-Related Deaths among HIV-Infected Patients: increasing problems with cancers & non-AIDS events - EDITORIAL COMMENTARY - (03/19/09)
     
  2148. New Apricitabine 96 Week Data, Phase 3 Data Expected - (03/19/09)
     
  2149. Depletion of CD4+ T Cells in Semen During HIV Infection and Their Restoration Following Antiretroviral Therapy - (03/19/09)
     
  2150. Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV Infection: naives with D/m progress more quickly, early ART? - (03/19/09)
     
  2151. CROI: Mitochondrial DNA Levels in Pregnancy Are Not Decreased in ARV-treated Women Compared to HIV- Controls - (03/18/09)
     
  2152. CROI: Raltegravir In Children and Adolescents: The French Expanded Access Program - (03/18/09)
     
  2153. CROI: Prognosis of Non-Hodgkin's Lymphoma in HIV-infected Patients - (03/18/09)
     
  2154. CROI: Influence of ART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin's Lymphoma: European Multi-Cohort Study, CD4 Predicts Non-Hodgkin's Lymphoma - (03/18/09)
     
  2155. CROI: Effect of HIV Co-infection on the Outcome of Viral Cirrhosis Liver Transplant Candidates on the Waiting List at a Reference Center from 2001 to 2008 - (03/17/09)
     
  2156. CROI: Liver Transplantation in 88 HIV-infected Patients - (03/17/09)
     
  2157. CROI: HCV Causes Neurcognitive Impairment in HIV+ - (03/17/09)
     
  2158. CROI: HCV Inflames the Brain in HIV Coinfected in Acute HCV - (03/17/09)
     
  2159. CROI: Review of HIV+ Patient's Immunological Response Rate to High-dose HBV Re-vaccination Series: Cd4 & viral load predict response - (03/17/09)
     
  2160. CROI: 5-Year Survival of HCV/HIV-co-infected Liver Transplant Recipients in Spain: A Case/Control Study - (03/17/09)
     
  2161. CROI: Predictors of Chronic HBV Infection in HIV-infected Individuals: HAART Can Prevent Chronic HBV - (03/17/09)
     
  2162. CROI: Interruption of ART and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in Strategies for Management of ART Viral Hepatitis-co-infected Participants and Matched Controls - (03/17/09)
     
  2163. CROI: Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Co-infected Patients - (03/17/09)
     
  2164. CROI: The Long-term Use of Tenofovir in HIV/HBV Co-infection Induces a Marked Decrease in Liver Fibrosis - (03/17/09)
     
  2165. CROI: ART Reinitiation and HBV Rebound among HIV/HBV-co-infected Patients following ART Interruption in the Strategies for the Management of ART Study - (03/17/09)
     
  2166. CROI: Association of Non-cirrhotic Portal Hypertension in HIV-infected Persons and ART with Didanosine - (03/17/09)
     
  2167. CROI: Prolonged ART and Risk for Chronic Elevation of Alanine Aminotransferase in HIV-infected Persons without HBV or HCV Co-infections - (03/17/09)
     
  2168. CROI: Incidence and Predictors of Acute Renal Failure in an Urban Cohort of Patients with HIV and Hepatitis C Co-infection - (03/17/09)
     
  2169. CROI: High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART - (03/17/09)
     
  2170. CROI: Progression of Liver Fibrosis in a Large Cohort of HIV Patients Over 4 Years: Emerging Contribution of Antiretrovirals and Metabolic Abnormalities - (03/17/09)
     
  2171. Human Immunodeficiency Virus in Semen and Plasma: Investigation of Sexual Transmission Risk Behavioral Correlates - (03/16/09)
     
  2172. CROI: Rosiglitazone Improves Lipoatrophy in Patients Receiving Thymidine-sparing Regimens - (03/16/09)
     
  2173. CROI: Platelet Hyper-Reactivity in HIV-1-infected Patients on Abacavir-containing ART - (03/16/09)
     
  2174. CROI: Association of Abacavir and HIV Disease Factors with Endothelial Function in Patients on Long-Term Suppressive Antiretroviral Therapy - (03/16/09)
     
  2175. CROI: HIV in Semen Despite Undetectable in Blood: "residual risk of transmission is still possible during unprotected intercourse" - (03/16/09)
     
  2176. HIV-1 Can Persist in Aged Memory CD4+ T Lymphocytes With Minimal Signs of Evolution After 8.3 Years of Effective Highly Active Antiretroviral Therapy - (03/12/09)
     
  2177. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults - (03/12/09)
     
  2178. CROI: Inflammatory Markers among Abacavir and non-Abacavir Recipients in the Womens' Interagency HIV Study and the Multicenter AIDS Cohort Study - (03/13/09)
     
  2179. CROI: High-density Lipoprotein Particles but Not Low-density Lipoprotein Particles Predict Cardiovascular Disease Events in HIV Patients: Strategies for Management of ART Study - (03/13/09)
     
  2180. How Inflammatory Disease Causes Fatigue: chronic inflammation infiltrates the brain but can be blocked - (03/10/09)
     
  2181. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction - (03/10/09)
     
  2182. New Microbcide Discovery in Monkeys from Ashley Haase - (03/10/09)
     
  2183. CROI: Microbicide gel PRO 2000 may help against HIV -Commentary - (03/10/09)
     
  2184. Response (safety, efficacy) to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection - (03/10/09)
     
  2185. National Women and Girls HIV/AIDS Awareness Day March 10, 2009 - - (03/10/09)
     
  2186. Use of Cognitive Enhancement Drugs - (03/10/09)
     
  2187. CROI: Antiretroviral agents that inhibit CCR5-utilizing HIV-1 - written by Eric S. Daar, M.D. (03/10/09)
     
  2188. CROI: Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (03/10/09)
     
  2189. CROI: Association between Modifiable and Non-modifiable Risk Factors and Specific Causes of Death in the HAART Era: The Data Collection on Adverse Events of Anti-HIV Drugs Study -DAD Study - (03/09/09)
     
  2190. CROI: Activation (Inflammation) and Coagulation Biomarkers are Independent Predictors for the Development of Opportunistic Disease in Patients with HIV Infection - (03/09/09)
     
  2191. CROI: Biological Determinants of Immune Reconstitution following Long-term HAART: host factors & persistent gut microbial translocation drive chronic immune activation - (03/09/09)
     
  2192. The Challenge of Finding a Cure for HIV Infection - (03/09/09)
     
  2193. CROI: HIV+ Die More Quickly in FRAM & Low CD4 Predicts Death - (03/09/09)
     
  2194. CROI: Inflammation, Cancers and Other Life Threats for People Living with HIV - written by David Alain Wohl, MD - (03/06/09)
     
  2195. WHO | The unexplored story of HIV and ageing - (03/05/09)
     
  2196. CROI: Osteopenia and Osteoporosis in HIV-infected Patients Are Associated with Reduced Frequency of Central Memory CD8+CD127+ T Cells: T-cell activation/senescence associated with bone loss - (03/05/09)
     
  2197. CROI: Evidence of persistent low-level viremia in long-term HAART-suppressed individuals - (03/05/09)
     
  2198. CROI: Brain Damage, Comorbidities and Early Death Threaten HIV+ - (03/05/09)
     
  2199. CROI: Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study: boosted PI+TDF associated with renal function - (03/05/09)
     
  2200. CROI: Viral Hepatitis is Associated with Reduced Bone Mineral Density in HIV-Infected Women but Not Men - (03/04/09)
     
  2201. CROI: First Report of Dose/Response Data of HIV-infected Men Treated with Vitamin D3 Supplements - (03/04/09)
     
  2202. CROI: Effects of Aging on HIV-1 Pathogenesis: HIV causes inflammation & T-cell activation, reported here to be more in postmenopausal women - (03/04/09)
     
  2203. CROI: Raltegravir Intensification, Viral Replication, HIV Reservoirs & HAART - (03/04/09)
     
  2204. CROI: Bone/Osteoporosis CROI 2009 Update - written by Todd Brown, MD, PhD (03/04/09)
     
  2205. CROI: Persisting High Prevalence of HIV Distal Sensory Peripheral Neuropathy in the Era of Combination ART: Correlates in the CHARTER Study - (03/04/09)
     
  2206. CROI: Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome and Mortality during a Randomized Trial of Early versus Deferred ART in the Setting of Acute Opportunistic Infections (ACTG A5164) - (03/04/09)
     
  2207. CROI: The Long Term Use of Tenofovir Disoproxil in HIV-HBV Co-Infection Induces a Marked Decrease in Liver Fibrosis - (03/04/09)
     
  2208. CROI: Viro-Immunologic Abnormalities in Gut Associated Lymphoid Tissue Caused by Acute HIV Infection are not Reverted by Early Initiation of HAART - (03/04/09)
     
  2209. CROI: Ongoing Viral Replication in the Gut Despite HAART Suppressive Viral Control: Lack of Compartmentalization of HIV HIV-1 Quasispecies and Circulation of CXCR4 using HIV-1 between Gut Associated Lymphoid Tissue (GALT) and the Peripheral Blood (PB) - (03/04/09)
     
  2210. CROI: HIV-1 Induces Apoptosis in primary Osteoblasts: an Alternative Mechanism in the Osteopenia/Osteoporosis Development - (03/04/09)
     
  2211. CROI: GENDER AND GONADAL FUNCTION DIFFERENCES IN THE PREVALENCE OF BONE MASS REDUCTION: higher rates of osteopenia and osteoporosis for men vs women and at early ages, in their 40s. - (03/04/09)
     
  2212. CROI: Immune Senescence, Activation and Abnormal T cell Homeostasis Despite Effective HAART, A Hallmark of Early Aging in HIV Disease - (03/03/09)
     
  2213. CROI: Changes in Bone Turnover, OPG/RANKL, and Inflammation with ART Initiation: A Comparison of Tenofovir- and Non-Tenofovir-Containing Regimens - (03/03/09)
     
  2214. CROI: Evaluation of peripheral DEXA Bone Densitometry to identify low bone mineral density in HIV- infected men in UK: 60% osteopenia, 13% osteoporosis- median age 41 yrs; t-score/dexa predicts fracture in HIV - (03/03/09)
     
  2215. CROI: Clinical Determinants of Bone Mineral Density (BMD) in Perinatally HIV-Infected Children - (03/03/09)
     
  2216. CROI: HIV Drug Pipeline at CROI - (03/03/09)
     
  2217. CROI: Bone Mineral Density in HIV+ Women: Relationship to Body Composition - (03/03/09)
     
  2218. CROI: Preferential Bone Demineralization at the Hip in Treated HIV+ Males: Another Example of Premature Aging? - (03/03/09)
     
  2219. CROI: Determinants (HIV, Cytokines) of Low Bone Density in Postmenopausal HIV+ Women - (03/03/09)
     
  2220. CROI: Short term bone loss in HIV infected premenopausal women - (03/03/09)
     
  2221. CROI: Back to Basics: the science at CROI focuses the tough questions that remain in HIV pathogenesis, Part 2 (focal points for new therapies.) - written by David Margolis MD, University of North Carolina - (03/03/09)
     
  2222. CROI: Back to Basics: the science at CROI focuses on the tough questions that remain in HIV pathogenesis - written by David Margolis, MD, University of North Carol